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Abstract 
Platelets and coagulation proteins work in concert to maintain proper blood flow through the vasculature. 
When an injury occurs, this hemostatic system must respond efficiently by sealing the wound to prevent 
excessive bleeding. Deviations from normal hemostasis arise in the clinic frequently; one such condition 
that is characterized by uncontrolled bleeding is known as trauma-induced coagulopathy (TIC). Severe 
platelet dysfunction is one key contributing factor to TIC, though its mechanistic causes are still yet to be 
fully understood. In order to investigate biological explanations for platelet dysfunction during trauma, 
various cell-based assays were designed and conducted in both healthy and patient populations. 
Specifically, intracellular calcium mobilization and other fluorescently tracked biomarkers were used as 
dynamic indicators of platelet activation in response to common agonists. Microtiter well plates prepared 
with liquid handling systems enabled high-throughput data collection and minimal manual pipetting. 
Significant platelet dysfunction in response to 31 unique stimulation conditions spanning several 
signaling pathways was observed in a cohort of trauma patients and tracked at multiple timepoints after 
initial hospital admission. In experiments designed to interrogate plasma effects on healthy platelet 
function, patient-derived plasma imparted significant inhibition which implied the presence of a unique 
soluble plasma species with downregulatory effects on endogenous and transfused platelets. With 
established knowledge of coinciding coagulant and lytic states during trauma, strategic addition of 
agonists to healthy platelet suspensions led to generation of soluble fibrin species and desensitization to 
agonist stimulation through glycoprotein VI (GPVI). Downstream platelet dysfunction was only observed 
when thrombin was added to the system to polymerize fibrin, whereas stimulation with other agonists or 
inhibition of various stages of coagulation had no effect on subsequent GPVI function. Maximal inhibition 
(~95%) was attained when tissue plasminogen activator (tPA) was also incorporated to lyse fibrin 
polymers into fibrin degradation products (FDP). Concentrations of a small FDP called D-dimer were 
elevated in trauma patient samples and inversely correlated with a quantitative measure of platelet 
function. Finally, preliminary results indicate potential binding affinity between platelet receptors and D-
dimer. These results shed light on specific biological entities that may be responsible for platelet 
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 Platelets and coagulation proteins work in concert to maintain proper blood flow 
through the vasculature. When an injury occurs, this hemostatic system must respond 
efficiently by sealing the wound to prevent excessive bleeding. Deviations from normal 
hemostasis arise in the clinic frequently; one such condition that is characterized by 
uncontrolled bleeding is known as trauma-induced coagulopathy (TIC). Severe platelet 
dysfunction is one key contributing factor to TIC, though its mechanistic causes are still 
yet to be fully understood. In order to investigate biological explanations for platelet 
dysfunction during trauma, various cell-based assays were designed and conducted in 
both healthy and patient populations. Specifically, intracellular calcium mobilization and 
other fluorescently tracked biomarkers were used as dynamic indicators of platelet 
activation in response to common agonists. Microtiter well plates prepared with liquid 
handling systems enabled high-throughput data collection and minimal manual pipetting. 
Significant platelet dysfunction in response to 31 unique stimulation conditions spanning 
several signaling pathways was observed in a cohort of trauma patients and tracked at 
multiple timepoints after initial hospital admission. In experiments designed to interrogate 
plasma effects on healthy platelet function, patient-derived plasma imparted significant 
inhibition which implied the presence of a unique soluble plasma species with 
downregulatory effects on endogenous and transfused platelets. With established 
knowledge of coinciding coagulant and lytic states during trauma, strategic addition of 
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agonists to healthy platelet suspensions led to generation of soluble fibrin species and 
desensitization to agonist stimulation through glycoprotein VI (GPVI). Downstream platelet 
dysfunction was only observed when thrombin was added to the system to polymerize 
fibrin, whereas stimulation with other agonists or inhibition of various stages of coagulation 
had no effect on subsequent GPVI function. Maximal inhibition (~95%) was attained when 
tissue plasminogen activator (tPA) was also incorporated to lyse fibrin polymers into fibrin 
degradation products (FDP). Concentrations of a small FDP called D-dimer were elevated 
in trauma patient samples and inversely correlated with a quantitative measure of platelet 
function. Finally, preliminary results indicate potential binding affinity between platelet 
receptors and D-dimer. These results shed light on specific biological entities that may be 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Hemostasis, Thrombosis, and Bleeding 
Following blood vessel injury, the body’s normal response to prevent excessive 
blood loss and restore fluid flow throughout the vasculature is known as hemostasis [1]. 
Though it is an incredibly complex process involving cells, proteins, and other biological 
entities, the hematology community generally classifies two main mechanisms: primary 
and secondary hemostasis [2]. Primary hemostasis relies on the functionality and activity 
of platelets to report to the injury site and aggregate into a “platelet plug” [2]. Initial platelet 
adhesion to the vessel wall takes place as a result of binding affinity between platelets 
and subendothelial collagen and von Willebrand Factor (vWF), both of which become 
exposed post-injury [2]. Several biophysical and biochemical events, notably the change 
of platelet cytoskeletal configuration from discoid to pseudopodia-rich shapes [3] and the 
release of intracellular granule contents [4], further potentiate the recruitment and 
activation of other circulating platelets. Located within platelet dense granules, adenosine 
diphosphate (ADP) and thromboxane A2 (TXA2) act as autocrine activators upon release 
and are among the most important contributors to positive feedback signaling and 
secondary platelet aggregation [4].  
Concurrent with the initial platelet response to a wound, oncoming blood flow is 
exposed to tissue factor (TF), which serves as a cofactor for the serine protease Factor 
VIIa (FVIIa) and subsequently triggers a series of reactions known as the coagulation 
cascade [5]. Coagulation can be TF-mediated, known as the extrinsic pathway, or 
activated through surface contact, referred to as the intrinsic pathway, but both routes lead 
to the generation of thrombin [2]. Thrombin is the most critical enzyme in secondary 
hemostasis, as it cleaves and polymerizes the plasma protein fibrinogen to an insoluble 
polymer aptly called fibrin [2]. Once sufficiently polymerized and cross-linked, fibrin acts 
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as a stabilizing mesh for the platelet aggregate and strengthens the clot to completely seal 
the damaged vasculature [6].  
In order to prevent excessive clot buildup, down-regulatory mechanisms exist to 
control the generation and activity of thrombin. Serine protease inhibitors (SERPINs), such 
as antithrombin and heparin cofactor II, and other circulating species like protein C, which 
elicits anticoagulant properties when activated by thrombin, are examples of naturally 
occurring inhibitors of the coagulation process [7]. Fibrinolysis is another reactive process 
which targets already existing fibrin networks. The plasma protein plasminogen circulates 
as an inactive zymogen until encountering endothelial-released tissue plasminogen 
activator (tPA), upon which it becomes activated to plasmin and is capable of dissolving 
polymerized fibrin [7,8].  
These antithrombotic mechanisms sometimes progress defectively, which has the 
potential to lead to bleeding in the case of insufficient clotting, or thrombosis, a condition 
characterized by excessive clot development and blockage of blood flow upon vessel 
occlusion [2]. Thrombi produced in arteries and veins typically exhibit different 
compositions, which are associated with different risk factors. Venous clots are comprised 
mostly of fibrin and red blood cells, whereas arterial clots are usually platelet-rich due to 
higher shear rates and ruptured atherosclerotic plaque [9]. Without proper identification 
and treatment, pathologic thrombi can lead to several life-threatening clinical 
presentations, including myocardial infarction (MI), stroke, venous thromboembolism 
(VTE) or pulmonary embolism (PE) [9]. On the other hand, bleeding presents its own set 
of concerns, though it is often more easily diagnosed than thrombosis. Despite the fact 
that most bleeding disorders are genetically inherited (e.g. hemophilia and Von Willebrand 
disease) [2], others can be developed as a result of coagulopathic behavior. One such 
example is trauma-induced coagulopathy (TIC), which commonly presents in patients who 
have experienced major injuries. This condition is known to be extremely complex, but is 
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broadly identified by impaired clotting activity, hyperfibrinolysis, and platelet dysfunction 
[10]. Understanding mechanisms of TIC has been a grand challenge over the years, and 
any significant progress has the potential to alter the treatment strategies currently 
employed in the clinic.        
 
1.2 Platelet Activation 
1.2.1 Platelets 
 The three main types of blood cells are red blood cells, white blood cells, and 
platelets. While the others feature nuclei and are larger in size, platelets are anucleate 
cells that typically range between 2-4 µm in diameter [11]. Also known as thrombocytes, 
platelets are generated through a process called thrombopoiesis which takes place in the 
bone marrow. After hematopoietic stem cells differentiate into megakaryocytes (among 
several other subclasses of blood progenitor cells) and with the aiding action of 
thrombopoietin, long protruding fragments called proplatelets are released from the 
cytoplasm and further divided into platelets [11]. Once introduced to the circulation, 
platelets have an average lifespan of about 7-10 days before being cleared by the spleen 
and liver. Younger platelets tend to exhibit higher responsiveness to stimuli than older 
platelets, primarily due to higher RNA content, but platelets of all ages can still participate 
in hemostasis and become activated by a plethora of signals and mechanisms [11]. 
 
1.2.2 Surface Receptors 
Platelets are decorated with numerous surface receptors, each of which is 
engaged by one or more specific ligands. Some receptors are involved in the initial 
adhesion process to a prothrombotic surface (e.g. damaged vessel wall), while others are 
called into action to bind soluble agonists or interact with other platelets. The variety of 
functions also pertains to subclasses of receptors that lead to either inhibitory or activating 
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processes, which work in concert to keep the level of platelet activation under control 
[12,13]. 
 For the studies in this work, receptors that trigger activating networks will be the 
primary focus. Receptors that initiate the platelet activation process are often classified 
into two main groups: immunoreceptor tyrosine-based activation motif (ITAM)-coupled 
receptors and G-protein coupled receptors (GPCR) [13]. Examples of ITAMs include 
FcRγ, which complexes with glycoprotein VI (GPVI) and GPIb-IX-V, and FcγRIIa, which is 
associated with the integrin αIIbβ3 and GPIb-IX-V, as well as C-type lectin-like receptor 2 
(CLEC-2) [13]. GPVI and GPIb-IX-V are each responsible for initial platelet recruitment 
and binding to endothelial-exposed collagen and vWF, respectively. Integrin αIIbβ3, also 
termed GPIIb/IIIa, attracts the plasma protein fibrinogen to link individual platelets together 
and strengthen the developing platelet mass. CLEC-2 is stimulated by the transmembrane 
protein podoplanin, which is commonly expressed on the surface of lymphatic endothelial 
cells (LEC), and is important for maintaining natural barriers between blood flow and the 
lymphatic system [13,14]. In addition to these naturally occurring receptor activators, lab-
based ligands have been discovered and developed, including convulxin for GPVI [15] 
and rhodocytin for CLEC-2 [16]. Different from GPCRs, which are discussed next, ITAM 
receptors are essential for maintaining vascular integrity at sites of inflammation in addition 
to promoting platelet function [14]. 
 The majority of platelet receptors that are activated by binding of soluble agonists 
to the cell surface belong to the GPCR family. Though GPCRs come in a variety of flavors, 
they are all composed of seven transmembrane domains that transmit intracellular signals 
upon activation by the appropriate ligand [13]. Most platelet agonists activate Gαq 
receptors—thrombin, the essential protease for coagulation described previously, also 
has platelet activation capability through its affinity for the two protease activated receptors 
1 and 4 (PAR-1,4) in human blood, and ADP and TXA2, important for secondary platelet 
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activation, bind the P2Y1 and TP receptors, respectively. Often, lab analogs with higher 
specificity and stability are substituted for these natural ligands. For example, the PAR-
specific peptide chains Ser-Phe-Leu-Leu-Arg-Asn (SFLLRN) and Ala-Tyr-Pro-Gly-Lys-
Phe (AYPGKF) are used to study PAR-1 and PAR-4, respectively [17,18], while U46619 
is a synthetic agonist for the TP receptor [19]. Gαi-coupled receptors, which include 
another ADP receptor called P2Y12, and the Gαs-coupled receptors, such as the inhibitory 
prostaglandin I2 (IP) receptor, round out the most well-studied platelet surface receptors 
and will be discussed at length throughout this work [13]. Recently, GPCRs and 
associated intracellular signaling pathways have gained interest as targets for drug 
development due to their involvement in the amplification of the platelet activation process 
[20]. This strategy enables initial platelet function to adequately seal a wound, but prevents 
excessive platelet activity which could lead to restriction of blood flow and other 
complications of thrombosis.   
As discussed previously, regulating mechanisms for controlling the extent of 
platelet activation exist in both damaged and healthy vasculatures. In order to maintain 
the normal quiescent state of circulating platelets, intact endothelium releases nitric oxide 
(NO) and prostacyclin (PGI2) as inhibitory signals [12]. Unlike prostacyclin which binds to 
the IP receptor and leads to the production of cyclic adenosine monophosphate (cAMP), 
nitric oxide does not physically bind to platelets. Rather, it suppresses platelet activity 
through the conversion of soluble guanyl cyclase to cyclic guanosine monophosphate 
(cGMP) [12]. Both cAMP and cGMP activate protein kinases (PKA and PKG, respectively), 
which contribute to the phosphorylation of numerous substrates. These phosphorylated 
entities carry inhibitory properties against platelet adhesion, aggregation, and other 





1.2.3 Common Signaling Pathways and Markers of Platelet Activation 
Binding or cleavage of platelet surface receptors by physiologic or mimetic ligands 
acts as the initiation step for several intracellular signaling pathways, many of which are 
depicted in Figure 1-1, that eventually lead to platelet activation events. Several receptors 
described in the previous section signal primarily through regulators of G-protein signaling 
(RGS), and each unique G protein can be activated by a multitude of different receptors. 
The vast majority of GCPRs, those that are Gαq-coupled, activate the β isoform of 
phospholipase C (PLCβ) which in turn catalyzes the hydrolysis of phosphatidylinositol 4,5-
biphosphate (PIP2) into the secondary messenger inositol triphosphate (IP3) [13]. The Gαi-
coupled class of receptors tend to signal both through PLCβ as well as against adenylyl 
cyclase (AC), which prevents inhibitory signals from being transmitted. Signaling through 
AC and guanylyl cyclase (GC) for that matter, through either Gαs-coupled receptors or 
nitric oxide donation through the plasma membrane, respectively, trigger inhibitory 
pathways via cAMP and cGMP synthesis as discussed above. Non-GPCRs, such as the 
ITAM receptors, are often associated with tyrosine phosphorylation by Src family kinases 
(SFK) and subsequent binding of spleen tyrosine kinase (Syk) to the intracellular domain 
of the receptor. This event then triggers activation of PLCγ and convergence to IP3 
generation as is observed through Gαq signaling [13].   
The example of ITAM signaling via GPVI activation and Gαq signaling both 
converging on IP3 synthesis exhibits the high degree of crosstalk between individual 
platelet activation pathways. Other examples include ADP signaling through two 
independent GPCR-dependent pathways, PAR4-P2Y12 dimerization, and inside-out 
integrin activation amplifying platelet responses to GPCR agonists [13,22]. This synergy 
and positive feedback is essential for ensuring proper platelet activation during 
hemostasis, as the cooperative effects of multiple pathways can overcome certain 
scenarios in which low levels of specific agonists are present. It is important to note that 
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the pathways outlined here and in Figure 1-1 are only a selection of the countless 
mechanisms of platelet activation. However, for the purposes of this work, analysis of 
these primary pathways will provide a holistic and sufficiently broad understanding of how 
platelets respond to various stimuli throughout the course of the hemostatic response. 
 
 
Figure 1-1. Schematic of common platelet signaling pathways 
The platelet surface (grey box) features several receptors that become activated by specific 
ligands. Certain ligand-receptor pairs lead to activating events (denoted by agonists in blue), while 
others trigger inhibitory signals to prevent excessive platelet activation (denoted by agonists in red). 
The intracellular signaling pathways are rather complex, which is often attributed to crosstalk 
between multiple events. Several markers of platelet activation, including dynamic calcium 
mobilization, phosphatidylserine (PS) exposure, and αIIbβ3 activation, are also indicated (shown in 
green).  
 
In a normal response to injury, there is typically a step-by-step sequence of events 
that leads to clot formation and restoration of blood flow: (1) initial adhesion and activation 
of platelets; (2) amplification of the platelet activation response and recruitment of 
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additional cells; (3) aggregation of activated platelets and stabilization through coagulation 
proteins. Even in this “healthy” process, there are several important players that contribute 
to addressing the issues presented by vessel damage, and understanding the individual 
significance of each signaling event as well as the importance of evidenced interactions 
gives rise to high-dimensional problems. The level of complication only increases when 
hemostasis fails in one way or another, an example being the case of a patient with pre-
existing medical conditions. Identification of specific markers of platelet function that are 
affected by multiple activation mechanisms (e.g. output-input systems) becomes crucial 
in the effort to simplify the study of platelet activation while still maintaining access to the 
inner workings of the aforementioned biochemical signaling processes. The experimental 
setups that are utilized in this work enable the collection of data representative of complex 
signaling situations, whether multiple platelet agonists are present simultaneously or 
sequentially. 
After the successful activation of a platelet through one or more signaling 
pathways, a number of events serve as indicators of the dynamics and extent of the 
activation state. Contained within quiescent platelets, content of intracellular granules 
becomes released as a result of platelet activation. There exist at least three different 
types of granules—α-granules, dense granules, and lysosomes—and each class is known 
to be composed of unique substances. For example, α-granules hold proteins like P-
selectin, vWF, fibrinogen, and other coagulation factors, while dense granules release 
secondary platelet agonists like ADP and serotonin among other non-protein molecules 
[23]. Intracellular granule release can be measured through luminescent assays in 
conjunction with platelet shape change and aggregation [24], and expression of specific 
granule content, notably P-selectin (CD62P), can be detected with monoclonal antibodies 
in a flow cytometry setting [25]. In a similar fashion as P-selectin, other markers on the 
platelet surface can be identified, including CD40L, CD63, activated integrin αIIbβ3, and 
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phosphatidylserine, as well as other entities like platelet-leukocyte aggregates, cross-
linking agent Factor XIII, and platelet-derived microparticles (PMPs) [25]. Finally, a marker 
of platelet activation that remains within the cell and must be probed by dyes that penetrate 
through the plasma membrane is the concentration of intracellular calcium, which is known 
to depend on two distinct but related mechanisms [26,27]. Each of these classical 
biomarkers, along with the specific principles of each assay, will be discussed in more 
detail in Chapter 2.  
 
1.3 Trauma-Induced Coagulopathy (TIC) 
1.3.1 Platelet Dysfunction in Trauma Patients 
Trauma-induced coagulopathy (TIC) is a complex clinical state that is 
characterized largely by a bleeding phenotype. Statistically, about 25% of patients 
admitted to a trauma unit due to severe physical injury will develop TIC, and about 10% 
of all worldwide deaths are linked to trauma [10]. These metrics increase when considering 
military subjects, and about half of trauma-related deaths are caused by immediate, rapid, 
and uncontrollable exsanguination. Though clinicians and emergency response teams 
have developed various treatment regimens for these patients, the mortality rate still 
remains high which presents significant room for improvement. Over the years, several 
groups have set out to understand the underlying biology of TIC in an effort to identify 
potential ways to design new therapies or preventative methodologies. However, one of 
the key obstacles in learning about mechanisms is that each trauma patient typically 
presents with unique conditions; in other words, no single trauma patient is identical to 
another. Previous medical history or medication use, as well as the relative severity of the 
injury, may complicate the analysis. Nevertheless, a great deal of work has identified a 
few key pillars of TIC, each with several contributing factors, that the majority of patients 
will experience due to drastic changes to their blood biochemistry. These contributing 
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factors include platelet dysfunction, decreased clotting factor activity, and 
hyperfibrinolysis, each of which will be discussed in more detail [10]. 
 To start with platelet dysfunction, several previous studies have utilized a variety 
of laboratory assays to characterize the inability of platelets to respond to activating 
stimuli. For example, one group employed thromboelastography with a platelet mapping 
feature to observe sensitivity to ADP stimulation and found about 80% reduction on 
average compared to a control response [28]. A separate study reported impaired 
aggregation potential in response to at least one stimulating agonist in almost half of the 
100 analyzed trauma patients upon admission and upwards of 90% of the patients at some 
point during their stay in the hospital [29]. Previous work from our lab using microfluidic 
technology also showed platelet function defects in terms of impaired deposition onto a 
prothrombotic surface in a majority of the patients studied [30]. Despite all this 
observational work, the community’s identification of specific physiologic events that carry 
direct implications in relation to platelet dysfunction is still lacking.  
Multiple pieces of literature, including those cited above, have confirmed this 
dysfunctional platelet phenotype and some have gone as far to identify it as a potential 
biomarker for TIC or the related traumatic brain injury (TBI) [31,32]. Traditionally, the first 
hypothesized cause of platelet dysfunction has been thrombocytopenia, or decreased 
platelet counts, as correlations between platelet number and survival have been drawn 
previously in various disease states. However, trauma patients largely present with normal 
platelet counts and acceptable levels of P-selectin, an important protein in the platelet 
activation process [33]. This observation sheds light on a few possible explanations: (1) a 
significant fraction of the circulating platelets are simply not functional [31]; (2) platelet pre-
activation upon initial shock results in “exhausted” cells that are unable to respond to 
stimuli upon arrival to the injury site [28]; (3) shedding or internalization of crucial surface 
receptors renders platelets from sequential activation [34,35]. Unfortunately, it has been 
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difficult to confirm or reject any of these hypotheses, though the likelihood of a combination 
of multiple contributing factors is high. In this work, we strive to improve the understanding 
of platelet dysfunction in trauma patients, while taking into consideration the progress 
already established. 
 
1.3.2 Coagulation Abnormalities and Hyperfibrinolysis 
Following the initial stages of hemostasis in which platelet activation and 
aggregation dominate, the effects of coagulation start to take effect. A sequence of serine 
protease-mediated cleavage events eventually concludes with the conversion of the 
inactive zymogen prothrombin into thrombin. In turn, thrombin generation leads to the 
enzymatic cleavage and polymerization of monomeric fibrinogen into its polymeric form 
called fibrin. Fibrinogen is a soluble plasma protein that circulates at ~3 mg/mL and is 
structurally composed of three unique disulfide-linked polypeptide chains, which are 
represented by E- and D-domains. Thrombin activity causes the release of two peptides 
from the central E-domain, called fibrinopeptides A and B (FPA/B), and enables interaction 
between the E-domain of one monomer with a D-domain of a second molecule [8]. This 
interaction begins to form a staggered, overlapping pattern of individual fibrinogen 
molecules. An additional coagulation factor, factor XIII, is also converted to its active form 
through the action of thrombin. Factor XIIIa acts on resulting fibrin polymers by cross-
linking multiple chains together via adjacent lysine residues in D-domains, which ultimately 
stabilizes the clot structure [8]. A simplified visual representation of the fibrin 
polymerization process with depictions of the changing protein structure from monomeric 





Figure 1-2. Classes of fibrin-related species 
Coagulation begins with the monomeric plasma protein fibrinogen (A), then proceeds to become 
polymerized into soluble fibrin (B) through the enzymatic action of thrombin. Soluble fibrin chains 
are cross-linked into an insoluble polymer mesh (C) via factor XIIIa, which is converted to its active 
form in the presence of thrombin. Fibrin polymers are degraded by plasmin into fibrin degradation 
products of various sizes and compositions (D, E).  
 
Once a stable fibrin aggregate is formed, it has the potential to serve as its own 
cofactor substrate for lysis. Another inactive zymogen, plasminogen, is known to be 
activated by two distinct proteases—tissue plasminogen activator (tPA) and urokinase 
plasminogen activator (uPA)—via different mechanisms [2,8]. Released from activated 
endothelium and understood to exhibit higher affinity for plasminogen, tPA physically binds 
to the fibrin surface with plasminogen to generate active plasmin. In the alternative case, 
uPA is produced by immune cells like monocytes and macrophages and imparts its ability 
to convert plasminogen to plasmin via the uPA receptor on various cell types [2,8]. 
Regardless of the mechanism, plasmin then proceeds to lyse fibrin at different sites and 
results in the release and circulatory uptake of fibrin degradation products (FDP) from the 
clot. Some examples of FDP generated from either soluble or cross-linked fibrin 
constructs, including D-dimer (the smallest known FDP) are shown in Figure 1-2. Similar 
to the naturally occurring anticoagulant mechanisms in the hemostatic system, there also 
exist regulatory systems to control the level of fibrinolysis and prevent excessive clot 
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degradation. Some key players that inhibit the fibrinolytic system are α2-antiplasmin and 
plasminogen activator inhibitors 1 and 2 (PAI-1, PAI-2), which downregulate the activity of 
plasmin, tPA, and uPA, respectively [2,8]. However, when these serine protease inhibitors 
(SERPINs) fail to function properly or cannot keep up with the rate of plasmin generation, 
a hyperfibrinolytic state may ensue. 
 Along with platelet dysfunction, hyperfibrinolysis is another reported contributing 
factor to the clinical bleeding phenotype commonly observed in TIC patients [10]. This 
observation has been made primarily on the basis of biological understanding as well as 
laboratory measurements of common markers of fibrinolysis. Upon severe tissue injury, a 
multitude of biochemical changes in the blood take place in response to extreme blood 
loss and associated shock. Firstly, several procoagulant mechanisms are upregulated 
which leads to increased potential of thrombin generation [36]. However, many more 
anticoagulant systems are triggered during trauma which contributes heavily to the 
observed coagulopathy in a significant portion of these patients. The existence of thrombin 
in the presence of thrombomodulin results in the activation of protein C (APC), a key 
anticoagulant. The endothelium also becomes highly activated, which leads to the 
shedding of the protective endothelial glycocalyx layer (EGL) and release of a number of 
anticoagulant components like chondroitin sulfate and heparin sulfate [10]. In addition, 
elevated fibrinolytic agents like tPA, and to a lesser degree decreases in PAI-1 levels, are 
crucial to the state of hyperfibrinolysis in several trauma patients [37]. This co-existence 
of procoagulant, anticoagulant, and fibrinolytic states is a perfect recipe for abnormally 
high production of FDP, which has been characterized by several studies, both in trauma 
patients and other related conditions like disseminated intravascular coagulation (DIC), 
and is commonly quantified by measuring the concentration of soluble fibrin or D-dimer in 
whole blood or plasma samples [38–41]. Though this is certainly not an exhaustive 
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discussion of fibrinolysis during trauma, further elaboration will be presented in the 
following chapters of this work.  
 With knowledge of elevated FDP in the blood of trauma patients, consideration of 
the time scales of circulation before clearance becomes important. Unless otherwise 
activated, platelets are known to survive in the bloodstream for 7-10 days before the bone 
marrow produces a new generation of cells [11]. On the contrary, the clearance rate of 
fibrin and FDP is likely faster, though different sources have reported different 
quantifications. One of the first reports studying uptake of coagulation products was 
performed using a rat liver, in which the authors concluded that the clearance half-life for 
FDP was at least 12 hours [42]. Another group set up an investigation in mice and 
considered several variations of FDP through different preparation schemes, as confirmed 
by gel electrophoresis characterization. Using a radio-labeled isotope tag, the authors 
concluded that the fragments ranged from 200-250 minutes in clearance half-life [43]. A 
third study calculated a half-life time of approximately 5 hours in acute myocardial 
infarction (AMI) patients after receiving thrombolytic therapy [44]. Though previous 
findings of FDP clearance have differed, there is relative agreement that the general time 
scale for clearance half-life is several hours, which would correspond to a few days before 
full clearance. It is unclear whether this lingering ability of FDP bears any physiological 
significance, especially in the context of trauma patients.   
  
1.3.3 Efficacy of Transfusion Strategies 
Trauma-induced coagulopathy is one of several conditions associated with major 
bleeding complications, though it may be at the top of the list as far as urgency to treat 
patients. The universally accepted and utilized immediate form of therapy for trauma 
patients is transfusion of a range of blood products depending on the specific components 
that may be most deficient for a given patient. Red blood cells are administered to treat 
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hemorrhaging patients and to aid in oxygen delivery to tissues, which are often common 
conditions in patients with anemia or sickle cell disease. Fresh frozen plasma (FFP) is 
delivered in an effort to promote coagulation and reduce the activity of natural 
anticoagulant mechanisms that may be upregulated. FFP can be further processed by 
centrifugation to yield fibrinogen-rich cryoprecipitate to be given to subjects with 
fibrinogenemia. Finally, fresh platelets from healthy pools are commonly transfused to 
patients with thrombocytopenia or platelet function defects [45]. Blood tests are performed 
upon arrival to the hospital to evaluate the state of the patient at hand and determine the 
best course of action to maximize the probability of survival. However, due to the non-
native sources of these blood products, there are risks associated with transfusions that 
may lead to both infectious and noninfectious complications. For example, allergic 
reactions, lung injury, or circulatory overload are among the most common setbacks that 
may occur as a result of transfusion [45]. Therefore, guidelines for the most effective use 
of blood products as treatment are constantly being amended to prevent these unintended 
life-threatening effects. 
 With more respect to platelets and functional defects that are well-understood as 
a key pillar of the coagulopathic phenotype in trauma patients, analyses of the efficacy of 
platelet transfusions in an attempt to help restore hemostasis have been conducted. In a 
systematic review of several independent studies, Thorn et al. focused on traumatic brain 
injury (TBI) patients that were treated with platelet transfusions, and ended up including 
10 articles in the analysis which amounted to >1000 patients from 14 hospitals [46]. The 
authors tracked several variables across the reports but the key result was comparing 
mortality rates between transfused and non-transfused patient populations. Surprisingly, 
most of the studies showed increased mortality in patients receiving platelet transfusions, 
indicating both lack of efficacy and potential harm with this method of treatment. Though 
it is possible that the higher death rates observed in transfused patients may also be a 
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result of more severe injury conditions, there is clearly a lack of evidence that platelet 
transfusions were effective. In a separate paper, Vulliamy et al. conducted a much smaller 
study inclusive of ~150 trauma patients and investigated the effects of platelet transfusion 
on restoring native platelet function [47]. To summarize the results, there was found to be 
no detectable improvement in the ability of platelets to aggregate or overall platelet count 
in patients receiving transfusions. However, there was a reduction in the level of fibrinolytic 
products in these patients, which may be attributed to corresponding increases in 
plasminogen activator inhibitor-1 (PAI-1).  
With knowledge of platelet activation defects, hyperfibrinolysis, and potential lack 
of efficacy in restoring cell function through transfusion in trauma patients, we strive to 
further understand the underlying mechanisms that contribute to these clinical 
observations. In this work, we will apply several common lab techniques to characterize 
various aspects of platelet function and simulate different scenarios with strategic 
experimental design. A key aspect of the work will rely on a collaborative effort with Penn 
Presbyterian Medical Center’s Acute Research Collaboration (PARC), through which 




CHAPTER 2: PLATELET FUNCTION PHENOTYPING METHODS 
 
 
2.1 Intracellular Calcium Mobilization 
Following initial platelet activation, increases in the level of cytosolic calcium (Ca2+) 
become incredibly important for the amplification of the hemostatic response, as it serves 
as a communicative measure for recruiting additional platelets to the developing thrombus 
[26]. As briefly discussed in Chapter 1, several distinct signaling pathways converge upon 
the intracellular mobilization of calcium ions, which then gives rise to “inside-out” activation 
of other important biological processes. Calcium mobilization is known to occur through 
two primary mechanisms which proceed in a sequential fashion and are depicted visually 
in Figure 2-1 [27]. First, internal stores which contain high concentrations of calcium ions 
in resting platelets release their contents upon agonist-induced activation. The stores 
typically mimic endoplasmic reticulum in other cells and are generally referred to as the 
dense tubular system (DTS). Activation via the binding of GPCR or ITAM ligands leads to 
phospholipase C (PLC)-mediated production of inositol triphosphate (IP3), which facilitates 
transport of Ca2+ through IP3 receptor (IP3R) channels and into the cytosolic space. As 
long as the Ca2+ concentration in the DTS does not become too low, this mechanism is 
prioritized and proceeds without significant interruption. Recirculation of Ca2+ back into the 
DTS to replenish the supply or escape into the extracellular space also occurs; these 
events are largely dependent on the action of sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPases (SERCA) or plasma membrane Ca2+ ATPases (PMCA), respectively [27].  
The second mechanism of calcium mobilization is initiated upon depletion of the 
internal stores and is termed store-operated calcium entry (SOCE). On the surface of the 
endoplasmic reticulum, stromal interaction molecule 1 (STIM1) acts as a sensor for the 
Ca2+ levels present in the stores. Upon failed binding to Ca2+ due to decreased 
concentrations, STIM1 opens SOC channels in the plasma membrane, which have been 
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discovered to be transmembrane proteins called calcium-release activated calcium 
modulator 1 (CRACM1, or the more conventionally used Orai1) [27]. The regulation of 
Orai1 permits additional extracellular calcium to be transported into the cell as a backup 
source for the internal stores. A few other mechanisms of calcium transport within platelets 
exist, but the aforementioned systems are predominantly responsible and are heavily 
studied in the platelet biology community. Since there are multiple entities with distinct 
roles in promoting and regulating calcium mobilization, potential for therapeutic target has 
been proposed and analyzed by several groups, primarily using mouse models. Calcium 
entry has been determined to be critical for thrombus development without direct 
implications on hemostasis [27].    
Calcium mobilization can be thought of as a dynamic flux of ions across physical 
barriers, and has been identified as a process that can be tracked in real time as platelets 
are activated by various stimuli. Harnessing fluorescent technology, several chemical 
calcium indicators have been designed for specific applications [48]. Most commonly used 
for cytosolic detection are high affinity dyes, which include Calcium Green-1, Fluo-3, Fluo-
4, Fura-2, Indo-1, and Oregon Green 488 BAPTA, among others. Each of these indicators 
carries benefits and drawbacks; some are single wavelength dyes for easier excitation, 
some are more suitable for microscopy, some are ratiometric for feasible quantification of 
ion concentrations. However, they all generally function by permeating into the cell of 
interest and binding to free calcium ions to produce fluorescent signals. Literature in the 
platelet biology field tends to highlight the use of Fluo-3, Fluo-4, and Fura-2 in studies of 
platelet function. Fluo-3 is one of the most popular single wavelength dyes and has 
sufficient affinity without risk of cytosolic buffering. Fura-2 is a widely used ratiometric dye, 
but requires dual wavelength excitation. However, in this work we will utilize Fluo-4 due to 
its overall similarity to Fluo-3 with brighter and more photostable properties [48]. Lower 
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Figure 2-1. Mechanisms of calcium mobilization in platelets 
Calcium ions are stored in the dense tubular system (DTS) and can transport into the cytosolic 
space upon platelet activation. The generation of IP3 via diverse signaling pathways causes 
outward calcium flux from the internal stores after binding to the IP3 receptor (IP3R). Calcium ions 
can also be transported back into the stores through sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPases (SERCA) or out of the cell via plasma membrane Ca2+ ATPases (PMCA). As the calcium 
concentration in the DTS depletes, a second mechanism called store-operated calcium entry 
(SOCE) is initiated by stromal interaction molecule 1 (Stim1) activation of Orai1 channels on the 
platelet surface. Permeable calcium dyes can be incubated with platelet suspensions to track the 
mobilization of ions over time following stimulation. 
 
Studying calcium signaling in platelets is of interest to several research groups, and 
has been documented in previous reports as well as in our lab over the years. Since 
multiple independent activation events converge upon calcium mobilization, it can be used 
as a single output in high-throughput experiments, and present a great opportunity to apply 
automated technologies in well-plate setups to collect large sets of data. The first evidence 
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of being able to use fluorescent imaging plate readers (FLIPR) with microplate formats to 
study calcium mobilization in platelet samples was provided by Liu et al. [49]. The authors 
employed the Fluo-4 dye and characterized the activation or inhibition potential of a few 
physiologic agents as a proof of principle. A few years later in 2010, our lab presented a 
similar approach but took advantage of the increased capacity of a 384-well plate to unlock 
the ability to observe combinatorial stimulation events [50]. The method is known as 
Pairwise Agonist Scanning and has been used extensively to characterize subject-specific 
platelet function phenotypes, predict increasingly complex stimulation conditions, and 
compare donors or patients based on demographics or clinical states to identify potentially 
hidden trends in hemostatic performance. Though calcium mobilization is certainly a 
reliable metric for measuring the dynamic processes of platelet activation, other methods 
are also traditionally used and should ideally be combined together to generate as 
concrete an understanding of platelet function as possible. 
 
2.2 Flow Cytometry 
Experimentalists are often interested in studying multiple characteristics of cells 
(e.g. size, granularity, receptor expression) simultaneously on a single-cell basis, which 
has led to the development of a technique called flow cytometry. This method is comprised 
of two main components: (1) a fluidic system, which handles dilute cell suspensions and 
orients cells individually through the use of a sheath fluid on either side of the primary 
sample flow path, called hydrodynamic focusing; (2) an optical system, which measures 
light scattering and fluorescence emission as the cells pass through the detection zone in 
a single file fashion [51]. The scattering of light is characterized by both forward and side 
scatter, and provides a representation of the relative size, shape, and other physical 
features of the cell. Fluorescent dyes or biomarkers specific for intracellular or extracellular 
targets of interest are also included in the sample, and are excited by an appropriate laser 
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beam during the data collection process. Many commonly used flow cytometry systems, 
such as the BD Accuri C6, are equipped with as many as four laser configurations to scan 
different wavelengths of transmitted light. A subclass of flow cytometry takes data 
processing a step further by sorting cells based on fluorescent properties, typically referred 
to as fluorescent activated cell sorting (FACS) [51]. Overall, flow cytometry and FACS 
have been used as a high-throughput technique for a variety of applications including 
characterization of cellular processes like apoptosis, expression of soluble regulators like 
cytokines, and phenotyping of blood cell populations. 
Flow cytometry has been used extensively in the hematology community, ranging 
from studies of immune cell markers to blood-related cancers to platelet biology [52]. In 
relation to this work, platelet analysis tends to include both structural and functional 
property assessment. For study of structural features, surface receptor expression and 
overall platelet count can be identified with platelet-bound antibodies to suggest potential 
thrombocytopathies or thrombocytopenias, respectively. Glanzmann thrombasthenia and 
Bernard-Soulier disease are examples of syndromes related to abnormal expression of 
surface glycoproteins important for platelet activation and aggregation, and can be 
detected in this assay by low levels of GPIIb/IIIa or GPIb, respectively [52].  
Markers of platelet activation, as discussed previously, can also be probed in flow 
cytometry [25]. Though GPIIb/IIIa (or integrin αIIbβ3) expression is often identified to 
diagnose or rule out Glanzmann thrombasthenia, the activated form of the molecule is a 
key indicator of outside-in platelet signaling. This active configuration is recognized by the 
PAC-1 monoclonal antibody, originally developed by Shattil et al [53]. P-selectin (CD62P), 
which is expressed on the platelet surface upon activation, is detected with fluorescent 
anti-CD62P antibodies. Phosphatidylserine (PS) exposure to the extracellular surface is 
measured by Annexin V binding to platelets in the presence of calcium, however this 
metric is also indicative of cellular apoptosis. As a result, PS measurements should be 
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conducted in conjunction with other markers to distinguish platelet-specific events. Other 
less common platelet activation markers studied in flow cytometry include platelet-derived 
microparticles (PMPs), platelet-leukocyte aggregates, and the transglutaminase factor XIII 
[25]. Sometimes individual markers are analyzed in simple studies, but the functionality of 
the flow cytometry design permits more complex experiments with multiple activation 
events to be conducted. For example, Jaeger et al. designed an assay with three different 
platelet activation markers in the setting of combinatorial stimulation with an array of 
platelet agonists [54].   
 
2.3 Platelet Aggregometry 
Perhaps a more simplified determination of platelet function is attained through a 
technique known as aggregometry, which was first introduced in the 1960s [55]. The basic 
principles rely on light transmission through a stirred cell suspension, which increases as 
a result of agonist addition [56,57]. Typically, fresh whole blood is split into two aliquots; 
one aliquot is centrifuged at a modest speed to generate platelet-rich plasma (PRP), while 
the other is centrifuged more aggressively to isolate platelet-poor plasma (PPP). The PPP 
sample serves as a reference standard and resembles pure 100% aggregation due to its 
relatively transparent appearance. As the cells in the PRP sample are activated 
exogenously, the transmission increases and approaches that of the PPP control, usually 
quantified on a percent basis [56]. A schematic of the underlying theory for light 
transmission aggregometry (LTA) is shown in Figure 2-2. 
Agonists commonly used for optical aggregometry include collagen, ADP, 
arachidonic acid (AA), epinephrine, and ristocetin. The assay is also often utilized to study 
inhibitory effects of antiplatelet drugs, and to identify dysfunction in surface receptors that 
lead to conditions like von Willebrand disease or Bernard-Soulier syndrome [57]. Certain 
aggregometry-measuring devices, such as Chronolog’s Model 700 aggregometer, are 
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also equipped with luminescence detection. This mode of operation is capable of detecting 
granule release via ATP monitoring with a luminescent tracker [24]. Understanding 
granule performance in conjunction with simultaneous platelet aggregation is important 
because these two concepts are related to each other in the hemostatic process. 
 
 
Figure 2-2. Platelet aggregometry experimental basis   
Whole blood is centrifuged at various speeds to isolate PRP and PPP. The cuvette loaded with 
PRP is also given a magnetic stir bar to agitate the cell suspension before and after agonist 
dispense. The PRP tube is initially cloudy due to dispersity of cells, but after stimulation the clarity 
of the sample increases due to platelet aggregation, allowing more light to pass through the sample. 
The amount of light transmission is compared to the theoretical maximum produced by the control 
PPP cuvette. 
 
Overall, platelet aggregometry has been used as the “gold standard” in studying 
platelet function, but more recently developed techniques are increasing in usage to 
assess activation profiles with more complexity. Additionally, aggregometry lacks in the 
high-throughput category, since only two experimental runs can be performed at the same 
time, and each sample must include hundreds of microliters of pure PRP, which impacts 
the amount of blood initially to be drawn. The calcium mobilization and flow cytometry 
assays described in the previous sections require significantly less whole blood, are 
usually conducted in dilute conditions, and can be run in microtiter well plates, all of which 
increase the quantity of data that can be collected per experiment. In this dissertation, 
24 
 
data attained from aggregometry experiments will be reported, but usually in a 
supplemental fashion to provide support to observations made in other assays.     
 
2.4 Thromboelastography (TEG) 
In clinical settings, rapid testing of hemostatic state is required in order to inform 
decisions regarding treatment options. First developed in the 1940s, thromboelastography 
(TEG) is a method used to evaluate several aspects of hemostasis and effects of different 
blood components on platelet function and coagulation. TEG utilizes principles of 
viscoelasticity to extract information about the strength and stability of thrombi throughout 
the stages of the hemostatic response [58]. The original assay design included a single 
reaction chamber – a whole blood sample would be inserted into a cup and a stationary 
pin capable of tracking movement would be immersed into the sample. The sample 
oscillates back and forth as an activator of the coagulation cascade is added, and the pin’s 
oscillations change over time as influenced by the dynamic clot strength. The resulting 
signal increases as a function of stronger clots and then decreases as the clot begins to 
break down due to shear forces [58]. A depiction of the visual output from a TEG 
experiment is shown in Figure 2-3.  
The graphic below is annotated with various parameters, details for each of which 
along with physiological significance and typical reference ranges are listed in Table 2-1. 
At the beginning of the experiment, a time delay between reagent addition and initial fibrin 
formation will occur, which is termed the reaction time (R). As the clot begins to develop, 
the signal read by the TEG device will increase exponentially and eventually reach an 
inflection point as the clot slows its growth. At this inflection point, the angle between the 
baseline and the generated curve (α-angle), sheds light on the kinetics of clot growth. An 
intermediate time, from the end of the reaction time to a pre-determined level of clot growth 
(e.g. 20 mm), is also recorded as the amplification time (K). The curve then asymptotically 
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approaches an upper limit, signifying the completion of thrombus development, and 
referred to as the maximum amplitude (MA) of the data. While the reaction and 
propagation times are typically indicative of coagulation-related processes, the point of 
maximum clot strength is highly dependent on platelet function and concentration. The 
rotational speed of the reaction chamber persists and imparts shear forces on the clot, 
which causes varying levels of degradation depending on the inherent strength of the clot. 
After 30 minutes have passed since attaining maximum development, the amplitude is 
again recorded and compared to MA to yield the LY30 parameter as a measure of clot 
breakdown via fibrinolysis [58]. The normal values for each parameter shown in Table 2-1 
and the general shape of the curve in Figure 2-3 are often used as reference to identify 
potential disorders in specific aspects of the clotting process or to confirm adequate 
hemostatic performance in an individual. 
 
 
Figure 2-3. Generalized TEG output 
Clot strength as a function of time is plotted during acquisition of TEG data, which generates a 
number of parameters to quantify various stages of hemostasis. The R and K parameters 
respectively represent the time to achieve initial coagulation and time to another stage of 
coagulation, dictated by the alpha angle as the maximum rate of clot formation. The maximum 
amplitude (MA) indicates the point at which the clot is strongest immediately prior to the beginning 
of lysis. After 30 min of lysis, LY30 indicates the degradation of the clot as a fraction of the maximum 




Though the overall principles of the assay have remained constant over the years, 
new designs to increase throughput and decrease required sample volume have been 
developed. Microfluidic technology-based, one-time use cartridges are now commonly 
employed as a plug-and-play method of generating TEG data with a custom analyzer. 
Additionally, different aspects of the coagulation cascade and platelet function can be 
studied using specifically designed cartridges. For example, certain cartridges are pre-
loaded with tissue factor and/or kaolin to simulate the extrinsic and intrinsic pathways, 
respectively, or a platelet mapping alternative (TEG-PM) enables analysis of platelet 
response to ADP stimulation. Unfortunately, the reliability and accuracy of TEG in general 
has become a topic of debate in the medical community [59]. 
 
 
Table 2-1. TEG parameters 
Common TEG parameters that are extracted from data depicted in Figure 2-3 each contribute 
specific information towards understanding the full scope of hemostasis. Reference ranges of 
normal values are often used to determine presence or absence of hemostatic disorders. 
 
TEG is often used by trauma units to guide surgeons and other physicians in the 
attempts to resuscitate injured patients with hemorrhage and other bleeding complications 
[60]. Different from other conventional tests like prothrombin time (PT) or partial 
thromboplastin time (PTT), TEG provides information about the evolution of clot 
development and highlights specific stages of hemostasis that may be under- or over-
performing. Since trauma patients often present with coagulopathic conditions, the best 
course of action is often to initiate massive transfusion protocols (MTP). The ratios of blood 
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products—platelets, plasma, red blood cells, etc—are often fixed and equivalent, but using 
TEG data can improve the recommendations for addressing a given patient [60]. For 
example, a patient may have a long R-time or K-time, indicating a potential coagulation 
factor deficiency that can be treated with additional plasma delivery. Therefore, application 
of TEG can allow for more strategic blood product transfusion that may improve mortality 





CHAPTER 3: SOLUBLE FIBRIN CAUSES AN ACQUIRED 





Thrombin generation within the systemic circulation can drive complex changes in 
blood associated with coagulopathy. During trauma, for example, major changes in blood 
biochemistry occur due to hemorrhagic shock, release of tissue factor (TF) into the 
vasculature, endothelial release of tPA, endothelial glycocalyx shedding, and systemic 
inflammatory events [61–63]. Following trauma, thrombin and plasmin are generated in 
the systemic circulation as indicated by elevated plasma levels of thrombin-antithrombin, 
fibrin degradation products, and activated protein C [33,64–66].   
Soluble fibrin monomer or soluble fibrin in various states of multimerization can 
circulate for several hours [67] and reach levels of 100 nM in trauma-induced 
coagulopathy (TIC) patients [38], 40 nM in Day 0 trauma patients (estimated from 
fibrinopeptide A levels) [68], 90 nM in neck fracture patients [69], 54 nM in sepsis patients 
[70], 42 nM in coronary artery disease patients [71], 30-300 nM in ECMO patients [72], 
and up to 67 nM in post-operative AAA patients [73], all relative to a healthy human 
baseline of ~7.5 nM soluble fibrin monomer [71].  Also, soluble fibrin exceeds 600 nM (50X 
baseline) in the rat model of Noble-Collip drum trauma [74]. 
Platelets obtained from trauma patients can display a hypofunctional phenotype, 
potentially contributing to TIC [28,32]. Platelet dysfunction after trauma has been detected 
by aggregometry [29,33], by thromboelastography [28], and by microfluidic assay of 
platelet deposition on collagen [30]. Interestingly, trauma patients often display no 
significant differences in baseline platelet count or platelet P-selectin levels compared to 
healthy individuals [33].  
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Platelet GPVI is an immunoglobulin superfamily receptor [75] present at about 4000 
copies/platelet [76], corresponding to about 1 nM concentration in platelet-rich plasma 
(PRP). Known GPVI-activating ligands include collagen, collagen-related peptide (CRP), 
and convulxin [77,78], as well as fibronectin [77], vitronectin [78], and laminins [79].  Within 
a forming clot and on fibrin-coated surfaces, insoluble fibrin has recently been described 
as a ligand and agonist of platelet GPVI signaling [75,80]. Platelet GPVI binding to fibrin 
surfaces increases platelet procoagulant activity [75], amplifies collagen-independent 
thrombin generation and platelet recruitment at the clot surface [80], and contributes to 
thrombus growth and stabilization [75,81].  
However, the function of soluble fibrin species on platelets in suspension is less well 
understood, since circulating platelets may eventually encounter a wound site presenting 
various adhesive matrix stimuli such as collagen, vitronectin, and laminin. Fibrinogen can 
be activated to desA and desB soluble fibrin monomer which will immediately bind 
fibrinogen (an assembly also considered, confusingly, as soluble fibrin monomer). 
Additionally, thrombin activity results in assemblies of sub-micron soluble fibrin multimers 
(<50 monomer units) which are easily detectable by light scattering. In diluted apixaban-
treated PRP where added thrombin is consumed without further thrombin generation, 
these dilute, soluble multimeric fibrin species are stable in suspension and never reach a 
concentration to form long fibrin strands, laterally aggregated bundles, or fibrin gels 
(insoluble fibrin). We use the term “soluble fibrin” to refer to sub-micron desA/B fibrin 
multimeric assemblies that may also contain bound fibrinogen. The fibrin polymerization 
inhibitor Gly-Pro-Arg-Pro (GPRP) keeps soluble fibrin monomer from binding fibrinogen or 
assembling into longer multimer units. 
We hypothesized that platelet hypofunction can result from exposure to low levels 
of thrombin and/or thrombin-generated plasma species such as soluble fibrin. Since 
elevated soluble fibrin levels have been implicated in trauma and disseminated 
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intravascular coagulation (DIC) [39,74,82,83], understanding GPVI signaling after soluble 
fibrin exposure has clinical implications. We developed approaches using apixaban-
treated, diluted PRP that allows addition of low-dose thrombin (t1/2~1 minute via inhibition 
by antithrombin) to trigger limited fibrin monomer generation without formation of an 
insoluble fibrin gel for studies of platelet GPVI signaling in the presence of soluble fibrin 
species. 
 
3.2 Materials and Methods 
3.2.1 Platelet calcium assays 
Apixaban and GM6001 (SelleckChem), Fluo-4 NW dye and probenecid 
(Invitrogen), ADP, GPRP, PGE1, apyrase, and Factor Xa (Sigma-Aldrich), convulxin 
(Cayman Chemical), thrombin and human fibrinogen (Haematologic Technologies Inc.), 
PAR-1/4 agonist peptides (Bachem), U46619 (Tocris Bioscience), T101 (Zedira), 
vorapaxar (Ryan Scientific), and GR144053 (R&D Systems) were stored and used 
according to manufacturers’ instructions. Whole blood was drawn by venipuncture from 
healthy donors with University of Pennsylvania Institutional Review Board approval into a 
syringe containing apixaban (final concentration, 250 nM) to prevent Factor Xa-driven 
generation of thrombin. Donors self-reported to be free of any medications or alcohol use 
for three days prior to the blood draw. Female donors self-reported not using oral 
contraceptives. 
Platelet calcium measurements were conducted in 384-well plate assay as 
previously described [84]. Briefly, 2 mL PRP was obtained from whole blood (120g 
centrifugation, 10 min) and incubated with a vial of Fluo-4 NW dye mixture reconstituted 
with 7.8 mL of sterile 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid) buffered saline (HBS, pH 7.4) and 200 µL of 77 mg/mL probenecid for 30 minutes. 
In some experiments, GPRP and/or vorapaxar were added with the calcium dye to give 
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final concentrations of 500 µM and/or 100 nM, respectively. Additionally, a 384-well plate 
containing platelet agonists was assembled, including thrombin, ADP, U46619 (a stable 
thromboxane analog), SFLLRN and AYPGKF (PAR-1 and PAR-4 receptor agonists), as 
well as convulxin (a potent and specific GPVI activator). Dye-loaded PRP was then 
dispensed into a 384-well plate. Both plates were loaded into a FlexStation 3 (Molecular 
Devices, Inc.) fluorescence reader. Agonists were dispensed column-wise to PRP, where 
dynamic fluorescence intensity F(t) was read and normalized by the pre-dispense baseline 
(Fo). For all experiments, 10 µL of agonist was added to 30 µL of PRP in each well, 
followed by a subsequent addition of 10 µL of convulxin at a later specified time. In each 
well, the final concentration of PRP after agonist addition was 12% PRP by volume. The 
fluorescence was read for 20 seconds before first dispense, and readings were taken 
every 2.5 seconds (Ex: 485 nm; Em: 525 nm). In previous tests, there was no evidence 
for autocrine signaling in the dilute PRP conditions of the experiment [84]. In calcium 
experiments using washed platelets instead of PRP, 500 nM human fibrinogen was added. 
In this case, the platelet pellet from 2 mL PRP was resuspended in 1.1 mL of HBS to 
obtain a washed platelet suspension. For calcium assay using type 1 fibrillar collagen 
(Chronolog), PRP was prepared as described, however the small FlexStation automation 
pipettes resulted in variable delivery, thus requiring manual pipetting and assay using a 
FluoroSkan Ascent 384-well plate reader. 
 
3.2.2 Microfluidic assays 
Fluorescent human fibrinogen (Thermo Fisher Scientific, Alexa Fluor® 647 
conjugate) was reacted with thrombin (2.5 nM final concentration) for 5 minutes after a 15-
minute incubation with either 5 mM GPRP or HBS (to prevent or allow fibrin 
polymerization, respectively), after which D-Phenylalanyl-prolyl-arginyl Chloromethyl 
Ketone (PPACK; Haematologic Technologies Inc.) was added (100 µM final 
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concentration) to inhibit thrombin. The mixture was then diluted 10-fold into whole blood 
that had been drawn into PPACK (100 µM) and apixaban (1 µM). Platelets were labeled 
using PE fluorescent anti-CD61 (BD Biosciences). The 8-channel microfluidic device was 
fabricated out of polydimethyl-siloxane (PDMS) (Ellsworth Adhesives) as previously 
described [85]. The device was blocked with 0.5% bovine serum albumin (BSA; Sigma-
Aldrich) for 30 minutes before sample perfusion (each channel: 60 µm high, 250 µm wide). 
Apixaban/PPACK-treated whole blood was perfused through the device using a syringe 
pump (Harvard Apparatus) at a wall shear rate of 200 s-1 over a patterned 250-µm long 
strip of 1 mg/mL fibrillar collagen type 1 (Chronolog). The deposited platelet and fibrin 
fluorescence intensities were recorded every minute for 6 minutes. 
 
3.3 Results 
3.3.1 Thrombin stimulation, but not ADP or U46619, attenuated subsequent platelet 
GPVI signaling 
Addition of thrombin (1-10 nM) to diluted apixaban-treated PRP caused a dose-
dependent calcium mobilization (Figure 3-1,A). Pretreatment with thrombin, however, 
resulted in a marked inhibition of calcium mobilization when 20 nM convulxin was added 
480 seconds after thrombin (Figure 3-1,A). In the absence of thrombin pretreatment, 
convulxin drives a massive and sustained calcium mobilization lasting over 700 seconds 
in the measurement. Dasatinib, a Syk inhibitor, blocked convulxin-induced GPVI signaling 
with minimal effect on Gαq agonists of calcium mobilization (via thrombin, U46619, and 
ADP), thus confirming that convulxin is activating GPVI with concomitant calcium 
mobilization dependent on Syk signaling (Supplemental Figure 1). Even the lowest dose 
of thrombin (1 nM), which caused minimal calcium mobilization, had significant inhibitory 
effect on GPVI activation by convulxin. However, convulxin-insensitivity was not observed 
when ADP or U46619 were added instead of thrombin (Figure 3-1,B-C) even though both 
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agonists caused dose-dependent calcium mobilizations similar to that evoked by thrombin 
treatment.  
When ADP was added instead of thrombin, a very low dose of ADP (10 nM) did 
not affect subsequent calcium response to convulxin compared to the control condition 
(Figure 3-1,B). Low to medium doses of ADP (100 nM-1 μM) slightly increased 
subsequent calcium response to convulxin. A high dose of ADP (10 μM) resulted in a 
detectable reduction in subsequent final platelet calcium response to convulxin, but not 
nearly to the extent seen in the case of thrombin. When U46619 was used as the first 
stimulus, very low to medium doses of U46619 (10 nM-1 μM) did not affect subsequent 
calcium response to convulxin compared to the control condition (Figure 3-1,C). Similarly, 
as seen in the case of ADP, a high dose of U46619 (10 μM) resulted in a detectable 
reduction in subsequent final platelet calcium response to convulxin, but not nearly to the 
extent caused by any dose of thrombin. In a related experiment, thrombin treatment of 
apixaban-treated PRP caused a marked loss in platelet sensitivity to CRP (Supplemental 
Figure 2), although 25 g/mL CRP was not as potent as 20 nM convulxin in activating 
platelet GPVI. Type I fibrillar collagen (20 µg/mL) was tested as a platelet agonist instead 
of convulxin. In this unstirred reaction, the platelet calcium response to collagen alone was 
slower than that observed with convulxin alone. As seen with convulxin and CRP, 
pretreatment of the PRP with thrombin (2-10 nM) resulted in a complete insensitivity to 





Figure 3-1. Thrombin but not ADP or U46619 blocks subsequent platelet GPVI activation by 
convulxin 
(A) Platelet activation by thrombin for 480 seconds causes a significant reduction in subsequent 
convulxin-induced calcium response. This effect was apparent for doses of thrombin (1 – 10 nM) 
treatment of diluted (12%), apixaban-treated PRP. (B) Platelet activation by ADP does not 
significantly attenuate subsequent convulxin-induced calcium response. (C) Platelet activation by 
the thromboxane analog, U46619, did not significantly attenuate subsequent convulxin-induced 




Figure 3-2. Thrombin treatment of platelets blocks subsequent activation via fibrillar 
collagen when measuring calcium mobilization 
Various doses of thrombin (A: 10 nM; B: 5 nM; C: 2 nM) prevent further downstream platelet 
activation via collagen (Chrono-log; 10 µg/mL), fully consistent with the previous findings using 
convulxin. Additionally, collagen and convulxin show significantly different kinetic profiles of GPVI 
signaling which can be attributed to the molecular composition of each species. Collagen, a larger 
and more fibrillar molecule, activates GPVI in a slower but more sustained manner, while convulxin 
elicits a rapid and transient response. 
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3.3.2 Thrombin-induced GPVI signaling defect was time dependent 
Convulxin (20 nM) was added to PRP at varying times after thrombin addition (1-
2 nM). When convulxin was added after low-dose thrombin (1 nM) incubation times of 150, 
210, and 335 seconds, the calcium signal in response to convulxin was comparable to the 
control condition in which PRP was not first activated by thrombin (Figure 3-3,A). 
However, when the incubation time with 1 nM thrombin increased to 480 seconds, 
subsequent calcium responses to convulxin decreased significantly. When a slightly 
higher dose of thrombin (2 nM) was first added to PRP, subsequent calcium responses to 
convulxin were not attenuated until incubation times increased to 210 seconds or higher 
(Figure 3-3,B). The onset time of convulxin-insensitivity depended on thrombin dose 
(Figure 3-3,C). In comparing peak calcium response to convulxin (no thrombin 
pretreatment) with that obtained with prior thrombin treatment, an incubation with 2 nM 
thrombin for 220 seconds or incubation with 1 nM thrombin for 500 seconds led to a 
marked 80% reduction in convulxin-triggered GPVI signaling. 
 
3.3.3 Activating PAR-1 and PAR-4 does not attenuate GPVI signaling     
Thrombin signals through Gq-linked PAR-1 and PAR-4 receptors in human 
platelets, but when PAR-1 and PAR-4 agonists (SFLLRN and AYPGKF) were added to 
PRP (instead of active thrombin), the subsequent platelet calcium response to convulxin 
was unaffected compared to the control condition (Figure 3-4,A). In combination with the 
observations with ADP and U46619, this result indicated that thrombin activity played a 
unique role other than through Gq-dependent signaling through PAR-1/4. When 
vorapaxar, a PAR-1 specific inhibitor was added, calcium signaling in response to 10 nM 
thrombin was fully blocked (Figure 3-4,B). However, when thrombin was added to PRP 
incubated with vorapaxar, the lack of thrombin-induced calcium mobilization had no effect 
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on the subsequent thrombin-dependent GPVI-signaling defect when convulxin was added 
(Figure 3-4,C). In separate calcium mobilization experiments using PAR-1 and PAR-4 
activating peptides, vorapaxar was found to be a PAR-1 selective inhibitor (Supplemental 
Figure 3), as expected. 
 
 
Figure 3-3. Effect of thrombin dose and exposure time to drive convulxin-insensitivity 
(A) When platelets were treated with low dose thrombin (1 nM), the reduction of convulxin-
sensitivity was time-dependent with strong onset detected between 335 and 480 sec of thrombin 
incubation. (B) When platelets were activated by a slightly higher thrombin dose (2 nM), thrombin-
induced convulxin-insensitivity was detected after 200 sec of thrombin incubation. (C) Sensitivity to 
convulxin decreased with thrombin incubation time (data fitted with a Hill function) with more rapid 




Figure 3-4. Attenuation of convulxin sensitivity was not observed by pretreatment with PAR-
1 and PAR-4 agonist peptides 
(A) Despite calcium mobilization through PAR-1 and PAR-4, platelet activation by PAR-1 and PAR-
4 specific agonist peptides (SFLLRN and AYPGKF) did not reduce subsequent convulxin-
insensitivity, as was observed with thrombin. (B) Vorapaxar, a PAR-1 antagonist, blocked thrombin-
induced calcium signaling. (C) The convulxin-insensitivity after thrombin treatment was still 
apparent in the presence of vorapaxar. (PAR-1=SFLLRN activation peptide; PAR-4=AYPGKF 
activation peptide; V, vorapaxar; T, thrombin; C, convulxin). 
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3.3.4 Soluble fibrin caused convulxin insensitivity independent of receptor shedding or 
fibrin binding to αIIbβ3 
The results shown in the previous figures are fully consistent with thrombin acting 
on a plasma element to attenuate platelet sensitivity to GPVI agonists. This was confirmed 
in an assay comparing the effect of thrombin pretreatment of washed platelets versus 
PRP. Thrombin pretreatment of washed platelets caused substantial calcium mobilization, 
but had little effect on the GPVI response to convulxin (Supplemental Figure 4), 
confirming the role of thrombin on a plasma component. We next tested the ability of 
GPRP to block soluble fibrin multimerization and rescue GPVI function in the presence of 
active thrombin. When thrombin was first added to PRP incubated with GPRP, subsequent 
calcium response to convulxin was completely normal when compared to the control 
condition where no thrombin was first added (Figure 3-5,A). This demonstrated that 
soluble fibrin assembly was essential for the thrombin-induced ablation of platelet 
sensitivity to convulxin. GPRP rescued GPVI sensitivity to convulxin for thrombin 
pretreatment concentrations ranging from 2-20 nM (Supplemental Figure 5). Unlike 
thrombin, the P2Y1/P2Y12 agonist ADP does not induce polymerization of fibrinogen into 
fibrin. Therefore, as expected, when the experiment in Figure 3-5,A was repeated with 
ADP instead of thrombin, GPRP had no effect on the subsequent calcium response to 
convulxin (Figure 3-5,B). Notably, in the calcium responses to thrombin alone, the calcium 
signal displayed an upward trend, consistent with soluble fibrin acting as a weak GPVI 
activator [75]. However, in cases with GPRP present, the thrombin-induced calcium 
mobilization was transient and eventually returned to baseline (Figure 3-5,C).  
Since fibrin assembly was required for convulxin insensitivity, we tested if FXIIIa 
activity played a role in thrombin-induced GPVI attenuation. Interestingly, the FXIIIa 
inhibitor T101 had little effect on platelet response to thrombin, but caused a marked 
reduction in the thrombin-induced convulxin insensitivity (Figure 3-6,A-B). Additionally, 
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T101 alone had little effect on the convulxin response of platelets without thrombin 
pretreatment. T101 was unable to overcome the attenuation of GPVI at the highest 
thrombin concentration tested (20 nM).  
Since GPVI activators like CRP (as well as thrombin) can cause GPVI dimerization 
[86,87] and shedding by metalloproteases such as a-disintegrin-and-metalloproteinase 10 
(ADAM10), we tested the role of shedding in thrombin-induced GPVI-signaling deficiency. 
Treatment of PRP with the metalloprotease inhibitor GM6001 had little effect on the ability 
of thrombin to attenuate platelet response to convulxin (Figure 3-6,C). GPRP maintained 
its ability to prevent thrombin-induced convulxin-insensitivity in the presence of GM6001. 
Use of the αIIbβ3 inhibitor, GR144053, inhibited fibrinogen-dependent platelet 
aggregation (via aggregometry) as expected, however GR144053 did not alter the 
thrombin-mediated attenuation of convulxin-induced signaling (Supplemental Figure 6). 
This finding eliminates the potential role of fibrin(ogen)-driven integrin αIIbβ3 outside-in 
signaling in the observed deficiency in response to GPVI agonists. These results indicate 
that GPVI shedding and αIIbβ3-mediated fibrin binding were not the cause of convulxin-
insensitivity in the presence of soluble fibrin, even when soluble fibrin served as a relatively 
weak agonist for platelet GPVI. When soluble fibrin is formed in the presence of vorapaxar 
(to prevent thrombin activation), there is little change in calcium signal (Figure 3-4,C), 
indicating that the generation of soluble fibrin is not strongly activating in this system. Still, 
in this experiment with vorapaxar present, a marked convulxin insensitivity was observed 






Figure 3-5. Inhibition of fibrin polymerization with GPRP prevents thrombin-induced 
convulxin-insensitivity 
(A) The thrombin-induced attenuation of platelet calcium GPVI signaling was not observed when 
GPRP was present. (B) Because platelet activation by ADP does not cause fibrinogen to 
polymerize into fibrin, GPRP has no effect on subsequent convulxin response. (C) Following 
thrombin stimulation of platelets, fibrin results in a sustained calcium mobilization that returned to 




Figure 3-6. Inhibition of cross-linking enzyme FXIIIa with T101 results in significant 
restoration of platelet GPVI activity and inhibition of ADAM10 shows no effect of GPVI 
shedding 
(A) Calcium dye-loaded platelets were incubated with 1 mM T101 for 10 minutes prior to activation 
with thrombin (2-20 nM). In the presence of the FXIIIa inhibitor, fibrin still polymerizes but cannot 
cross-link to form the traditional mesh network which is crucial for clot stabilization. The plot shows 
the effect of T101 towards greatly restoring convulxin-induced platelet activation. (B) Platelet GPVI 
exhibits a marked increase in sensitivity, especially at intermediate concentrations of thrombin (n=4 
donors, * p<0.05). (C) Thrombin-induced convulxin-insensitivity does not require GPVI shedding. 
Activation of platelets by thrombin resulted in attenuation of subsequent convulxin-induced calcium 
mobilization even in the presence of GM6001, which blocks GPVI shedding. When GPRP was 
present to block fibrin polymerization, thrombin treatment had no effect convulxin sensitivity, even 
in the presence of GM6001 which blocks GPVI shedding.   
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3.3.5 Thrombin treatment of washed platelets in purified fibrinogen displays convulxin 
insensitivity 
Since thrombin can act on numerous proteins in plasma, washed platelets were 
placed in a buffer containing purified fibrinogen to explore the role of soluble fibrin 
generation. Distinct from PRP, this buffer does not contain plasma antithrombin or FXIII. 
The washed platelets were incubated with human fibrinogen (500 nM) with and without 
GPRP for 10 minutes before the assay (Figure 3-7,A). Exposure for 480 seconds of the 
washed platelets in purified fibrinogen to a low dose of thrombin (1 nM) caused a marked 
attenuation of the subsequent convulxin response (Figure 3-7,B). Similar to the PRP 
experiments, GPRP prevented the thrombin-dependent signaling defect in response to 
convulxin. Soluble fibrin assemblies reached a size of 1.095±0.347 µm after 10 min of 
thrombin-fibrinogen reaction, as detected by light scattering (Supplemental Figure 7).  
 
3.3.6 Soluble fibrin reduces platelet deposition to collagen under flow 
Fluorescent fibrinogen (0.788 mg/mL) was incubated in either 5 mM GPRP or HBS 
(control condition) for 10 min. Following incubation, 2.5 nM thrombin was added to 
generate either soluble fibrin monomer (GPRP present) or soluble fibrin polymer (HBS 
control). After 300 seconds, thrombin activity was inhibited with 100 µM PPACK. The 
resulting solutions were diluted by a factor of 10 in PPACK/apixaban-treated whole blood 
(treated to prevent endogenous thrombin production or thrombin activity). Platelet 
deposition from whole blood with 230 nM soluble fibrin monomer (GPRP condition) or 230 
nM soluble fibrin polymer (HBS control condition), nominal concentrations assuming 100% 
fibrinopeptide release by thrombin, was then tested on collagen at a wall shear rate of 200 





Figure 3-7. Thrombin activation of washed platelets in purified fibrinogen reduced 
subsequent activation by convulxin, an effect blocked by GPRP 
(A) Schematic of experimental protocol. (B) In a washed platelet and fibrinogen (500 nM) mixture, 
low dose of thrombin (1 nM) at 480 seconds incubation time significantly attenuated subsequent 
convulxin response. 
 
As expected, 5 mM GPRP substantially blocked the amount of fibrin that co-
deposited with the platelets (Figure 3-8,C-E). This indicated that ~8000 nM fibrinogen in 
whole blood outcompeted 230 nM fibrin monomer for platelet binding. In contrast, 230 nM 
soluble fibrin polymer added to whole blood co-deposited with platelets, even in the 
presence of normal levels of fibrinogen. When GPRP is present, there still appears to be 
a small amount of fibrin detected by fluorescence, which can be attributed to platelet-
bound fibrinogen or soluble fibrin monomer. Consistent with a defect in collagen-induced 
platelet activation via GPVI, the presence of soluble fibrin polymer (HBS control condition) 
caused a substantial reduction of platelet deposition on collagen (Figure 3-8,B-E), 
especially after ~100 seconds when ADP and thromboxane release are especially 




Figure 3-8. Under thrombin-free conditions, presence of soluble fibrin in whole blood 
reduces platelet adhesion on collagen under flow 
(A) Schematic of experimental protocol. Fluorescent fibrinogen was exposed to 2.5 nM thrombin 
with either 5 mM GPRP (inhibit fibrin formation) or HBS (control). After 300 s, the thrombin was 
quenched with 100 μM PPACK. This reacted fibrinogen/fibrin solution was diluted by a factor of 10 
into PPACK/apixaban-inhibited whole blood with either 5 mM GPRP or HBS and then perfused 
through an 8-channel microfluidic device at 200 s-1 over a collagen surface. (B) GPRP increased 
platelet deposition on the collagen surface after 60 s. (C) Fibrin co-deposition with platelets was 
significantly decreased with 5 mM GPRP. (D) At 120 s, soluble fibrin monomer (GPRP present) 
resulted in more platelet deposition to collagen, while soluble fibrin polymer (no GPRP) resulted in 
less platelet adhesion to collagen. (E) At 240 s, platelet deposition and aggregation on collagen 





In coagulopathic blood, low levels of thrombin in the systemic circulation may 
generate soluble fibrin monomers and small submicron-scale soluble protofibrils (<10-50 
monomers) that never reach the point of gelation. Several lines of evidence are presented 
that soluble fibrin, not thrombin cleavage of PARs, was the cause of GPVI-signaling 
deficiency in response to convulxin, CRP, and collagen. PAR-1 and PAR-4 activating 
peptides that trigger calcium mobilization had no effect on convulxin response. Vorapaxar, 
which blocked thrombin-induced calcium signaling, had no effect on thrombin-mediated 
convulxin-insensitivity. Agonists such as ADP and U46619, which similarly trigger 
signaling through Gq-coupled receptors, were not able to alter subsequent convulxin 
sensitivity. Importantly, GPRP blocked the ability of thrombin to attenuate platelet 
sensitivity to convulxin.  Also, the time of thrombin exposure and kinetics of onset were 
consistent with fibrin monomer generation and soluble fibrin multimerization. Thrombin 
treatment of washed platelets did not induce convulxin-insensitivity, unless platelets were 
supplemented with purified fibrinogen. Both the calcium mobilization assay with fibrillar 
collagen (Figure 3-2) and microfluidic platelet deposition from flowing whole blood on 
collagen-coated surfaces (Figure 3-8) indicated that exposure of plasma to thrombin 
drives an attenuation of platelet GPVI signaling in response to collagen. 
To test the findings under non-dilute PRP conditions, we used aggregometry to 
generate soluble fibrin under non-static conditions and challenge GPVI through addition 
of convulxin.  The results were consistent with those observed in the calcium mobilization 
experiments: a low dose of thrombin with stirring (1200 rpm) permitted fibrin 
polymerization and subsequent addition of GPVI agonists shows a significant (~35%) 
reduction in aggregation compared to the control, a result which is completely reversed 
with GPRP (Supplemental Figure 8). Platelet aggregation in PRP and platelet deposition 
from whole blood in a microfluidic device were reduced by a similar amount when fibrin 
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was allowed to polymerize, an effect reversed by GPRP. Given the multimeric nature of 
most GPVI activators, it was not unexpected that fibrin monomer which exists in the 
presence of GPRP was insufficient to block GPVI activation. 
GPVI-deficiency is extremely rare and not linked to a strong bleeding phenotype in 
healthy individuals. However, GPVI-deficient patients can display spontaneous bleeds 
[89]. The potential risk of genotypic GPVI-deficiency in combination with trauma is 
unknown. Importantly, a combined deficiency in mouse platelet PAR-4 and GPVI causes 
a severe bleeding phenotype in the tail bleed assay [90]. A level of only 1% conversion of 
fibrinogen (90 nM soluble fibrin) would be sufficient to overwhelm platelet GPVI which 
exists at ~1 nM in PRP, as the avidity of binding between polyvalent soluble fibrin and 
clustering receptors on platelets may be much stronger relative to the Kd of the monovalent 
affinity involving soluble forms of ligand and receptor. Since soluble fibrin can circulate 
without rapid clearance and GPVI signaling through fibrin is fairly weak compared to that 
driven by collagen, platelet hypofunction of endogenous or transfused platelets may be a 
cofactor in certain coagulopathies.    
We are much obliged to highlight recent work demonstrating platelet GPVI as a 
receptor for fibrin, which was also found to bind to a distinct configuration of GPVI [91]. In 
that study, sonicated crosslinked fibrin (but not D-dimer) caused <10% washed platelet 
aggregation over 6 min, while 30 µg/mL D-dimer substantially inhibited platelet 
aggregation by subsequent challenge by 0.1-0.3 µg/mL collagen (but interestingly not 
higher doses of collagen). As noted in [91], an agent that selectively blocks the interaction 
of fibrin but not collagen with GPVI has the potential as antithrombotic therapy with 
reduced bleeding risk. Such an agent might hypothetically also protect circulating platelet 
function in trauma patients with circulating levels of soluble fibrin polymer and lytic 
assemblies of D-dimer. 
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Our results and prior studies of fibrin activation of GPVI during thrombosis [75,80] 
are not particularly discordant on close examination. To mimic systemic blood changes 
and subsequent local hemostatic response, we challenge GPVI with a subsequent agonist 
after pre-exposure to soluble fibrin. In studies of thrombus generation at a wound site, 
there is no additional GPVI ligand added to the assay other than the original fibrin 
generated in the clot [75,80]. Also, there is no reason to expect sub-micron soluble fibrin 
multimers bound to a platelet in suspension to induce the same signaling as a spread 
platelet experiencing large expanses of solid-phase fibrin gel. Since platelets (and many 
other cell types) can sense the rigidity of their adhesive-mechanical environment [92], we 
suggest that platelet signaling on solid fibrin presented on glass/plastic or in a clot may be 
different from platelets in suspension interacting with soluble fibrin. We also observed that 
soluble fibrin multimers induce a weak signal in our assay that was blocked by GPRP 
(Figure 3-5,C). 
We found GPVI attenuation occurred acutely at ~200 seconds with 2 nM thrombin 
treatment (Figure 3-3,B-C) and was not blocked by a metalloprotease inhibitor (Figure 
3-6,C). This timescale of GPVI attenuation and the potency of GPRP to block convulxin-
insensitivity was fully consistent with the known dynamics of fibrin polymerization, which 
typically requires <5-10 minutes. Several prior studies have demonstrated minimal soluble 
GPVI release over 60 min exposure of PRP to tissue factor (200 nM peak thrombin) or to 
thrombin (1 U/ml), both of which generate fibrin in PRP [93,94]. Thrombin alone does not 
release soluble GPVI from washed platelets [95], fully consistent with an absence of 
convulxin-insensitivity following strong thrombin stimulation of washed platelets 
(Supplemental Figure 4).  Even strong agonists like collagen, convulxin, or Factor Xa 
typically require 60 min for full release of soluble GPVI. The exposure of washed platelets 
to one of the most potent inducers of shedding, Factor Xa, did not phenocopy the kinetics 
or severity of GPVI-signaling defects (Supplemental Figure 9) that we observed with 
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soluble fibrin generation. Thus, the observed rapid and acute attenuation of convulxin-
sensitivity is highly unlikely to be caused by fibrin-induced GPVI shedding, which is also 
fully consistent with the lack of effect of GM6001 (Figure 3-6,C). GM6001 is a known 
inhibitor of ADAM-mediated GPVI shedding [93–96]. Platelet GPVI shedding is regulated 
primarily by ADAM10 [97], and may also be facilitated by other members of the a-
disintegrin-and-metalloproteinase family (such as ADAM17) [34]. The GM6001 result 
supports the conclusion that soluble fibrin polymer blocks other more potent ligands from 
binding GPVI, an effect not requiring GPVI shedding. Since fibrin in clots is known to bind 
GPVI, soluble fibrin is likely serving as a receptor antagonist to sterically block other 
ligands from binding. The observed data do not prove mechanism, but are most consistent 
with (1) steric hindrance of GPVI by soluble fibrin species bound to the receptor and/or (2) 
soluble fibrin-triggered GPVI signaling that desensitizes the receptor. The observations 
were not consistent with GPVI shedding, Gαq-dependent GPVI attenuation, or αIIbβ3-
mediated GPVI attenuation as mechanisms of the observed phenotype.   
Distinct from the role of intrathrombus generation of fibrin, low levels of non-gelling, 
soluble fibrin may function differently in the context of trauma to cause an acquired GPVI-
signaling defect in the systemic circulation. Generation of low and transient levels of 
thrombin in coagulopathic blood may generate circulating soluble fibrin able to bind 
platelet GPVI to cause platelet insensitivity to stronger GPVI agonists such as collagen. 
Soluble fibrin is a long-lived species once it is generated, so platelet transfusion therapies 
for high-risk trauma patients may become affected by these pre-existing species in the 
systemic circulation. If transfused platelets display an acquired deficiency in GPVI-
signaling in trauma patients with elevated soluble fibrin, the extraordinary hemostatic 




CHAPTER 4: PLATELET DYSFUNCTION DURING TRAUMA 
INVOLVES DIVERSE SIGNALING PATHWAYS AND AN 




Traumatic injuries are one of the most common causes of death in the United States 
and abroad, accounting for about 10% of fatalities worldwide [10]. Trauma is well 
recognized as the leading cause of death for younger populations (persons aged 30-40) 
[10,61]. Upon admission to trauma centers for a wide range of mechanisms of injury (MOI), 
approximately 25% of patients will present with a condition known as trauma-induced 
coagulopathy (TIC) [10,31], a complex clinical state highlighted by impaired activity of 
important blood clotting proteins, excessive fibrinolysis, and significant platelet dysfunction 
[10]. The intersection of these phenomena tends to lead to a coagulopathic bleeding 
phenotype which becomes difficult to treat and increases the chance of mortality by more 
than 4-fold [64].  
Several events may combine to drive TIC. For example, perturbation of the 
endothelium during a response to a traumatic episode can lead to generation of activated 
protein C (APC) and glycocalyx shedding, both of which serve anticoagulant and 
profibrinolytic roles [10]. Other biochemical changes also occur in concert with 
hemorrhagic shock, including release of tissue factor (TF) and tissue plasminogen 
activator (tPA), which lead to thrombin and plasmin generation in the circulation [36,61,98]. 
The coinciding coagulant and lytic processes are responsible for elevated levels of soluble 
fibrin species, which have traditionally been quantified by plasma levels of fibrin 
degradation products such as D-dimer [38–40,68]. However, the full extent and 
mechanisms of acquired platelet dysfunction remain poorly understood.      
Platelet dysfunction in trauma patients has been reported in several studies through 
the use of traditional assays like aggregometry, thromboelastography (TEG), and 
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microfludics [28–30,33]. Key findings include decreased aggregation responses to an 
array of platelet agonists in about half of the tested subjects [29], 80% inhibition of ADP-
induced platelet function [28], and defects in deposition to collagen under flow in two-thirds 
of the patient cohort [30]. The concept of an “exhausted” platelet arises from initial 
hyperstimulation in response to tissue damage and eventual tiring of the cell as it 
continues in circulation [28]. Proteolysis or internalization of platelet receptors, including 
glycoproteins VI (GPVI) or Ib (GP1b), might also play a role in downregulation of platelet 
function [34]. Soluble fibrin has been shown to cause a signaling defect in GPVI [99], 
possibly contributing to impaired initial platelet adhesion to exposed collagen at the site of 
vascular injury if platelets interact with circulating fibrin species prior to encountering a 
wound site in need of hemostatic response.      
Studies of platelets from trauma patients have typically only used one or two major 
agonists. With technologies for high dimensional phenotyping of calcium signaling 
pathways [50,84,100], building patient-specific phenotypic profiles of blood cell function 
may provide more information for treatment decisions. This work focuses on assessing 
platelet function in trauma patients using a high-throughput technique to interrogate up to 
six platelet signaling pathways via combinatorial stimulation of surface receptors and using 
intracellular calcium mobilization as a dynamic readout. Additionally, we investigated 
platelet dysfunction during trauma by examining the effects of trauma patient plasma on 
healthy platelets. By all metrics, platelets from trauma patients frequently display a defect 








4.2 Materials and Methods 
4.2.1 Reagents 
Apixaban (SelleckChem, Houston, TX, USA), D-phenylalanyl-prolyl-arginyl 
chloromethylketone (PPACK; Essex Junction, VT, USA), adenosine 5’-diphosphate 
sodium salt (ADP), prostaglandin E1 (PGE1), citrate concentrated solution, and apyrase 
(Sigma-Aldrich, St. Louis, MO, USA),  the GPVI agonist convulxin (Cayman Chemical, 
Ann Arbor, MI, USA), the TP agonist U46619, the IP agonist iloprost (Tocris Bioscience, 
Bristol, UK), the PAR4 agonist peptide H-Ala-Tyr-Pro-Gly-Lys-Phe-NH2 trifluoroacetate 
salt (AYPGKF) and the PAR1 agonist peptide H-Ser-Phe-Leu-Leu-Arg-Asn-OH 
trifluoroacetate salt (SFLLRN) (Bachem, Torrance, CA, USA), Fluo-4 NW calcium dye and 
probenecid (Invitrogen, Carlsbad, CA, USA), and FITC mouse anti-human PAC-1, PE 
mouse anti-human CD62P, and Cy5 Annexin V fluorescent antibodies (BD Biosciences, 
San Jose, CA, USA) were used and stored according to manufacturers’ instructions. 
HEPES-buffered saline (HBS, pH 7.4) was prepared with 20 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES, Fisher Scientific, Fair Lawn, 
NJ, USA) and 150 mM NaCl (Fisher); Tyrode’s buffer (pH 7.4) was prepared with 10 mM 
HEPES, 127.2 mM NaCl, 11.9 mM NaHCO3 (Fisher), 5 mM KCl (Fisher), 0.4 mM NaH2PO4 
(Fisher), 1 mM MgCl2 · 6 H2O (Sigma), and 5 mM D-glucose (Sigma). Where specified, 
Ca2+ HBS was prepared by dissolving CaCl2 · 2 H2O in HBS to achieve a calcium 
concentation of 2 mM. 
 
4.2.2 Study design 
Under Institutional Review Board approval, blood was obtained from trauma 
patients (n=16) who had been admitted to the Penn Presbyterian Medical Center Level 1 
Trauma Center following a severe injury. Patients who are 18-years-old or older, present 
as a trauma alert, and are admitted to the Trauma and Surgical Intensive Care Unit 
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(TSICU) were eligible for the study. Upon arrival to the trauma bay, a research blood 
sample (15 mL) and clinical data were collected by Penn Acute Research Collaboration 
(PARC) research staff. The legal authorized representative and/or patient is consented 
once available and after being debriefed by the clinical care team. Descriptions of patient 
demographics and clinical presentations are outlined in Table 4-1. 
 
 
Table 4-1. Summary of patient demographics and clinical presentations 
Data were collected for 16 enrolled trauma patients to Penn Presbyterian Medical Center’s Trauma-
Induced Coagulopathy and Inflammation (TrICI) study. Patient ages were distributed over a wide 
range (median=31.5, IQR=32.0), and gender distribution was 14 males (87.5%) and 2 females 
(12.5%). Patients presented with a variety of injuries, though the mechanisms were limited to gun 
shot wounds, stab wounds, motor vehicle crashes, and falls. Injury severity scores (ISS) were 
calculated as a measure of the extent of trauma (median=24.5, IQR=15.0), where ISS>15 




For each enrolled patient, blood samples were taken at specific time points (0, 3, 
6, 12, 24, 48, and 120 h) after initial admission. Several aliquots with specific 
anticoagulants were prepared for various clinical tests according to the previously 
established protocol; one such tube pre-loaded with apixaban (1.25 µM, final 
concentration) and PPACK (100 µM, final concentration) was prepared for the studies in 
this paper. Collecting blood (2 mL) into two anticoagulants ensured inhibition of factor Xa-
mediated thrombin generation and thrombin activity, respectively. The sample was split 
into two microcentrifuge tubes to isolate platelet-rich plasma (PRP) for immediate platelet 
function studies and platelet-poor plasma (PPP) to be frozen for future analysis. In addition 
to the patient cohort, a set of healthy donors (n=11) was recruited to donate blood 
according to University of Pennsylvania Institutional Review Board approval. Donors self-
reported to being free of any medication or alcohol use for 3 days leading up to the blood 
draw. Additionally, female donors self-reported to not using oral contraceptives. 
 
4.2.3 Intracellular calcium mobilization assays 
Platelet calcium measurements were conducted using a 384-well plate format as 
previously described [99]. Briefly, PRP was prepared via centrifugation of whole blood 
(120g, 10 min) and incubated with Fluo-4 NW calcium dye for 30 min. The dye was 
reconstituted with 5 mL HBS and 200 µL probenecid (77 mg/mL) to prevent dye leakage 
from cells during incubation. One 384-well plate was filled with dilute, dye-loaded PRP 
(12% final concentration after agonist dispense), while a second plate was prepared with 
platelet agonists at specified concentrations. Using the pairwise agonist scanning (PAS) 
method as motivation [50,84], an array of combinatorial stimuli (platelet 
agonists/antagonists) was used to develop subject-specific phenotypic profiles of platelet 
activity. As reported previously, PAS involves exposing dilute PRP to all single and 
pairwise combinations of up to six stimuli at low, medium, and high concentrations, 
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resulting in 154 unique conditions. In order to complete two replicates/condition, ~15-20 
mL of whole blood is required to isolate the necessary amount of PRP. However, due to 
volume constraints in the protocol (2 mL whole blood per patient sample), the 
combinatorial space was restricted to 31 unique conditions – single combinations of five 
agonists (ADP, EC50=1µM;  U46619, EC50=1µM; convulxin, EC50=2nM; SFLLRN, 
EC50=10µM; and AYPGKF, EC50=300µM) at three dosage levels each (0.1x, 1x, 10xEC50), 
and pairwise combinations of the same five agonists as well as one antagonist (iloprost, 
EC50=0.2µM) with each component present at a medium dose (1xEC50) (Supplemental 
Figure 10). Validation of this restricted combinatorial space was performed by training 
neural networks on data acquired from the smaller set of conditions and using the models 
to predict the responses for the full 154 conditions. A relatively reliable correlation 
(R=0.8125) was observed between the measured and predicted data sets after 10 neural 
networks per donor (80 total) were averaged together (Supplemental Figure 11). The 
two well plates were then inserted into a FlexStation 3 automated plate reader (Molecular 
Devices, Sunnyvale, CA, USA) and liquid handling functions were used to dispense 20 µL 
of agonist(s) directly into each well of 30 µL PRP. The fluorescence of the plate was read 
column-wise (Ex: 485 nm; Em: 525 nm) for 20 s prior to dispense and then for an additional 
4 min; the dynamic signal F(t) was also normalized to the pre-dispense baseline Fo. As a 
metric of each platelet sample, the amount of calcium mobilized for all stimuli can be 
calculated as the Total Platelet Calcium Mobilization (TPCM) by Equation (1): 
 
 𝑇𝑜𝑡𝑎𝑙 𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡 𝐶𝑎𝑙𝑐𝑖𝑢𝑚 𝑀𝑜𝑏𝑖𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 = ∑ (𝐶𝑎








4.2.4 Flow cytometry assays 
Monitoring platelet activation via flow cytometry was conducted as documented 
previously [54]. In short, PRP was isolated as described above and diluted to 10% v/v with 
Ca2+ HBS. In each test tube, 10 µL dilute PRP was added to 74 µL Ca2+ HBS and 2 µL 
each of three fluorescently-labeled antibodies (FITC anti-PAC-1 for α2bβ3 activation, PE 
anti-CD62P for P-selectin expression, and Cy5 Annexin V for PS exposure). Prior to 
analysis, 10 µL of platelet agonists were added to the tubes and allowed to incubate in the 
dark for 10 min. Each sample was analyzed using an Accuri C6 Plus flow cytometer (BD 
Biosciences, San Jose, CA, USA), setting the flow rate to low (14 µL/min, 10 µm core) and 
reading for 60 s. Data were collected and reported as mean fluorescence intensity (MFI) 
for activated α2bβ3 and P-selectin, or % PS-positive cells as determined by pre-set gating 
techniques.  
 
4.2.5 Washed platelet preparation for plasma reconstitution experiments 
Plasma samples were collected from healthy/patient whole blood and stored at -
80°C for future analysis. Healthy washed platelets (WP) were prepared fresh following 
standard procedures. Specifically, whole blood was drawn into syringes containing citrate 
concentrated solution (4% w/v) in a 1:9 citrate:whole blood ratio and apixaban (1.25 µM). 
PRP was isolated as described above, incubated in calcium dye for 30 min, and recalcified 
with 2 mM CaCl2. The PRP mixture was diluted into Tyrode’s buffer supplemented with 1 
µM PGE1 and 1 U/mL apyrase prior to further centrifugation (1200g, 14 min). The 
supernatant was removed and the resulting platelet pellet was resuspended in Ca2+ HBS. 
Washed platelets were combined with plasma samples at specified volume fractions and 
incubated for approximately 30 min prior to platelet function challenge with various 
agonists (Supplemental Figure 12). For example, a final plasma concentration of 12% is 
achieved by addition of 6 µL PPP to 24 µL WP and 20 µL agonist. Calcium mobilization 
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Blood samples were collected on arrival to the trauma bay (T0), and at 3h, 6h, 12h, 
24h, 48h, and 120h and immediately aliquoted into tubes containing distinct 
anticoagulants for assessment of platelet function or hemostasis state using the TEG 6s 
Hemostasis system (Haemonetics Corp., Braintree, MA, USA) as per the manufacturer’s 
instructions. To monitor the kinetics of patient blood clotting, one mL of blood was mixed 
with 15.87 units of heparin (Sagent Pharmaceuticals, Schaumburg, IL, USA) and was 
pipetted into the PlateletMapping ADP cartridge (Haemonetics, 07-615-US). Separately, 
whole blood was anticoagulated in 3.2% buffered sodium citrate (BD Vacutainer, Becton, 
Dickson & Co., Franklin Lakes, NJ, USA) and pipetted into the Citrated Multichannel 
Cartridge (Haemonetics, 07-601-US) which provides clotting characteristics data 
simultaneously from four independent assays. The de-identified data was stored in a 
secure server. 
 
4.2.7 Statistical analysis 
Analysis of raw calcium fluorescence data was performed by MATLAB version 
R2016a (MathWorks, Natick, MA). Statistical significance tests of results based on 
experimental condition were conducted using a two-tailed unpaired Student’s t-test in 








4.3.1 Calcium mobilization measurements indicate global platelet dysfunction in trauma 
patients… 
A total of 31 blank, single, and pairwise mixtures of platelet agonists were prepared 
as shown in the color-coded concentration map (Figure 4-1,A) where each row 
corresponds to a specific input agonist mixture (dark blue = no agonist; light blue = low 
concentration; yellow = medium concentration; red = high concentration). Each stimulation 
condition yields a normalized calcium trace [F(t)/Fo] and all 31 traces are shown as 31 
rows in a heatmap (Figure 4-1,B-C). Comparison of the platelets from healthy donors 
(Figure 4-1,B) and trauma patients (Figure 4-1,C) demonstrate a markedly dysfunctional 
phenotype in the trauma patient platelets across all types of agonist stimuli. While trauma 
platelets responded best to the highest dose of convulxin, this response was greatly 
attenuated compared to healthy platelets. Overall, the healthy donor pool exhibited a 
significantly greater extent of TPCM than the trauma patient cohort (Figure 4-1,D-E). The 
average TPCM for healthy platelets was 220 ± 62 a.u. (Figure 4-1,D), greater than that 
found for every trauma patient at the initial time point of the test 0-hr TPCM (Figure 4-1,E). 
TPCM was depressed for every patient in blood samples tested between 0 and 12 hr. In 
general, TPCM displayed an increasing trend with time in several patients, but only 4 
patients (Patients 014, 019, 020, 038) had a single reading in the healthy range at times 





Figure 4-1. Trauma patients exhibit a severely impaired calcium mobilization phenotype in 
response to platelet agonists 
(A) Five platelet agonists (ADP, U46619, convulxin, SFLLRN, and AYPGKF) and one platelet 
antagonist (iloprost) were prepared according to the concentration map shown. Low, medium, and 
high doses (0.1x, 1x, and 10x EC50) of the five platelet agonists as well as pairwise combinations 
of the full six compounds at medium doses (1x EC50) resulted in 31 total conditions including a null 
buffer control. Representative calcium responses to the array of agonists are shown for a healthy 
donor (B) and a trauma patient (C). Observations are quantified on the basis of total area under 
the curve for all conditions (Eq. 1) and results for 11 healthy donors (D) and 15 trauma patients (E) 
are shown. The mean and standard deviation of the healthy donor responses are overlaid on the 
plot of patient data to provide context as to the extent of coagulopathy observed in trauma patients 
and the ability of certain patients to show recovery in platelet function over 120 hr. 
 
4.3.2 Trauma patient platelets exhibit decreased α2bβ3 activation, P-selectin expression, 
and phosphatidylserine exposure upon stimulation in flow cytometry 
Beyond calcium mobilization, platelet activation also can drive integrin activation, 
granule release and phosphatidylserine exposure (especially with collagen/thrombin 
stimulation). Fluorescently activated α2bβ3 antibody (PAC1), P-selectin antibody, and 
annexin V were used in a flow cytometry assay to measure platelet activation in the healthy 
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and patient cohorts. Dilute (1%) PRP was stimulated with calcium-containing HBS, ADP 
(2 µM), or convulxin (4 nM). Unstimulated trauma platelets displayed low levels of 
activated α2bβ3, P-selectin, and PS indicating that they were not in a classically “activated” 
state at the start of the assay. The trauma platelets, however, were able to display 
stimulated levels of α2bβ3, P-selectin, and PS, but to an extent much lower than that seen 
with healthy platelets (Figure 4-2,A-C). As was observed in the calcium mobilization 
assay, addition of convulxin caused the greatest response in both healthy subjects and 
trauma patients. Significant PS exposure was only observed in healthy donors when 
subjected to convulxin; the other data showed no detectable difference above the buffer 
control response (Figure 4-2,C). A representative set of results for a healthy donor is 
shown in Supplemental Figure 13. 
 
4.3.3 Thromboelastography (TEG) data reveal patient platelet defects in whole blood 
samples… 
Whole blood samples from trauma patients were anticoagulated with sodium 
citrate or heparin and dispensed into TEG cartridges to measure platelet function and/or 
hemostatic state. For each test using citrated blood, the machine generates an output of 
five parameters describing different aspects of the clot formation process: the time to initial 
fibrin formation (R), the time to achieve a certain level of clot strength (K), the rate of clot 
generation (angle), the strongest point of fibrin clot (MA), and the extent of fibrinolysis 30 
min after achieving MA (LY30). Using the RapidTEG reagent to interrogate both the 
intrinsic and extrinsic coagulation pathways with kaolin and tissue factor, respectively, 
patient blood samples exhibit relatively accelerated coagulation characteristics, namely 
clotting times and rates, with little to no observed lysis (Figure 4-3,A-D). However, 
platelet-driven clot development and strength appear to be diminished during the first six 
hours post-trauma, as suggested by the MA parameter (Figure 4-3,E), typically most 
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indicative of platelet function [58]. Further, ADP stimulation of heparinized whole blood 
reveals a distinct platelet aggregation defect on par with the results from calcium 
mobilization and flow cytometry experiments (Figure 4-3,F). 
 
 
Figure 4-2. Trauma patient samples show impaired integrin α2bβ3 activation, P-selectin 
expression, and phosphatidylserine exposure in flow cytometry 
Fluorescence-activated cell sorting (FACS) was used to detect platelet activation following 
stimulation with ADP (2 µM), convulxin (4 nM), or buffer. Fluorescent antibodies against the 
activated form of integrin α2bβ3 (A), P-selectin (B), and exposed phosphatidylserine (C) were 
incubated with dilute PRP (1% final concentration) prior to agonist stimulation. Conditions were 
tested in replicate for each donor/patient and mean fluorescent intensities (MFI) of each peak were 
calculated. For PS exposure, the percentage of positive cells were determined by the relative 




Figure 4-3. Thromboelastography results for patient samples over time 
Five important parameters describing clot formation and strength were measured at different 
timepoints using a TEG® 6s Hemostasis System (A-E). Averaged data for trauma patients (n=14) 
are shown for citrated whole blood treated with RapidTEG® reagent (dried kaolin + tissue factor) 
and CaCl2 for recalcification. The reported normal ranges (shaded) are: R=4-8 min; K=1-4 min; 
angle=47-74°; MA/max amplitude=55-73 mm; LY30=0-8%. Additionally, platelet function was 
measured using the compatible PlateletMapping cartridge. Data was collected using heparinized 
whole blood and the final metric of platelet activation was calculated as percent aggregation in 




4.3.4 Healthy human platelets exhibit impaired function in plasma from trauma 
patients… 
Freshly prepared washed platelets reconstituted with plasma (12% v/v plasma, 
final concentration) were challenged with agonists at high doses (10xEC50). Responses to 
convulxin, ADP, U46619, and SFLLRN were significantly reduced when platelets were in 
the presence of plasma isolated from trauma patient blood samples (Figure 4-4,A-D). 
Specifically, the signals were 54%, 56%, 59%, and 54% lower in terms of area-under-the-
curve (AUC) when the system contained patient plasma compared to healthy plasma. 
These data indicate a clear role for a plasma component on platelet function, perhaps 
polymerized fibrin or its degradation products as suggested in other work [91,99,101]. 
ELISA for D-dimer, the smallest fibrin degradation product (FDP) in terms of size, showed 
~30-fold increase in D-dimer concentration in trauma patient plasma in comparison to 
healthy plasma (Supplemental Figure 14). The patient and healthy plasma samples used 
in the experiment shown in Figure 4-4 contained 21.9 nM and <1 nM D-dimer, 
respectively.   
 
4.3.5 Healthy plasma imparts a detectable inhibition of washed platelet activation but 
patient plasma samples result in more potent effect 
The previous experiment was repeated with a screen of plasma samples from 
several healthy donors and trauma patients to detect the range of effects of each class of 
plasma. A control condition (no plasma addition) served as a baseline response to which 
wells containing healthy or trauma plasma were normalized. High concentrations of 
convulxin (20 nM) or ADP (10 µM) were used as challenging stimuli and the calcium 
mobilization AUC result for each platelet/plasma pair are plotted as percent of the control 
response (Figure 4-5,A-B). In the case of each stimulating agonist, presence of healthy 
plasma resulted in ~25% reduction of the control response, whereas addition of patient 
plasma samples further decreased the observed signal to ~50% on average. Each dataset 
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shows statistical significance from the others, with the difference between the control 
condition and the trauma plasma samples being the most signficant for both agonists. 
 
 
Figure 4-4. Healthy donor platelets lose function when reconstituted in trauma patient-
derived plasma 
Washed platelets from healthy donors were prepared according to standard protocol and 
resuspended in platelet-poor plasma (PPP) from healthy donors or trauma patients. The platelet-
plasma systems were incubated for about 10 min prior to exposure to various platelet agonists to 
test cell functionality. The agonists tested were 20 nM convulxin (A), 10 µM ADP (B), 10 µM U46619 
(C), and 100 µM SFLLRN (D). In each case, platelets in a trauma plasma setting showed ~50% 






Figure 4-5. Screening several plasma samples reveals a more potent inhibitory effect in 
trauma samples than healthy samples 
Functionality of platelets from healthy donors (n=3-4) was screened in the presence and absence 
of PPP from several other healthy donors and trauma patients using the same protocol as Fig. 4. 
Responses to 20 nM convulxin (A) and 10 µM ADP (B) were normalized to the control condition 
(no plasma). Though healthy plasma showed a down-regulation of platelet function, plasma derived 
from trauma patients showed a more potent inhibition in both agonist tests. Data are presented as 
mean ± SEM. (**p<0.01, ***p<0.001, ****p<0.0001). 
 
4.3.6 Plasma concentration is correlated with decreased platelet function 
All platelet-plasma combination experiments in previous sections were comprised 
of 12% plasma and a clear down-regulatory effect was observed. The effect of final plasma 
content was studied by titrating a range of concentrations (1-30%) and challenging platelet 
function with 20 nM convulxin, 100 µM SFLLRN, or 10 µM ADP. For each of the agonists, 
a negatively-sloping dose-response curve was created in which platelets incubated in 
increasing levels of healthy donor-derived or trauma patient-derived plasma steadily 
became hypofunctional (Figure 4-6,A-C). The negative correlation between platelet 
calcium mobilization and plasma concentration was evident in both healthy and patient 
plasma settings, though there was clear parity between the two plasma classes at each 




Figure 4-6. Increasing plasma concentrations reduces the calcium fluorescent signal in both 
healthy and patient plasma settings 
Plasma concentration was varied from 1% to 30% and healthy washed platelets were incubated in 
the presence of healthy (autologous/nonautologous) plasma or trauma plasma. A control repsonse 
(no plasma) was also prepared for data normalization purposes. All conditions were challenged 
with a potent dose of convulxin (20 nM) and data were plotted as a dose-response curve showing 
a negative relationship between plasma concentration and platelet response. Data are presented 





In an effort to better understand platelet dysfunction in trauma patients, we present 
new results confirming the phenotype in several functional assays. Combinatorial agonist 
stimulation revealed significant depression of platelet calcium mobilization in patient 
samples compared to healthy controls, though it appeared the two populations show 
similar sensitivity to strong agonist conditions (e.g. high dose CVX) (Figure 4-1). Patient 
responses varied widely, perhaps due to diverse injury conditions or treatment strategies, 
and partial recovery of platelet function was observed in one-third of the patients. Trauma 
patients also showed low α2bβ3 activation, P-selectin display, and PS exposure following 
stimulation via flow cytometry (Figure 4-2), and thromboelastography (TEG) data showed 
relatively fast clotting times (R,K) and rates of clot formation (angle), but initially diminished 
clot development (MA) and platelet aggregation (Figure 4-3). The patient sample size in 
this study (n=16) may prevent the generalizable nature of the results and certainly 
warrants further investigation, but we have validated the coagulopathic phenotype of 
platelet dysfunction through the use of several lab and clinical techniques, which has not 
been reported previously to our knowledge.  
A potential link between these results is the injury severity score (ISS), an 
anatomical quantification system to describe the extremity of a patient’s injured state. The 
ISS accounts for multiple regions of the body, with scores ranging from 0-75 and the 
threshold for major trauma set at ISS=15 [102,103]. Individual ISS scores for the cohort of 
16 trauma patients are listed in Table 4-1 (median=24.5, IQR=15). This large range led 
us to hypothesize that the extent of platelet dysfunction may be correlated with the severity 
of the condition. However, we found no such relationship (Supplemental Figure 15), 
suggesting an added emphasis on the plasma effect observed in Figure 4-4, Figure 4-5, 
and Figure 4-6. The final ISS assigned to a patient is often determined at some later time 
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point during or even after the patient’s stay and does not account for the patient’s previous 
medical history, which may explain the lack of correlation. 
We also show a negative influence of plasma on platelet function. Diluting PRP with 
PPP to normalize platelet count has previously been shown to impair platelet aggregation 
[104]. Further, cellular microparticles isolated from traumatic hemothorax blood, and to a 
lesser extent shed frozen plasma, inhibit platelet response to ADP, arachidonic acid, and 
collagen [105]. The effect we observed was more potent with trauma patient-derived 
plasma, implying an amplified role of certain soluble species on cell viability. Other groups 
have shown elevated levels of soluble FDPs in trauma patient plasma [39,40], which we 
confirmed via D-dimer ELISA (Supplemental Figure 14). The role of circulating fibrin 
fragments on inherent and transfused platelet function is a subject of continuing study, but 
initial results show binding sites for fibrin on GPVI [91] and signaling defects following 
thrombin-mediated platelet activation and fibrin polymerization [99]. At this point it is 
difficult to elucidate whether these species (e.g. D-dimer) are meant to simply serve as a 
biomarker or if there exists an important mechanistic explanation linking elevated plasma 
concentrations and platelet dysfunction. Other possible hypotheses include roles of 
platelet-silencing species such as cAMP and cGMP, which are reported as elevated in 
trauma platelets and correlated with injury severity [106].  
With the sustained prevalence and diversity of trauma-related injuries and 
mortalities, understanding the mechanisms of action as well as developing sufficient 
treatment strategies is becoming increasingly necessary. We highlighted the development 
of phenotypic profiles of platelet function to be used to guide clinicians in making informed 
decisions. Additionally, the observation of a plasma-mediated inhibitory effect gives rise 
to implications of transfusion therapies being ineffective or uninformed. Recent work has 
debated the appropriate volumes and ratios of blood products to administer to 
coagulopathic patients [107,108], but perhaps transfusions are not always optimal. In fact, 
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platelet transfusions in trauma patients have been shown to have little effect on platelet 
function recovery [47] and resuscitation of hemorrhagic rats via whole blood delivery failed 
to restore platelet viability [109]. Healthy platelets may inherit the “zombie” nature of the 
unresponsive but still circulating cells upon exposure to the patient’s plasma, as suggested 




CHAPTER 5: D-DIMER AND FIBRIN DEGRADATION PRODUCTS 
IMPAIR PLATELET SIGNALING: PLASMA D-DIMER IS A 
PREDICTOR AND MEDIATOR OF PLATELET DYSFUNCTION 




Trauma-induced coagulopathy (TIC) is a relatively common condition observed in 
patients following severe injuries, and is mainly characterized by an excessive bleeding 
phenotype attributed to hyperfibrinolysis, coagulation factor deficiency, and platelet 
dysfunction [10]. Hemorrhagic shock in trauma patients often results in significant 
thrombin generation and release of tPA, leading to a state of both systemic consumptive 
coagulation and thrombolysis [36,61]. As a result, fibrin degradation products and D-dimer 
are produced in large quantities and tend to circulate for extended periods of time [39,40]. 
Platelet dysfunction in these patients has also been identified as one of the key features 
of the coagulopathic phenotype. Though endpoint measurements tend to vary amongst 
studies due to the growing diversity of functional assays, there is general agreement 
regarding decreased platelet activity in injured patients. Several aspects of the hemostatic 
response, including aggregation [29,33], calcium mobilization [110], and deposition on 
prothrombotic surfaces under flow [30], have been shown to be impaired in trauma patient 
blood. Despite the breadth of literature related to platelet dysfunction following trauma, the 
underlying mechanisms contributing to the phenotype are not fully understood.    
The “exhausted platelet syndrome” has been hypothesized as a potential 
explanation, in which circulating platelets experience prolonged activation and eventual 
“tiring” that leads to acquired defects in younger platelets [28,111]. A recent report has 
suggested potential mechanical damage to platelets during trauma which may impact the 
cytoskeleton or configuration of integrins on the cell surface [112]. However, on a more 
biochemical basis, inhibitory effects of factors found in the plasma of traumatized patients 
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have been reported [110], and the effectiveness of platelet transfusions in restoring in vivo 
function in hemorrhaging patients is sub-optimal [47]. These latter results have given our 
group reason to believe certain plasma proteins, specifically fibrin-related species, may 
carry interfering effects on the ability of platelets to function properly. To our knowledge, 
there have been no published reports of potential causal relationships between measured 
D-dimer concentrations and observed platelet dysfunction in trauma, an area we are 
interested in exploring.    
Platelets are dynamic cells that participate in several processes ranging from 
signaling through a multitude of surface receptors, amplification of the hemostatic 
response through release of internal granule contents, and interplay with other blood cells 
and proteins. One of the key interactions that governs platelet aggregation is between the 
platelet integrin αIIbβ3 and the plasma protein fibrinogen. Additionally, platelets can interact 
with several other coagulation enzymes in a protective manner against inhibitors which 
reduces the risk of conditions like disseminated intravascular coagulation (DIC) [113]. This 
knowledge, and previous work from our group and others, has led us to conjecture there 
exists an important physical affinity between platelets and D-dimer or other fibrin-related 
species. This relationship and its impact on platelet function become especially meaningful 
in settings of elevated FDP levels. In this work, we attempt to better understand the factors 
that contribute to platelet dysfunction in trauma by phenocopying patient settings with 
healthy blood. Further, we investigate the effect of D-dimer on platelet function and 








5.2 Materials and Methods 
5.2.1 Reagents 
All reagents were used and stored according to manufacturers’ instructions. Fluo-
4 NW calcium dye and probenecid were obtained from Invitrogen (Carlsbad, CA). Human 
D-dimer ELISA Kit, native human D-dimer protein, and recombinant human tissue 
plasminogen activator (tPA) protein were purchased from Abcam (Cambridge, MA). ADP 
and citrate concentrated solution were from Sigma-Aldrich (St. Louis, MO). Apixaban was 
obtained from SelleckChem (Houston, TX), thrombin and D-phenylalanyl-prolyl-arginyl 
chloromethylketone (PPACK) from Haematologic Technologies Inc. (Essex Junction, VT), 
convulxin from Cayman Chemical (Ann Arbor, MI), PAR-1/4 activating peptides and fibrin 
polymerization inhibitor GPRP from Bachem (Torrance, CA), αIIbβ3 antagonist GR144053 
from R&D Systems (Minneapolis, MN), Factor XIIIa transglutaminase inhibitor T101, 
1,3,4,5-tetramethyl-2-[(2-oxopropyl)thio] imidazolium chloride, from Zedira GmbH 
(Darmstadt, Germany), type I fibrillar collagen from Chrono-log (Havertown, PA), and 
APC-conjugated D-dimer antibody from AssayPro (St. Charles, MO). HEPES-buffered 
saline (HBS) was prepared with 20 mM HEPES and 150 mM NaCl, after which pH was 
adjusted to 7.4 with 1 N NaOH, all from Fisher Scientific (Fair Lawn, NJ). Tyrode’s buffer 
was prepared with 10 mM HEPES, 127.2 mM NaCl, 11.9 mM NaHCO3 (Fisher), 5 mM KCl 
(Fisher), 0.4 mM NaH2PO4 (Fisher), 1 mM MgCl2·6 H2O (Sigma), and 5 mM D-glucose 
(Sigma).  
Agonist and other reagent concentrations were chosen based on both previous 
studies and published physiologic ranges. Inhibitor concentrations (GPRP, T101, 
GR144053) were five to ten-fold greater than the minimum doses required to see 
anticoagulant or antiplatelet effects, ensuring complete inhibition. Doses of the fibrinolytic 
agent tPA were supported by published values of plasma levels in trauma patients [47] 
and purified D-dimer concentrations used in the aggregometry assay were determined by 
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our D-dimer ELISA results (Figure 5-3,A). The antibodies used in the D-dimer ELISA and 
the flow cytometry assays were able to recognize both D-dimer subunit and D-dimer 
multimers present in other fibrin degradation products.  
 
5.2.2 Phlebotomy and patient enrollment 
 Whole blood was freshly drawn via venipuncture from volunteer donors following 
University of Pennsylvania’s Institutional Review Board-approved protocols. Syringes 
were pre-loaded with anticoagulants based on the specific assay being performed: 1.25 
µM apixaban to block endogenous thrombin generation through factor Xa activity, 100 µM 
PPACK to inhibit thrombin activity, or 4% citrate concentrated solution (1 part citrate:9 
parts blood) to chelate calcium. Donors self-reported to be free of all medications for seven 
days and alcohol use for three days leading up to the blood draw and female donors were 
free of oral contraceptive use. 
For patient studies, blood was obtained from a subset of enrolled subjects in the 
Penn Acute Research Collaboration’s Trauma-Induced Coagulopathy and Inflammation 
study, as documented in previous work [110]. Briefly, patients admitted to the trauma unit 
who fulfilled enrollment criteria (≥18 years old, present as trauma alert, and admitted to 
Trauma and Surgical Intensive Care Unit) were monitored over the course of 5 days via 
blood collection at specified timepoints (0, 3, 6, 12, 24, 48, and 120 hr). For this work, 
blood was drawn into 1.25 µM apixaban and 100 µM PPACK to ensure negligible thrombin 
generation and activity. General characterizations of trauma patient and healthy control 
cohorts are provided in Table 5-1. All trauma patients and healthy controls were screened 











Subject characteristics    
     Age, y 39.5 ± 19.0 32.3 ± 8.2 0.34 
     Male (n, %) 17 (77%) 5 (71%)  
     Prev. conditions/meds (n, %) 0 (0%) 0 (0%)  
     Mechanism of injury (n, %)    
          Gunshot wound 12 (54%) n/a  
          Motor vehicle accident 7 (32%) n/a  
          Fall 3 (14%) n/a  
     ISS 21.4 ± 9.8 n/a  
    
Laboratory measurements    
     Platelet count (x103/µL) 185.4 ± 44.7 209.3 ± 96.0 0.39 
     Fibrinogen, mg/dL 425.0 ± 109.5 (150-400)*  
     D-dimer, ng/mL DDU 9474 ± 9861 194.6 ± 73.1  0.02 
     Ca2+ mobilization, AUC 57.9 ± 54.0 238.7 ± 85.6 <0.0001 
Values are presented as mean ± SD. 
ISS: Injury Severity Score; AUC: area under curve; DDU: D-dimer units 
*Typical reference range for fibrinogen in healthy plasma 
 
Table 5-1. Summary of subject characteristics for complete study cohort 
Populations of healthy donors (n=7) and trauma patients (n=22) were analyzed in this study. 
General demographics, clinical presentations for the patient cohort, and lab measurements of 
common hemostatic variables are summarized in the table. A student’s t test was run to compare 
healthy and patient data for each parameter, and statistical significance is identified by p<0.05. 
Interestingly, platelet function as measured by calcium mobilization experiments was significantly 
lower in the patient population, while D-dimer concentrations were significantly higher compared to 
the healthy control population.   
 
 
5.2.3 Intracellular calcium mobilization 
 For calcium mobilization experiments investigating platelet response to 
combinatorial stimuli in healthy and patient cohorts, platelet-rich plasma (PRP) was 
isolated from apixaban- and PPACK-treated whole blood via moderate centrifugation 
(120g, 10min, 20°C), diluted in HEPES-buffered saline (HBS) and incubated with Fluo-4 
NW fluorescent dye as described in previous work [99]. Briefly, two independent 384-well 
plates were prepared: one plate containing dye-loaded PRP and another containing 
platelet agonists or other reagents. Dynamic data collection was performed with a 
FlexStation 3 (Molecular Devices, Inc., Sunnyvale, CA), an automated plate reader with 
liquid handling functions.  
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 In a separate set of experiments designed to mimic coagulant and lytic states 
during trauma, healthy PRP treated with apixaban only was exposed to a sequential 
addition of thrombin and tPA, followed by platelet function challenge with glycoprotein VI 
(GPVI)-activating convulxin. In some experiments, inhibitors of fibrin polymerization and 
cross-linking (GPRP and T101, respectively) were added to PRP-containing wells 5 min 
prior to reaction activation (Supplemental Figure 16,A). Calcium mobilization traces were 
all normalized by the initial pre-dispense baseline Fo.    
 
5.2.4 Platelet aggregometry 
Platelet aggregation experiments were performed using a Model 700 Whole 
Blood/Optical Lumi-Aggregation System (Chrono-log, Havertown, PA). Healthy PRP or 
washed platelets were prepared as described previously [114] from citrated whole blood 
followed by recalcification with 2 mM CaCl2 (Sigma). Platelet-poor plasma (PPP) or 
Tyrode’s buffer were used as respective controls. Platelet agonists were manually 
dispensed into sample cuvettes at 37°C and aggregation was monitored for 4 min in the 
presence and absence of purified human D-dimer protein. For study of dense granule 
function, Chrono-Lume® reagent (Chrono-log) was added to the cuvette and incubated 
for 5 min prior to beginning the experiment. 
 
5.2.5 ELISA 
 D-dimer plasma concentrations were measured using the Human D-dimer ELISA 
Kit from Abcam (PN: ab196269), which recognizes D-dimer and other FDPs containing 
the D-D epitope. Due to the sandwich nature of the assay with both capture and detector 
antibodies against D-dimer, we believe that the majority of the signal is indicative of D-
dimer presence. Platelet-poor plasma (PPP) samples were prepared via centrifugation of 
apixaban- and PPACK-treated whole blood (2000g, 10min, 20°C) and diluted adequately 
76 
 
in supplied diluent buffer to ensure the final optical density measurements (450 nm) fell in 
the pre-determined standard curve range. The assay duration time was about 2 hr from 
sample preparation to final endpoint read on EnVision 2102 Multilabel Reader 
(PerkinElmer, Waltham, MA). The ELISA kit was also utilized to measure resulting 
concentrations in final reaction volumes. Specifically, aliquots from wells described above 
were analyzed for D-dimer content under differing reaction conditions. Further, reactions 
of washed platelets and trauma patient plasma samples with elevated D-dimer levels or 
purified D-dimer were monitored over time to observe the ability of platelets to bind D-
dimer (Supplemental Figure 16,B). Samples of the reactions were taken at specified time 
intervals and platelets were removed prior to protein content analysis of the supernatant. 
  
5.2.6 Flow cytometry 
 Surface binding of D-dimer to platelets was measured via fluorescently conjugated 
anti-D-dimer antibody designed for flow cytometry applications. Dilute (1%) PRP was 
isolated from apixaban- and PPACK-treated whole blood, prepared in HBS supplemented 
with 2 mM CaCl2, and incubated with 10 µL antibody prior to analysis. In some 
experiments, specified inhibitors were also included to investigate the role of certain 
surface receptors on D-dimer binding. Samples were analyzed on an Accuri C6 Plus flow 
cytometer (BD Biosciences, San Jose, CA) for 1 min using the low flow rate setting (14 
µL/min, 10 µm core). Data are reported as mean fluorescent intensity (MFI).  
 
5.2.7 Statistical analysis 
 Fluorescence data were analyzed and plotted with MATLAB (MathWorks, Natick, 
MA). Statistical significance levels between data sets were calculated using a two-tailed 
unpaired t test in Prism version 8.2.1 (GraphPad, San Diego, CA) and set as follows: 
*p<0.05, **p<0.01, ***p<0.001. Correlations between data were tested using the curve-
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fitting function in OriginPro 9 (OriginLab Corporation, Northampton, MA). Confidence 
intervals at the 95% confidence level and Pearson’s correlation coefficients were reported 
to indicate the strength of the best-fit line.   
 
5.3 Results 
5.3.1 Factor XIIIa and fibrinolysis contribute to platelet signaling defect 
 Treatment of diluted PRP (12 vol%) with thrombin (5 nM) caused a transient 
increase in intracellular calcium mobilization (Figure 5-1,A), consistent with previous 
results [99]. After 300 s of thrombin activity, tPA (50 nM) was added to certain wells to 
drive fibrinolysis without eliciting calcium mobilization (Figure 5-1,A). Finally, adding 
convulxin (CVX, 20 nM) to activate GPVI revealed drastically different results depending 
on the composition of each well, specifically whether tPA or inhibitors of fibrin 
polymerization (GPRP) or FXIIIa-mediated cross-linking (T101) were included in the 
pretreatment.  
 The addition of thrombin alone to generate cross-linked soluble fibrin species 
caused up to 90% inhibition of platelet GPVI signaling induced by convulxin (red, Figure 
5-1), consistent with previous results [99]. Incorporating tPA into the system to produce 
cross-linked FDP further reduced platelet response to CVX (black, Figure 5-1). These 
conditions were repeated in the presence of the FXIIIa inhibitor T101 (1 mM) to investigate 
the importance of fibrin cross-linking, with and without fibrinolysis. Non-crosslinked soluble 
fibrin (green, Figure 5-1), formed in the presence of thrombin and T101, showed only 
moderate inhibitory effect on GPVI signaling. Adding tPA to generate non-crosslinked FDP 
(T101 present) showed substantial inhibition of GPVI signaling (pink, Figure 5-1). Full 
platelet function was recovered when fibrin polymerization was inhibited with 5 mM GPRP 
(yellow, Figure 5-1) as previously observed [99]. The extent of platelet inhibition was 
quantified by calculating the integrated area under the curve after CVX dispense and 
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comparing it to the control condition (blue, Figure 5-1). Each colored bar in Figure 5-1,B 
corresponds to the signal derived from the colored trace in Figure 5-1,A. The relative 
potency of these species to inhibit convulxin-induced GPVI signaling was: cross-linked 
FDP (D-dimer) ≥ cross-linked soluble fibrin > non-crosslinked FDP >> non-crosslinked 
soluble fibrin >>> fibrin monomer. This assumes 50 nM tPA is sufficiently high enough 
dose to fully dissolve soluble fibrin under the well-mixed conditions of the assay. 
To further test that the effect of cross-linked FDP was more inhibitory than cross-
linked soluble fibrin (thrombin+tPA vs. thrombin only, respectively), we decreased the 
thrombin concentration while maintaining the tPA dose. Decreased thrombin 
concentrations (<5 nM) in control wells showed a dose-dependent restoration of response. 
The addition of tPA, however, consistently impaired GPVI calcium mobilization 
(Supplemental Figure 17,A). This suggests that, of all fibrin-related species, cross-linked 
FDP of various sizes (including D-dimer) are the most inhibitory. Generation of the D-
dimer epitope in thrombin-treated PRP required tPA and was confirmed by sampling 
aliquots of the reaction mixtures and measuring plasma concentrations via ELISA 





Figure 5-1. Effect of cross-linked fibrinolytic products on healthy platelet function 
Fibrinolysis was simulated in vitro by sequential addition of thrombin and tPA to dilute, calcium dye-
loaded PRP isolated from healthy donors. Platelets were then challenged with a potent dose of 
CVX. Representative calcium mobilization traces for various conditions (A) and quantification of 
GPVI signaling based on area-under-the-curve following CVX dispense in comparison to a null 
control condition (B) are shown. 
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5.3.2 D-dimer impairs platelet aggregation in response to various agonists 
To further examine the effect of FDP on platelet function, we conducted 
aggregometry experiments in the presence and absence of purified human D-dimer. 
Healthy PRP or washed platelets (WP) were incubated with 50 µg/mL D-dimer or HBS 
and subsequently stimulated with collagen (2 µg/mL), PAR-1 activating SFLLRN (26 µM), 
or ADP (10 µM). In each condition, platelet aggregation was impaired in the presence of 
D-dimer, both qualitatively (Figure 5-2,A-D) and quantitatively (Figure 5-2,E). When 
washed platelets were isolated and concentrated, creating a fibrinogen-reduced setting, 
D-dimer strongly inhibited aggregation (Figure 5-2,A). In PRP aggregometry, the 
aggregation was initially identical in the D-dimer and control conditions, but D-dimer soon 
prevented further aggregation and drove disaggregation (Figure 5-2,B-D). This feature is 
often indicative of defective granule release and is important for secondary aggregation 
and clot development (confirming data showing dysfunctional ATP release by lumi-
aggregometry in Supplemental Figure 18) [56]. Recent data has suggested alpha 
granule release is intact in trauma through the monitoring of P-selectin display [112]. Our 
data suggest that diminished ATP levels following platelet stimulation in the presence of 





Figure 5-2. Effect of presence of D-dimer on healthy platelet aggregation following agonist 
stimulation 
PRP or washed platelets were prepared from healthy citrated whole blood and incubated with 
human D-dimer or buffer control. Cells were stimulated with common agonists and aggregation 
was measured via light transmission. (A-D) Collagen, SFLLRN, and ADP were used as stimuli at 




5.3.3 Plasma D-dimer is a predictor of trauma-induced platelet dysfunction 
 Using blood from healthy donors and trauma patients, total platelet function in 
response to an array of stimuli (single and pairwise combinations of six common agonists) 
was calculated as Total Platelet Calcium Mobilization (TPCM), defined and measured in 
previous work [110] (see  
Supplemental Figure 19 for details). Agonists included ADP, thromboxane A2 analog 
U46619, convulxin, PAR-1/4 specific peptides SFLLRN and AYPGKF, and IP-receptor 
activator iloprost and were used at 0.1x, 1x, and 10x EC50, as previously determined [50]. 
Though TPCM is a quantitative measure of platelet function, it should be interpreted more 
as a global comparative metric to indicate deviations from normal or healthy behavior, 
since it is calculated from several independent measurements.  
 Plasma D-dimer concentrations were measured via ELISA, which provided a 
metric of D-dimer equivalents for FDP and fully degraded D-dimers in the trauma plasma. 
Healthy donor blood samples exhibited much higher platelet function and much lower D-
dimer concentration than trauma patient-derived samples (Table 5-1, Figure 5-3). The D-
dimer concentrations of both populations were consistent with previous literature 
[39,41,115], which increases our confidence in the reliability of the ELISA employed. 
Analyzing healthy and patient data together showed an inverse correlation between D-
dimer concentration and TPCM (R=0.8236, Pearson’s correlation coefficient), indicating 
that D-dimer was a predictor of platelet dysfunction within the power of the correlation 
presented (Figure 5-3,A). When the calcium traces were analyzed further by investigating 
agonist-specific induction (Supplemental Figure 20) or patient-specific trends (not 
shown), D-dimer remained a strong predictor of poor calcium mobilization. Both platelet 
dysfunction and elevated D-dimer have been reported previously in trauma, but the strong 




Figure 5-3. Correlation between D-dimer level and total platelet calcium mobilization 
TPCM and plasma D-dimer concentrations were calculated for several healthy subjects and trauma 
patients. (A) The two parameters display a strong negative correlation when plotted against each 
other. Confidence intervals at 95% confidence level are shown as dotted lines. (B, C) A time 
dependence of recovery of platelet function and reduction of D-dimer concentration amongst 
trauma patients is shown. D-dimer concentrations were plotted on a log-scale. 
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 Averaging patient data into bins based on time of sample collection and 
experimentation revealed statistically significant recovery of platelet function (Figure 
5-3,B) and declining D-dimer levels (Figure 5-3,C). However, full return to healthy 
baseline was not achieved after several days of hospital treatment, indicating complete 
restoration of initial hemostatic state in trauma patients is a slow process.  
 
5.3.4 Healthy washed platelets bind D-dimer over time and trauma platelets feature D-
dimer on cell surface 
 We tested the capability of platelets to bind D-dimer by incubating freshly prepared 
healthy washed platelets with plasma samples from trauma patients. Plasma D-dimer was 
measured with time of incubation. Compared to control experiments in which no platelets 
were added to the system and D-dimer levels were constant (data not shown), D-dimer 
concentrations decreased over the course of 1 hr with platelet incubation (Figure 5-4,A). 
Lower volume fractions of plasma (meaning more platelets present in the system) resulted 
in a greater decrease in D-dimer concentration; 20 vol% plasma systems achieved ~20% 
decrease after 60 min, while 10 vol% plasma reactions concluded with ~40% reduction in 
initial D-dimer level. Additionally, using purified human D-dimer (1.5 µg/mL) in place of 
plasma samples showed a similar kinetic profile (Figure 5-4,A). These results indicate 






Figure 5-4. Binding of D-dimer by platelets over time 
(A) Healthy washed platelets were reconstituted with trauma patient plasma as a D-dimer source 
or purified human D-dimer. Decreases in protein content over time imply platelet uptake of D-dimer. 
(B) Calculations of D-dimer occupancy on the platelet surface were performed. (C) Flow cytometry 




Using the data in Figure 5-4,A, we estimated D-dimer occupancy on a normalized 
per-platelet basis. For ~200,000 platelets/µL and incubation in 10 vol% and 20 vol% 
plasma, we calculated approximately 10,000 D-dimer equivalents bound per platelet 
(Figure 5-4,B). In the 20 vol% plasma scenario, cellular uptake was more gradual and 
constant over time. When more platelets were present (10 vol% plasma system), most of 
the D-dimer uptake took place in the first 10 min (Figure 5-4,B). However, when the 
calculation was performed on the system in which platelets interacted directly with purified 
human D-dimer, only 4,000 molecules/platelet were observed after 1 hr. This may be due 
to the diversity in size and composition of fibrin degradation products in plasma that signal 
positive for D-dimer in the ELISA being used, which has been discussed as a potential 
limitation. Certain small oligomers containing the cross-linked D-domain moiety, which 
may contribute to the total detected protein concentration, may also be able to bind the 
platelet surface. Considering reported receptor copy numbers in platelets (αIIbβ3: 40,000-
80,000; GPVI: 4,000) [116,117], we hypothesize that most of the observed uptake of D-
dimer involved both αIIbβ3 and GPVI. 
Trauma patient blood samples also exhibited higher, though not statistically 
significant, quantities of D-dimer on the platelet surface as quantified by flow cytometry 
(Figure 5-4,C). In contrast to healthy platelets, there was about a 3-fold increase in the 
mean fluorescent intensity in the patient platelets. In an experiment to explore which 
platelet receptors were involved in D-dimer binding, we used GR144053 to block integrin 
αIIbβ3 and saw a partial reduction in the bound D-dimer signal. Some of our previous work, 
as well as that of other groups [91,99,118,119], has implied that GPVI may also be a 







Fibrinolytic products, like D-dimer, have traditionally been used as biomarkers for 
deep vein thrombosis (DVT), venous thromboembolism (VTE), and disseminated 
intravascular coagulation (DIC) [120,121]. For example, Bounameaux et al. first reported 
elevated levels of D-dimer in subjects with pulmonary embolism in 1991 [122]. Despite the 
number of papers highlighting D-dimer as a biomarker for thrombosis and elevated D-
dimer during trauma, there are few studies investigating the potential mechanistic 
contributions of these degradation products to dysfunctional hemostasis or platelet 
activity. In trauma patients whose systemic circulation is exposed to both tissue factor and 
tPA, elevated levels of soluble fibrin, FDP, D-dimer, F1.2, thrombin-antithrombin complex, 
and fibrinopeptide A/B are expected [40]. 
Using a 384-well plate assay, we explored the effect of various fibrin species on 
platelet function using diluted PRP exposed to the sequential addition of thrombin and 
tPA. Characterizing the inhibitory effects of various fibrin-related species on downstream 
platelet signaling through the collagen receptor GPVI led us to develop a hierarchy of 
GPVI signaling inhibition from the most potent species (D-dimer) to essentially inactive 
(fibrin monomer) (Figure 5-1). As expected, plasma D-dimer concentrations were notably 
higher in a trauma patient population compared to healthy controls (Table 5-1), as 
measured by sandwich ELISA with specificity for D-dimer and other D-D-containing 
oligomers. Interestingly, plasma D-dimer was inversely correlated with a metric of platelet 
function spanning six independent signaling pathways (Figure 5-3,A). Addition of pure D-
dimer to PRP interfered with platelet aggregation following stimulation with several 
agonists (Figure 5-2). Taken together, these data suggest that D-dimer can both predict 
and act as a mediator of platelet dysfunction.  
Using D-dimer as the primary measure of fibrinolysis, we also report that trauma 
patient platelets have elevated levels of bound D-dimer and D-dimer in trauma plasma 
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can be bound by healthy platelets (reaching ~10,000 D-dimer equivalents/platelet), which 
may have direct implications regarding the functionality of transfused platelets in trauma 
patients with high D-dimer levels (Figure 5-4). These data suggest that platelet 
transfusions and anti-thrombolytic drugs may not immediately rescue platelet calcium 
mobilization.  
The platelet receptors that bind D-dimer likely include GPVI (Figure 5-1) and αIIbβ3 
(Figure 5-4,C); our hypotheses and proposed understanding of platelet-fibrin interactions 
are presented visually in Figure 5-5. Due to structural similarities with fibrinogen, fibrin 
degradation products can also occupy the αIIbβ3 complex [123]. In continuing studies of 
the role of different GPVI configurations in D-dimer and fibrin recruitment, one group 
identified the monomeric form of GPVI as the responsible receptor for fibrin and D-dimer 
binding [91]. A separate group implicated both αIIbβ3 and, to a lesser extent, GPVI-dimer 
as capable of recognizing the D domain of fibrin-related species [118], and an earlier 
report postulated that fragment D has inhibitory effects on fibrin-dependent platelet 
activation [124]. In response to the lack of agreement between these groups, a follow-up 
article considered the role of inconsistent assay procedures and the need for 
standardization to elucidate the correct biology [119]. Our work does not specifically 
interrogate preferential activity of monomeric or dimeric GPVI but rather relies on the 
endogenous platelet repertoire of receptors. While GPVI shedding is highly relevant to 
pathological states, the conditions of Figure 5-1 and Figure 5-2 are far too rapid to include 
shedding mechanisms. Importantly, the sheddase inhibitor GM6001 was previously 





Figure 5-5. Overall summary schematic showing proposed understanding of interactions 
between platelets and fibrin-related species 
Platelet surface receptors are shown with known ligands. Fibrin-related species generated 
throughout the coagulation process and their respective hypothesized roles in interfering with 
platelet activation are also shown. Our main focus in this paper is the potent inhibition of D-dimer 
(and to a lesser extent cross-linked soluble fibrin), as shown by its observed interaction with GPVI 
and potentially αIIbβ3. 
 
Several different factors during trauma may account for platelet dysfunction. We 
report in this pilot study that D-dimer is a predictor of this platelet dysfunction and may be 
a causative agent, along with soluble fibrin and FDP, to interfere with platelet ATP release, 
aggregation, and signaling. Considering the complex nature of TIC, we are not fully 
attributing the observed platelet dysfunction phenotype to these fibrinolytic products but 
rather we are identifying a significant biological role of these species that has not been 
reported previously. There are likely several other contributing mediators besides D-dimer 
and FDP and other areas of investigation that need to be considered, but the progress in 
understanding the multidimensional phenomena that contribute to TIC is encouraging 
[125]. Further study of platelet structural changes, exposure of surface receptors, and 
correlation with in vivo experiments is certainly warranted to evaluate our observations. 
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CHAPTER 6: OTHER STUDIES 
 
 
6.1 Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with 
shear-dependent effects on platelet-collagen binding and thrombin 
generation 
6.1.1 Introduction 
Antithrombotic drugs are typically classified into one of three major categories: 
antiplatelet, anticoagulant, or fibrinolytic agents [126,127]. Common antiplatelet 
therapeutics include aspirin and clopidogrel which both inhibit secondary platelet agonist 
generation (thromboxane A2 and ADP, respectively) [126–128], as well as inhibitors of the 
integrin ɑIIbβ3 [129]. Anticoagulants are responsible for preventing thrombin generation 
and fibrin polymerization. Warfarin and various heparins have been used as an oral and 
parental anticoagulant for several decades, but recent advances have focused on 
specifically targeting coagulation factors, such as thrombin and factor Xa [126]. Finally, 
fibrinolytic or thrombolytic drugs (most notably tPA: tissue plasminogen activator) promote 
the generation of plasmin, an enzyme that cleaves fibrin [130]. 
With increasingly complex cardiovascular disease states comes a need for the 
administration of multiple antithrombotics with different mechanisms of action. While 
certain classes of drugs have the potential to function synergistically, there is an 
associated increased bleeding risk as the number of drugs increases [131,132]. Therefore, 
identifying a method for combining the antithrombotic functions of antiplatelet and 
anticoagulant agents into a single therapy can have a potentially great impact on the field, 
as uncertainty regarding optimal use remains [132].      
Heparin (usually referred to as unfractionated heparin; UFH) is yet another 
common clinically-used antithrombotic agent which carries anticoagulant behavior through 
its binding and activation of antithrombin. Antithrombin then works to deactivate circulating 
thrombin and factor Xa to hinder the coagulation process [133]. Heparin can bind directly 
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to thrombin (Kd=100 nM) resulting in anticoagulant behavior [134]. Heparin is derived from 
mast cells which line the vascular walls usually in the same general location as tissue 
factor (TF). Upon tissue injury, mast cells are activated and release heparin proteoglycans 
(HEP-PGs) which are much higher in molecular weight than UFH [135,136]. These 
structures have been shown to exhibit both anticoagulant features, as does heparin 
typically [137], as well as specific antiplatelet properties, most notably involving the 
platelet-collagen interaction and subsequent aggregation and fibrin polymerization [135]. 
The unconventional ability for a heparin-based entity to impact collagen-dependent 
platelet activation could be attributed to the fact that type I collagen has binding sites for 
heparin, in addition to the heparin binding site to von Willebrand Factor (vWF) bridging 
platelets with collagen, relevant under arterial shear rates [138]. The concept of designing 
synthetic HEP-PG mimetics, structured with a protein core and conjugated with UFH, has 
been demonstrated [135,136,139,140]. 
Despite various results comparing the ability of HEP-PGs and UFH to inhibit 
collagen-mediated platelet aggregation and serotonin release under flow conditions [135], 
previous work with dual anticoagulant and antiplatelet (APAC) conjugates has been 
focused primarily on in vitro platelet aggregometry studies and in vivo vascular models 
[136,140]. The importance of understanding the functionality of APACs, as is the case with 
any novel therapy, in more pathophysiologic scenarios in vitro is crucial. Thus, the focus 
of this work was to compare the results obtained from various in vitro experimental 
techniques to gain a broader understanding for the potential therapeutic effect of synthetic 
HEP-PG mimetics with varying heparin conjugation levels (CL10, CL18, HICL).   
 
6.1.2 Methods 
Reagents were obtained as follows: Anti-human CD61 (BD Biosciences, San Jose, 
CA), Alexa Fluor® 647 conjugated human fibrinogen (Life Technologies, Waltham, MA), 
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corn trypsin inhibitor and D-Phe-Pro-Arg-chloromethylketone (CTI and PPACK, 
respectively; Haematologic Technologies, Essex Junction, VT), Sigmacote® siliconizing 
reagent (Sigma, St. Louis, MO), Dade® Innovin® PT reagent (Siemens, Malvern, PA), 
collagen Type I Chrono-Par™ aggregation reagent (Chrono-log, Havertown, PA). Whole 
blood was drawn via venipuncture from healthy donors following University of 
Pennsylvania Institutional Review Board approval into a syringe loaded with 100 µM 
PPACK (to inhibit thrombin activity altogether for the study of platelet deposition on 
collagen only) or 40 µg/mL CTI (to inhibit contact pathway and measure platelet and fibrin 
deposition). Prior to each blood draw, donors self-reported to be free of any medications 
for 7 days and alcohol use for 48 hours. Additionally, female donors self-reported to not 
using oral contraceptives. 
Apixaban (SelleckChem, Houston, TX), HEPES (Fisher Scientific, Hampton, NH), 
Fluo-4 NW calcium dye and probenecid (Invitrogen, Carlsbad, CA), ADP (Sigma-Aldrich, 
St. Louis, MO), U46619 (Tocris Bioscience, Bristol, UK), convulxin (Cayman Chemical, 
Ann Arbor, MI), type I fibrillar collagen (Chrono-log, Havertown, PA), thrombin 
(Haematologic Technologies Inc., Essex Junction, VT), and SFLLRN and AYPGKF amide 
(Bachem, Torrance, CA), Protein A Sepharose CL-4B (GE Healthcare, US), vWF 
(Wilfactin®, 100 IU/mL, LFB Biomedicaments, Les Ulis, FR), rabbit polyclonal anti-vWF 
(DAKO, Glostrup, DK), enhanced chemiluminescent (ECL) detection reagents (GE 
Healthcare, US), goat anti-rabbit HRP, (Jackson Immunoresearch, Westgrove, PA, US), 
streptavidin-ATTO647 (Immune Biosolutions, Sherbrooke, QE, CA) were stored and used 
according to each manufacturer’s instructions. Three different APAC molecules were 
synthesized (Aplagon, Helsinki, Finland) as previously described [136,140]. In brief, dual 
antiplatelet and anticoagulant (APAC) conjugate comprises of protein core, where UFH 
chains are bound by covalent di-sulfide bridges provided by a cross-linker molecule to 
reach various conjugation levels (CL) of heparin. 
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Measurements of platelet calcium mobilization were conducted in 384-well plate 
assay format, as described previously [84]. Briefly, fresh whole blood treated with 250 nM 
apixaban (a Factor Xa inhibitor used to eliminate endogenous thrombin generation) was 
centrifuged (120g, 10 min) to isolate platelet-rich plasma (PRP). The PRP was incubated 
with a vial of Fluo-4 NW calcium dye prepared by reconstitution with sterile 20 mM HEPES-
buffered saline (HBS, pH 7.4) and 77 mg/mL probenecid to prevent dye leakage for 30 
min. After incubation, two separate 384-well plates were assembled. One plate contained 
dye-loaded PRP (30 µL/well) and the other plate contained platelet agonists at previously 
determined EC50 concentrations [50,84], as well as serial dilutions of three different APAC 
molecules of varying heparin conjugation levels (CL10, CL18, HICL). The agonist-
containing plate was prepared using a JANUS liquid handling system (PerkinElmer, Inc., 
Waltham, MA) such that all 144 combinations of the six platelet agonists and eight APAC 
concentrations (0, 1.56, 3.12, 6.25, 12.5, 25, 50, 100 µg/mL) were prepared in a time-
efficient manner with replicates. The two plates were loaded into a FlexStation 3 
microplate reader (Molecular Devices, Inc., Sunnyvale, CA) and agonists (20 µL/well) 
were dispensed column-wise into PRP. The dynamic fluorescence intensity F(t) was read 
and normalized by the pre-dispense baseline (Fo) for 4.5 min with readings every 2.5 s 
(Ex: 485 nm; Em: 525 nm). The final PRP concentration after agonist addition was 12% 
by volume and previously no evidence of autocrine signaling has been reported in these 
dilute conditions [84]. Testing of type I fibrillar collagen (20 µg/mL) in the platelet calcium 
assay was performed as previously described [99], in which manual pipetting and reading 
using a Fluoroskan Ascent plate reader was required due to variable delivery of collagen 
by the FlexStation automated pipetting system. 
Platelet aggregation studies were performed using a Chrono-log Model 700 Whole 
Blood/Optical Lumi-Aggregation System. Whole blood was drawn via venipuncture into a 
syringe loaded with 250 nM apixaban and 4% (w/v) sodium citrate (Sigma-Aldrich) under 
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the same IRB approval as above. Citrated whole blood is commonly used to chelate 
calcium ions and prevent platelet activation, but here we use citrate in conjunction with 
apixaban to further ensure minimal endogenous thrombin generation. Type I fibrillar 
collagen (1 µL) was added to PRP after 10 min incubation of APAC (or buffer as control) 
and aggregation was measured for 4 min post-dispense. 
 
6.1.3 Results and Discussion 
Intracellular calcium mobilization of dilute apixaban-treated PRP in response to 
several platelet agonists was measured in the presence and absence of three different 
APAC molecules. Platelet agonists included thrombin (20 nM), convulxin (a potent platelet 
glycoprotein (GPVI) activator derived from snake venom; 2 nM), ADP (1 µM), U46619 (a 
stable thromboxane A2 analog; 1 µM), fibrillar collagen (20 µg/mL), and two PAR-specific 
ligands SFLLRN (PAR-1 agonist; 10 µM) and AYPGKF (PAR-4 agonist; 300 µM). All 
APAC concentrations (1.56-100 µg/mL) reduced the platelet calcium response to thrombin 
and collagen at least 50% compared with the negative control condition. Representative 
results for 12.5 µg/mL of APAC are shown in Supplemental Figure 21. 
For each condition, the area under the curve of the resultant calcium fluorescence 
trace was calculated and converted to a percentage of the control response (Figure 6-1). 
The effect of heparin conjugation level was also identified to impact the extent of inhibition. 
Incubation of PRP with CL10 resulted in a 76% decrease in thrombin-induced platelet 
calcium signal and 51% reduction in the collagen response. CL18 showed the highest 
attenuation of calcium mobilization, yielding an 83% and 95% reduction in response to 
thrombin and collagen, respectively. However, increasing the conjugation level above 18 
(HICL) still exhibited a statistically significant inhibition, but slightly less than that seen with 
CL18 and closer to that of CL10.  For each of the other five agonists tested, virtually no 
inhibitory effect was observed, as is evident by ~100% calcium mobilization (Figure 6-1). 
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Heparin inhibition of thrombin-mediated platelet calcium mobilization was fully consistent 
with accelerated thrombin complexation with antithrombin via the heparin functionality of 
the constructs, while maintaining PAR-1/4 functionality as evidenced by the unchanged 
responses to SFLLRN and AYPGKF stimuli. In addition to this anticoagulant feature, 
previous work has shown the APAC conjugates to also display antiplatelet effects [136], 
however the effects on intracellular calcium mobilization have not been reported. The 
antiplatelet effects appear to be specific to collagen and thrombin, since all other platelet 
signaling pathways and receptor agonists (CVX, ADP, U46619, SFLLRN, and AYPGKF 
for GPVI, P2Y1/12, TP, PAR1, and PAR4, respectively) were active in the presence of 
APAC.  While collagen can bind heparin, convulxin has no known heparin-binding domain, 
thus likely explaining the striking difference in APAC activity against collagen stimulation 
of the platelets that remain fully responsive to the GPVI activator, convulxin.      
In a similar test as previously reported [136], aggregometry was used to investigate 
the antiplatelet features of the heparin proteoglycan mimetic APAC. Each individual APAC 
(100 or 200 µg/mL final concentration) or buffer was added to PRP, and type I fibrillar 
collagen (2 µg/mL) was used as the stimulus to measure platelet aggregation in citrated 
PRP with apixaban addition. The negative control condition (buffer treatment) produced 
70% aggregation over the course of the experiment (4 min). For each APAC species 
(CL10, CL18, and HICL), aggregation was impaired in a dose-dependent manner (Figure 
6-2,A-C). In all cases, the maximal aggregation was lowered, the lag time prior to 
aggregation was prolonged, and the slope and area under the curve were reduced. The 
intermediate-chain conjugated species (CL18) was again observed to have the most 
significant effect, as platelet aggregation was completely abolished at high concentrations 
(200 µg/mL) (Figure 6-2,B). Other platelet agonists were screened in aggregometry and 
the same observations were made in that APAC conjugates only affect thrombin- and 
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collagen-mediated platelet aggregation (Supplemental Figure 22), confirming the 
calcium mobilization results. 
 
 
Figure 6-1. Thrombin- and collagen-dependent calcium mobilization is specifically reduced 
in the presence of APAC 
Previously determined EC50 concentrations of several platelet agonists were added to dilute 
apixaban-treated PRP to stimulate platelet activation. A control condition (absence of APAC) was 
used as the 100% calcium mobilization baseline to which the effect of three APACs (12.5 µg/mL) 
was compared. Antiplatelet effects were seen by reduced activation levels in cases where thrombin 
and fibrillar collagen were used as the stimulus. However, all other platelet agonists were not 
significantly hindered by APAC. Final agonist concentrations: thrombin, 20 nM; collagen, 20 μg/mL; 
CVX, 2 nM; ADP, 1 μM; U46619, 1 μM; SFLLRN, 10 μM; AYPGKF, 300 μM. (n=3 donors, * p<0.05, 





Figure 6-2. Platelet aggregation in PRP is inhibited by APAC 
A dose-dependent reduction in collagen-mediated aggregation of apixaban/sodium citrate-treated 
PRP was observed for each of three APACs (A. CL10; B. CL18; C. HICL). A high dose of CL18 
was shown to have the greatest effect as aggregation was almost completely abolished, consistent 





Concern of bleeding risks associated with combinations of two or more blood 
modulating drugs have sparked interest in developing cardiovascular therapies with dual 
antiplatelet and anticoagulant (APAC) activity. Using naturally-produced HEP-PGs as a 
framework for synthetic alternatives, protein functionalized with conjugated UFH chains 
offers a promising route [136,140]. With our 8-channel device, we demonstrated APAC 
antiplatelet activity with PPACK-treated blood perfused upon collagen. Secondly, we 
analyzed the ability of APAC to interfere with the thrombus growth when CTI-treated blood 
was perfused upon a collagen/TF surface. We also provide evidence that APACs can 
directly interact with collagen to reduce platelet deposition under flow and to decrease 
collagen-induced calcium mobilization. Additionally, the increased inhibitory activity 
against platelets under arterial flow conditions suggests that APAC when studied in the 
absence of any other anticoagulant may also reduce vWF binding to collagen or modulate 
the VWF-GPIbα interaction. APAC interaction with vWF was supported by the 
immunoprecipitation studies where vWF captured APAC.  
 To investigate the observed antiplatelet effects of APAC more specifically, we 
utilized intracellular calcium mobilization as a metric to test the influence of APAC on 
various platelet signaling pathways. The activation of several platelet receptors leads to 
distinct signaling cascades that converge on mobilization of calcium ions, so we can infer 
the level of agonist-induced activation through this reading. A screen of seven common 
platelet agonists in the presence and absence of three APAC conjugates revealed 
inhibitory action only towards thrombin and fibrillar collagen (Figure 6-1, Supplemental 
Figure 21). All other agonists (ADP, U46619, convulxin, SFLLRN, and AYPGKF) were 
sufficiently active with respect to the control buffer condition. Collagen-induced 
aggregation was also impaired by each APAC molecule (Figure 6-2). These results 
suggest that APAC has specific antiplatelet targets without being a universal inhibitor of 
platelet activation, leaving the other activation routes intact. 
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 Other than its traditional anticoagulant mechanism, heparin has been implicated 
to exhibit other antithrombotic effects such as inhibiting endoperoxide metabolites that 
lead to thromboxane A2 production, suggesting aspirin-like functions [141]. Also, collagen 
has previously been reported to have unique heparin-binding sites separate from those 
involved in heparin-triggered thrombin inactivation [138,142,143]. Though the functional 
significance of heparin-collagen binding is still unclear, it may explain the observed 
inhibitory phenomenon of heparin proteoglycans and synthetic APAC conjugates on 
collagen-induced platelet aggregation, especially under blood flow. 
 Collagen activates platelets primarily through GPVI, a uniquely non-G protein-
coupled receptor. GPVI belongs to a class of proteins known as immunoreceptor tyrosine-
based activation motifs (ITAM) [13]. The converse to ITAM receptors are immunoreceptor 
tyrosine-based inhibition motifs (ITIM), which inhibit ITAM signaling in order to suppress 
platelet activation, a pathway that functions along with the prostacyclin-activated IP 
receptor [12,144]. Upon first consideration, it would appear, that the APAC conjugates 
would qualify as ITIM-activating molecules, but the calcium mobilization results showing 
full GPVI activity via convulxin disproves this hypothesis and points more towards the 
collagen-heparin interaction. Though certain explanations may be incorrect, and collagen 
and thrombin appear to be the sole targets, more work should be performed to further 
refine the specific antiplatelet and platelet anticoagulant mechanisms of APAC.  
 Currently available treatment by antithrombotics is available only systemically. In 
our previous publications we have shown that during local application at the injury site, 
either in vivo (arterial model of crush injury in baboon) or on the collagen coated surface 
ex vivo (collagen coated chamber - shunt model in baboons) APAC has potency to inhibit 
platelet thrombosis and reduce platelet accumulation under arterial shear forces [136]. In 
addition, we have previous data to show by PET scan that APAC (Cu64-APAC) binds at 
the injury site with extended retention time in respect to UFH (Cu64-UFH) [140]. Our recent 
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data [145] also shows localization of APAC at the injury site in porcine models of balloon 
denuded iliac and carotid arteries and at the arteriovenous fistula of femoral artery and 
vein. Based on the results of the current manuscript showing reduced platelet deposition 
on the highly thrombogenic collagen/tissue factor surface and the inhibition of collagen-
induced platelet aggregation support the suggestion to combine antiplatelet and 
anticoagulant action in a single antithrombotic, locally acting modality. Importantly, 
polyvalent APAC constructs may offer PK/PD advantages relative equivalent free drug. 
 
6.2 Testing efficacy, potency, and specificity of platelet inhibitors 
6.2.1 Effect of PAR-4 specific antagonist  
 When developing new antithrombotic drugs, one of the most important 
considerations for research groups is the potential for bleeding risk in patients. In order to 
address this concern, receptors with less significant contributions to platelet activation and 
clot formation are becoming promising targets for drug development. One such receptor 
of interest lately has been protease-activated receptor 4 (PAR-4) [146,147]. PAR-4 is one 
of two platelet receptors with affinity towards thrombin, the other being PAR-1. Though 
both PARs have been studied extensively, there have only been antagonists developed 
against PAR-1. Vorapaxar is a specific and potent PAR-1 inhibitor approved in 2014, 
though its benefits are limited due to its requisite administration with other antiplatelet 
therapies like aspirin. As a result, the bleeding risks associated with vorapaxar treatment 
are still an ongoing issue [148].  
 Thrombin is known to activate the two PARs in a concentration-dependent manner. 
First, at low to moderate thrombin levels, PAR-1 is the primary target for thrombin-
mediated platelet activation. As the concentration of thrombin increases to saturating 
levels, PAR-1 activation is overcome by PAR-4 signaling [149]. Thus, targeting PAR-4 is 
thought to be a gentler and more controlled manner of platelet inhibition, and the necessity 
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of high thrombin concentrations ensures that coagulation will also be largely in effect to 
further prevent excessive bleeding. One of the first and most promising reports of drug 
screening and development for PAR-4 inhibition was published by Wong and colleagues 
at Bristol-Myers Squibb [150]. Currently their drug, BMS-986120, is commercially available 
for lab purposes and has been tested in animal models. In follow-up work, other iterations 
of this and similar molecules are under investigation to improve the potency of the inhibitor, 
which had previously been reported to have an IC50 of ~10 nM [150]. One such variant is 
known as BMS-986141, and our group was asked to test its activity and potency in some 
of our assays using human blood.  
 The first round of experiments we conducted were dose-response experiments 
against PAR-4 signaling specifically, which was achieved by challenging platelets with the 
PAR-4 activating peptide AYPGKF. In calcium dye-loaded PRP, we found the inhibitor’s 
potency to be about 10-fold higher than BMS-986120 (IC50~1.3 nM) (Figure 6-3,A-B). 
Next, we checked the specificity of BMS-986141 by stimulating platelets with other 
agonists. No off-target effects were observed, and there was some inhibition against 
thrombin-mediated platelet signaling which is to be expected (Figure 6-3,C-H). 
These preliminary data are certainly encouraging and should be validated in other 
assays. In the future, it would be interesting to study how the inhibitor functions under flow 
conditions and in living organisms. Our lab is equipped to run in vitro microfluidic 
experiments, but investigating the specificity of this inhibitor against PAR-4 may not be 
trivial. The microfluidic channels are typically coated with collagen and/or tissue factor to 
observe both coagulation pathways, so additional inhibitors may have to be included in 
order to pinpoint effects against the receptor of interest. One initial idea for an experiment 
may be to include the PAR-1 inhibitor, vorapaxar, at a moderate dose, and high 
concentrations of tissue factor to ensure a PAR-4 response, followed by dose-response 
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concentrations of the PAR-4 inhibitor. In this way, we may be able to separate PAR-1 from 
PAR-4 signaling as was done in the well-plate experiments. 
 
 
Figure 6-3. Effects of PAR-4 antagonist BMS-986141 on array of platelet agonists 
Calcium dye-loaded PRP was incubated with different concentrations of BMS-986141, a specific 
PAR-4 inhibitor created by Bristol-Myers Squibb. Dose-response experiments of the inhibitor 
against a strong concentration of PAR-4 activating peptide AYPGKF confirm reported IC50 value of 
~1 nM (A, B). Target specificity was analyzed by activating platelets with several agonists in the 
presence and absence of BMS-986141 at potent doses (C-H). Other than AYPGKF and thrombin, 
which also activates PAR-4 physiologically at high concentrations, no significant inhibitory effects 




6.2.2 Effect of custom GPVI inhibitor 
Despite the fact much is known about interactions between platelet glycoprotein 
VI (GPVI) and its primary physiologic ligand collagen, drastically different approaches 
towards inhibiting the receptor’s activity have been reported. Inhibition of GPVI has shown 
to have clinical benefit other than the expected antithrombotic effects, including protection 
against myocardial ischemia-reperfusion injury and increased efficacy of cancer treatment 
by inducing intra-tumor hemorrhage [151,152]. These studies made use of monoclonal 
antibodies (mAb) directly targeting and blocking the functionality of GPVI. In addition to 
these mAb strategies, a few small molecules have been developed with affinity for the 
GPVI receptor. Losartan and honokiol are examples of these small molecules that impart 
inhibitory effects on platelet aggregation in response to collagen stimulation [153]. 
Specifically, losartan is hypothesized to block the critical GPVI clustering and dimerization 
processes, while honokiol has shown direct binding affinity to the receptor though its 
potency is not very impressive (µM range of concentrations). To this point, it is unclear if 
either of these small molecules is a reliable method for blocking GPVI activity and likely 
requires much more work and characterization. Finally, a third class of approaches, which 
is less direct though seemingly still effective, involves understanding and targeting entities 
involved in GPVI-mediated intracellular signaling. For example, tyrosine kinase inhibitors 
like dasatinib, ibrutinib, acalabrutinib, and others prevent platelet activation through the 
GPVI pathway [99,154]. Phosphorylation of spleen tyrosine kinase (Syk) and Bruton’s 
tyrosine kinase (Btk) are essential for successful platelet activation, so inhibiting these 
intermediate steps can also be useful techniques.  
Considering this project’s interest in GPVI signaling and the observed down-
regulation in platelet response to convulxin stimulation in the presence of soluble fibrin 
and FDP, we became interested in using GPVI inhibitors for general mechanistic studies. 
Many of the function-blocking antibodies used by other groups are custom-made and not 
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available for purchase, and our attempts towards testing small molecules like honokiol 
were unsuccessful in calcium mobilization experiments (data not shown). Therefore, we 
turned our attention to designing a single-chain variable fragment (scFv) using plasmid 
technology in collaboration with Reaction Biology Corporation. In short, the scFv was Myc-
tagged for visualization purposes and subcloned into E. coli prior to expression and 
purification. The first iterations of this production unfortunately yielded low purity (~50%), 
and relatively high concentrations were required when we tested its capability to inhibit 
GPVI signaling (Figure 6-4,A). A dose-response experiment indicated 100 µg/mL as the 
approximate IC50 concentration, but when we investigated off-target effects by stimulating 
platelets with ADP or U46619, we found the scFv also inhibited these modes of platelet 
signaling (Figure 6-4,B-C). Our initial hypothesis is that the low purity of the prepared 
constructs may be responsible for this lack of specificity and low potency, which should 
be addressed in future iterations of this custom GPVI inhibitor.  
         
 
Figure 6-4. Inhibitory effects of custom scFv against GPVI 
PRP was loaded with calcium fluorescent dye and incubated with various concentrations of a 
single-chain variable fragment (scFv) designed in collaboration with Reaction Biology Corporation 
to target the platelet GPVI receptor. (A) Dose-response effects of the custom inhibitor indicate 
relatively high concentrations (>100 µg/mL) are required to impart significant inhibition when 
platelets are stimulated with convulxin. (B, C) Off-target effects are also observed when ADP or 
U46619 are used to activate platelets, perhaps a result of the low purity of the final formulation. 
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6.2.3 Effect of N-acetylcysteine on platelet activation 
 N-acetylcysteine (NAC) is a common nutritional supplement that has been shown 
to have mucolytic properties when used alone or in combination with other medications. 
Some applications for NAC administration are the neutralization of acetaminophen 
overdose often observed during pregnancy which may lead to severe liver damage, and 
the treatment of asthma [155]. Recently, several groups have also implicated efficacy of 
NAC as a therapy with antithrombotic effects, which may be effective in diabetic patients 
who tend to have hyperfunctional platelet activity [156,157]. The idea that NAC can be 
used to inhibit platelet function, however, has been known for several decades now, dating 
back at least to the work of Stamler et al., which suggested NAC involves endothelium-
derived relaxing factor (EDRF) and subsequently enhances the generation of cyclic GMP, 
a well-understood negative regulator of platelet activation [158]. Other groups have also 
tried to use knowledge of the chemical structure of NAC to elicit thrombolytic effects 
through interactions with von Willebrand Factor [159]. However, few if any of these studies 
investigating the effects of NAC on platelets included complete analysis of platelet 
signaling pathways, which we have preliminarily designed experiments to address. 
  To gain an understanding of impacts of NAC on individual platelet receptors, we 
screened six common ligand-receptor pairs in the presence and absence of NAC, and its 
amino acid parent, cysteine. The two molecules share much of the same atomic 
composition, though they differ in the inclusion of an acetyl group one end of the NAC 
structure. Both compounds exhibit a free thiol group, which has been implicated to be the 
critical functional group for reducing disulfide bonds that are important for clot strength 
and integrity [159]. Calcium-dye loaded PRP was incubated with one of the two cysteine 
derivatives at a potent dose (30 mM), followed by agonist challenge with ADP, U46619, 
convulxin, SFLLRN (PAR-1 activating peptide), AYPGKF (PAR-4 activating peptide), or 
thrombin. All agonists were prepared at 10x EC50 concentrations to ensure maximum 
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dynamic range to observe inhibitory effects. Representative data for these experiments 
are shown in Figure 6-5,A-F, and quantified as a fraction of the control response on the 
basis of area-under-the-curve (Figure 6-5,G). 
          
 
 
Figure 6-5. Global antiplatelet effects of cysteine derivatives 
PRP was loaded with calcium dye and incubated with N-acetylcysteine (NAC, 30 mM) or L-cysteine 
(30 mM) prior to agonist challenge. ADP, U46619, convulxin, SFLLRN, AYPGKF, and thrombin 
were added to platelet suspensions and showed varying extents of inhibition when cysteine-derived 
molecules were present (A-F). The data is quantified as % control response on the basis of area-




 From these preliminary experiments, it appears both NAC and cysteine impart 
antiplatelet effects to varying degrees with respect to specific surface receptors. 
Significant inhibition was observed when challenging with any PAR agonists (SFLLRN, 
AYPGKF, and thrombin) as well as with ADP, whereas less dramatic effects were 
observed in the presence of U46619, and challenge with convulxin yielded virtually no 
separation from the control response. Though these results warrant follow-up 
experiments, it is interesting that the cysteine derivatives don’t affect GPVI signaling, 
which is the only non-GPCR that was studied in this pilot experiment. The concentration 
of convulxin may also have been too high, causing any potential inhibitory activity to be 
overwhelmed by the agonist. Nevertheless, conducting future work in this area would be 
interesting, especially with regard to the specific significance of the free thiol group present 
in these compounds. Investigation into other thiol-containing molecules may pave the way 
towards a better understanding of the biochemical mechanisms of platelet function 
downregulation in general. 
 
6.3 Computational modeling of the coagulation response during trauma 
6.3.1 Introduction 
Hemostasis is the body’s primary response to vessel injury. During trauma, this 
pathway may be pushed to its biochemical and physical limits to stop blood loss. 
Additionally, dramatic changes in inflammation, platelet function, and blood biochemistry 
set the stage for trauma-induced coagulopathy (TIC). Excessive blood loss (hemorrhagic 
shock) in combination with tissue trauma, NETosis, endothelial dysfunction, and excess 
fibrinolysis are evolving components that drive a multi-scale pathogenesis and high 
dimensional risk for these patients. This section reviews computational modeling efforts 
to help quantify the interplay of hemodynamics and bleeding. Specifically, simulation tools 
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(bottom-up and top-down) to describe platelet function and clotting under flow are 
presented in the context of bleeding. 
 
6.3.2 Coagulation during bleeding 
Platelets are essential to both hemostasis and thrombosis with extremely complex 
metabolism driven by receptor signaling. Bottom-up models of platelet signaling have 
treated calcium regulation by ADP [160,161] or thrombin [162]. Flamm et al. developed a 
stochastic, patient-specific model of thrombosis under 2D flow over tissue factor surface 
conditions [100]. The model used the Lattice Kinetic Monte Carlo (LKMC) method to solve 
for the stochastic platelet motion and binding events, the Finite Element Method (FEM) to 
solve for the concentration profiles of soluble agonists as a function of time and space, 
the Lattice Boltzmann (LB) method to solve for the velocity profile over the growing clot, 
and a neural network (NN) model to predict platelet activation states. The NN was trained 
via the pairwise agonist scanning (PAS) method (described in more detail later in this 
chapter), where individual and pairwise combinations of agonists are used to predict a 
donor’s platelet calcium concentration over time [50,84]. Interestingly, the model was 
highly predictive of microfluidic experiments of whole blood flowing over a collagen patch 
and predicted a ranked order of sensitivity to drugs such as indomethacin, aspirin, and 
iloprost. Lu et al. extended the model to include a time-dependent thrombin flux at the TF 
surface since this is validated by experimental measurements and is more efficient than 
solving the entire coagulation cascade continuously [163]. 
While these models of coagulation aid in understanding clot formation on a 
surface, they primarily relate to thrombosis and are not suitable for simulating bleeding, 
hemostasis, or TIC. There are several key differences that must be accounted for before 
they can be used in these cases, however. Blood flowing into a region of vessel damage 
will exit the vessel as a clot builds up to stop flow. The blood that pools around the wound 
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extravascularly experiences stasis, has prevailing hematocrit, and will undergo 
contraction. The clot at the wound wall-blood boundary experiences high shear stresses 
and is platelet rich with fibrin polymerizing on the wound boundary. A core-shell 
morphology is typical of these wounds as visualized in animal models [88] or in 
microfluidics with human blood [164]. These laser-injury models of clot structure, to date, 
have typically used healthy animals.   
During trauma, there are dramatic changes in coagulation proteins and platelet 
function. Trauma may present as a consumptive coagulopathy with excessive fibrinolysis, 
endothelial glycocalyx shedding, excessive inflammation, and neutrophil NETosis. 
Furthermore, some injuries, typically traumatic brain injury (TBI), can lead to defective 
platelets which is believed to be a key contributor to TIC [32]. In moderate to severe 
injuries (injury severity score > 15), elevated levels of D-dimer and high prothrombin times 
have been observed [165]. A model of a severe trauma patient experiencing TIC must 
account for these differences.  
Common platelet activators include collagen (lab analog: convulxin), ADP, 
thromboxane A2 (lab analog: U46619), and thrombin, the latter of which also plays key 
enzymatic roles in coagulation (e.g. fibrin polymerization and cross-linking). Following 
these “outside-in” binding events, cytosolic calcium concentrations rise via two different 
mechanisms [22,27], which then leads to “inside-out” activation of additional receptors 
important for platelet aggregation via the plasma protein fibrinogen, among other 
phenomena [22]. A relatively simplified schematic of external and internal platelet 
activation with common ligand-receptor interactions is shown in Figure 1-1. 
 
6.3.3 Data-driven development of subject-specific platelet function profiles 
To phenotype platelets, Chatterjee et al. designed a dual experimental-
computational technique known as pairwise agonist scanning (PAS) [50]. Essentially, 
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platelet-rich plasma (PRP) was prepared via centrifugation following collection of whole 
blood from a consenting donor or patient and incubated with a fluorescent dye that tracks 
changes in intracellular calcium concentration upon agonist stimulation. In order to 
generate sufficiently diverse training data for the machine learning algorithm, single and 
pairwise combinations of six different platelet agonists (or inhibitors) at low, medium, and 
high concentrations were prepared with liquid handling machines and then dispensed into 
the cell suspensions for dynamic data collection. In all, the combinatorial space amounted 
to 154 unique conditions, and the experiment lasted about 2 hr from start to finish. Next, 
a multi-layer supervised neural network (NN) model could be trained by using the agonist 
concentrations and corresponding calcium time series as input-output pairs, and then 
predictions of responses to higher order or more complex stimulation conditions could be 
generated. Once trained, the NN models serve multiple purposes: (1) phenotypic 
development of individualized platelet function profiles for each subject included in the 
study and (2) input into the multiscale models of platelet aggregation discussed previously 
[100,163]. The general workflow from initial experiments to NN training to multiscale 
simulation to validation against microfluidic experiments in shown in Figure 6-6. There 
have been other reports of computational simulation of platelet deposition and activation, 
such as that developed by Sorensen et al. [166,167], but few if any feature capability to 
predict distributions and effects of multiple stimuli on overall hemostatic state. 
Initially, the PAS method was developed using mostly non-physiological activating 
agents [50], but then was expanded to include the effects of thrombin by Lee et al. for 
more representative simulation of the hemostatic response [84]. This approach reliably 
interrogates multiple platelet signaling pathways, and with simple experimental 
implementation can accurately predict platelet reactivity in the presence of multiple stimuli 
working in concert. Platelet activation is a highly dynamic process with several contributing 
factors, which sheds light on the importance of understanding how these factors work 
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synergistically (or antagonistically) during clot development. Until recently, only healthy 
human subjects (no previous medical conditions or medications) had been studied with 
the PAS-NN method. 
 
 
Figure 6-6. Connecting experimental measurements and numerical predictions of platelet 
activation state 
PAS experiments were performed and used to train a NN ensemble to predict calcium response 
for an average healthy person and was incorporated into the multiscale model to predict platelet 
activation. An effective boundary flux term was imposed. Thrombus growth dynamics can be 
predicted by the multiscale model and were compared against microfluidic experiments on healthy 
human blood conducted under identical conditions. Reprinted with permission from [163]. 
  
Verni et al. developed a modified version of PAS with fewer (n=31) agonist 
conditions, comparing healthy donors with coagulopathic trauma patients [110]. The data 
indicated a severe level of platelet dysfunction across multiple signaling pathways, as 
shown in heatmap form in Figure 4-1, which was supported by several previous reports 
[10,29,31]. These other groups typically only characterized platelet function on the basis 
of single-agonist stimulation or with clinical assays such as thromboelastography (TEG), 
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which provide useful but limited information. Demonstration of the utility of this high-
throughput assay technique in a trauma patient population opens the door for studying 
countless other patient cohorts. 
The principles of PAS can be applied in other assays as well. The original design 
relied on intracellular calcium mobilization as the primary readout, which is universally 
recognized to be a correlate of platelet function and activation. However, other markers of 
activation exist downstream of calcium mobilization and are well-studied among groups in 
the platelet biology community. For example, upon initial stimulation, the surface integrin 
ɑIIbβ3 converts to an activated state to enable platelet aggregate formation, ɑ granules fuse 
to the plasma membrane and release contents such as P-selectin, and phosphatidylserine 
(PS) is exposed on the membrane to provide a charged surface for facilitation of 
coagulation [23,168].  
Observation of multiple biomarkers simultaneously is difficult with traditional well-
plate reader technology, but can be achieved by using flow cytometry. Jaeger et al. 
developed a PAS analog known as pairwise agonist scanning-flow cytometry (PAS-FC) in 
which each of the activation events discussed above were tracked as a function of 
combinatorial agonist stimulation [54].  
Machine learning provides access to understanding basic biological mechanisms 
and, perhaps more significantly for the progress of biomedicine, developing diagnostic 
applications as well. The work by Verni et al. with respect to trauma patients presents a 
framework to understand platelet dysfunction and potentially influence transfusion 
strategies employed in the emergency room [110]. Currently, work is being performed to 
fully simulate a trauma patient’s hemostatic state, with the influence of patient-specific NN 
models and extension to 3D geometries.  
Additionally, other machine learning algorithms can be developed that consider 
relative influences of various clinical variables (e.g. vital signs, demographics, previous 
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medical history) to make predictions of patient outcomes and inform appropriate treatment 
regimens. Yoon et al., have published an approach for diagnosing disseminated 
intravascular coagulation (DIC). DIC is notorious for its lack of accepted biomarkers, so 
using readily available patient data to train machine learning models, certainly carries 
significant weight. For example, the DIC diagnostic NN model rank-ordered importance of 
32 variables and identified platelet count, D-dimer content, and clinically assigned scoring 
systems as parameters with most direct implication to development of DIC [169]. Such 
models, with sufficient learning, have the potential to be used in real-time to obtain a rough 
understanding of patient prognosis based on previous cases, and perhaps provide hints 
towards the best method of treatment. Ultimately, all of this work lends itself to the long-
term goal of personalized medicine for countless disease states. 
  
6.3.4 Conclusions 
The multi-factorial nature and ever increasing complexity of physiological 
responses to blood vessel injury have been the focus of several efforts of computational 
modeling. Some groups have chosen to focus on the role and interplay of various 
coagulation proteins, while others have strived to understand the mechanisms of blood 
cell (specifically platelet) function and activity. The ultimate goal of simulating hemostasis 
as completely as possible is becoming more achievable with integration and development 
of models that span multiple orders of magnitude and combine several individual 
components together. Applying data-driven modeling approaches that are dependent on 
bench-scale experimentation and post-simulation verification has proven to be an 
incredibly valuable method that takes advantage of the power of machine learning 
technology. Additionally, recent advances have begun to model non-healthy populations 
(e.g. patient cohorts experiencing coagulopathy and acute inflammation) in an effort to 
better understand patient prognoses and potentially guide diagnosis and treatment 
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strategies. Using the examples discussed above as motivation for the future, there should 
be great optimism for development of similarly structured models for other clinical 
conditions and diseases. 
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CHAPTER 7: FUTURE WORK 
 
 
7.1 Further characterization and study of physiological significance of fibrin 
species distribution in trauma patient blood 
7.1.1 Using gel electrophoresis and western blot to analyze size and composition of 
fibrin-related species 
In Chapters 4 and 5, we presented data from enzyme linked immunosorbent 
assays (ELISA) designed to detect the relative plasma concentrations of D-dimer and 
other cross-linked fibrin degradation products. Elevated levels were observed in samples 
obtained from trauma patients and were strongly correlated with a dysfunctional platelet 
phenotype. Though ELISA is a great method for determining presence or absence of 
proteins of interest, it lacks the ability to specify other proteins that may also be present in 
the sample. Due to the heterogeneity of fibrinolytic products in terms of size, composition, 
and other physical attributes, additional techniques can be applied to learn more about 
the distribution of fibrin-related species in trauma patient blood.  
For example, gel electrophoresis is a commonly used tool to analyze DNA, RNA, 
or protein content in a given sample on the basis of molecular size. By applying an electric 
field across a polyacrylamide gel pre-loaded with protein samples in individual lanes, the 
samples begin to mobilize through the gel and separate as a function of ability to transport. 
The distance travelled through the gel is inversely proportional to the size of the molecule, 
meaning smaller molecules will be found towards the end of the gel at the end of the 
experiment. After this separation step, the gel can be stained through techniques like 
western blotting which enables visualization of individual protein constructs and relative 
quantities in the original sample. The gel is transferred to a membrane and is then 
sandwiched by fiber pads and filter paper to protect the membrane and blot the gel, 
respectively. Primary and secondary antibodies are used to identify the proteins and a 
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reference ladder of general molecule sizes is used to determine the size of the protein 
corresponding to each band [170].   
Applying the principles of gel electrophoresis and western blotting can be applied 
to samples of blood proteins such as the family of fibrin degradation products (FDP) that 
are produced through the action of plasmin on a fibrin mesh. Analysis of size and 
composition of FDP has been conducted previously. One study included the design of a 
system to develop a fibrin-rich clot, perfuse plasmin through the mass, and collecting the 
effluent material for analysis. Using multi-angle light scattering, size exclusion 
chromatography, and sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE), the group identified FDP ranging from 105-107 g/mol [171]. The lower limit was 
representative of D-dimer, which has been discussed at length in this dissertation as a 
product with potential clinical significance, and the authors suggested that these smaller 
FDP can be approximated as rigid rods with little flexibility. Even earlier than this work, 
another group investigated FDP in acute myocardial infarction (AMI) patients [172]. Blood 
was collected prior to and after fibrinolytic therapy administration, and serum was isolated 
for subsequent protein analysis. Specifically, the authors were interested in differentiating 
between cross-linked fibrin degradation products and fibrinogen degradation products, 
and gel electrophoresis was used to distinguish the two groups.  
Using these success stories as motivation, future work with the trauma patient 
collaboration should focus on further physical and biochemical characterization of the 
specific protein complexes that may carry stronger mechanistic implications than others. 
Plasma samples or serum samples can be prepared following whole blood collection 
according to the methods outlined in Chapter 4, and separation assays can be run to 
observe the prevalence of each type of FDP. It is clear that D-dimer and cross-linked fibrin 
degradation products are present, but to this point the presence of other fibrin-related 
species specifically in trauma-derived samples is unknown.  
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7.1.2 Observing interactions between D-dimer and platelets under flow conditions in 
microfluidic device 
Virtually all of the experiments discussed in this work have utilized well-plate 
technology, which enable high-throughput data collection and excellent analysis of cellular 
signaling processes mediated by ligand-receptor interactions, but typically employ static 
reaction conditions. Considering the fact that hemostasis is a dynamic process that is 
highly dependent on the flow properties of blood, recreating these physiologically relevant 
conditions is crucial for developing a complete understanding of all aspects of the 
hemostatic response. In light of this, our group and several others have applied principles 
of biomaterials and soft lithography to fabricate controllable in vitro models of blood flow 
through miniaturized channels. Over the years, members of our lab have designed various 
microfluidic schemes for simulating a plethora of hemodynamic scenarios [173]. The 
flagship device design is comprised of eight independent channels, each supplied by its 
own inlet reservoir and operated by a syringe pump pulling through a single outlet port 
[85]. Each of the channels includes a region patterned with prothrombotic entities, where 
fluorescently labeled blood components can be visualized as the hemostatic response is 
triggered. This setup permits up to 24 test conditions when three devices are run in parallel 
and is ideal for dose-response characterization of antiplatelet and anticoagulant drugs as 
well as customized study of specific facets of hemostasis. 
To continue the work with trauma patients and assess the validity of the 
observations regarding the effects of D-dimer and fibrin degradation products on platelet 
signaling, we plan to employ microfluidic technology to determine how our results compare 
to those obtained with the incorporation of flow conditions. A previous lab member had 
also shown similar dysfunctional phenotypes in patients, but did not pursue the underlying 
mechanisms [30]. Moving forward, it would be interesting to design phenocopying 
experiments similar to those outlined in Figure 3-8, but also with the incorporation of tPA 
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or plasmin to generate fibrinolytic products or direct addition of purified D-dimer to the 
initial whole blood sample. In addition to fluorescently labeling platelets and fibrin, it would 
be important to include a detector of D-dimer and visualize whether or not the platelet and 
D-dimer signals indicate colocalization. We used a fluorescent anti-D-dimer antibody 
validated for the flow cytometry experiments in Chapter 5, but other options are available 
which are more suitable for immunofluorescence applications. A proposed schematic of 
the experimental design is shown below in Figure 7-1. Treatment of apixaban-
anticoagulated whole blood with thrombin, tPA/plasmin/D-dimer, and fluorescent 
antibodies will occur prior to loading into the microfluidic device or a coverslip. After 
sufficient incubation, both the flow experiment over a collagen patch and the static 
interaction visualization assay will be conducted. Our hypotheses would include 
decreased platelet deposition to the collagen surface as well as colocalization of platelets 
and FDP to further strengthen the notion that the two components contain binding affinity 
for one another. 
 
 
Figure 7-1. Proposed experimental setup for microfluidic investigation of platelet-FDP 
interactions 
Full-scale fibrinolysis will be simulated with thrombin and tPA or plasmin sequential addition prior 
to microfluidic assay or microscopic visualization of resulting clot components. Parameters such as 
reagent concentrations and incubation times would require optimization. 
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7.1.3 Studying mechanisms of D-dimer binding in mouse knockout cell lines 
A common method for determining specific effects of genes or transcribed proteins 
on observed phenotypes, or for identification of new functions, is the generation of 
knockout models with targeted modification of genetic material. These studies are often 
performed in mice, which have been shown to have relatively high degrees of homology 
with respect to genetic content compared to humans. Countless knockout mouse models 
have been developed and studied for all sorts of medical conditions, and this technique 
can certainly be applied to follow up on the major conclusions made in this work. In 
Chapters 3 and 5, we showed distinct platelet signaling defects through the GPVI receptor 
when soluble fibrin and fibrin degradation products were present in solution prior to agonist 
challenge. Also in Chapter 5, we presented preliminary data using an inhibitor of the 
integrin αIIbβ3 to imply decreased interactions between platelets and D-dimer when the 
receptor was hindered. Though there may be additional surface receptors to consider, we 
have proposed two candidates to study further. Despite the fact that our lab does not have 
much expertise in mouse models, we have collaborators in the medical school who could 
be included to assist in the development of knockout models and cell lines for additional 
analysis.  
Studying functionality of platelet receptors has previously been performed in 
knockout mice missing key receptors such as GPIb and GPVI, the PARs, P2Y1 and 
P2Y12, and integrin  αIIbβ3 [174]. Specifically, one group showed that thrombasthenic mice 
with knockout of the αIIb gene fail to bind fibrinogen and aggregate adequately, leading to 
bleeding disorders comparable to those observed in Glanzmann thrombasthenia patients 
[175]. For the purposes of our interests, we would be interested in a similar model, though 
ideally a full αIIbβ3 knockout, to use in D-dimer binding assays utilizing flow cytometry 
technology or surface plasmon resonance (SPR). Hypothetically, if a myriad of knockout 
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mouse models would be generated, we could screen several receptors for potential 
binding interactions to identify targets for future drug development with more confidence.   
 
7.2 Comparison of PAR signaling via activation with thrombin or synthetic 
peptide combination 
 
7.2.1 Investigating trends in different measures of platelet function 
Though thrombin is the physiologic activator of the two protease-activated 
receptors (PAR) expressed in human platelets, PAR-1 and PAR-4, ex vivo studies of 
individual activation schemes of each receptor are often performed with synthetic 
peptides. Other published work has investigated functional responses and clinical 
implications of PAR activation [176,177]. In a study of PAR-1 signaling by agonist peptides 
and thrombin, different mechanisms of activation were observed and were determined to 
be dependent on intracellular components [176]. Though this study focused on endothelial 
cells rather than platelets, which function differently, the relative dose-response results 
were similar to those observed in platelets. Another group conducted work in extracted 
cardiovascular tissues from umbilical arteries and similarly investigated effects of PAR-1 
activation via thrombin or PAR-1 activating and inhibiting peptides [177]. The conclusions 
of this study showed similar effects on arterial blood flow when either thrombin or a PAR-
1 peptide was utilized, indicating physiological significance of the receptor for 
cardiovascular applications extending beyond platelet activation. These reports do not 
consider platelet PAR activity specifically, which presents an opportunity for future 
directions. It would be interesting to try to determine dosages of various PAR agonists that 
produce similar platelet responses, and also to extend this notion to multiple metrics of 
platelet activation to obtain a full understanding of PAR signaling and inform future 
experiments as to the appropriate peptide concentrations that will mimic a physiologic 
response in the presence of thrombin. 
121 
 
Preliminary work with respect to this objective has been completed, though there 
is still ample room for further study. First, calcium mobilization experiments were designed 
with the goal of producing virtually identical data when platelets were subjected to 
thrombin stimulation or activation by a combined cocktail of PAR-1 and PAR-4 agonists, 
SFLLRN and AYPGKF. After several iterations of trial and error, it was determined that 
high concentrations of thrombin (200 nM) as well as the individual PAR peptides (100 µM 
SFLLRN + 300 µM AYPGKF) generated starkly similar calcium release profiles (Figure 
7-2,A). This agonist ratio was held constant and other conditions were tested to determine 
the generalizability of the observations. Using area-under-the-curve (AUC) as a 
quantitative measure, and plotting the thrombin-mediated results against the peptide-
mediated data, a strong linear correlation was observed (Figure 7-2,B). Though there may 
be other agonist concentrations that yield similar results, this initial outcome is 
encouraging. Similar experiments, in which flow cytometric detection of integrin αIIbβ3 
activation and P-selectin exposure were performed, produced comparable results (Figure 
7-2,C-F). However, the relative agonist concentration ranges for the calcium and flow 
cytometry assays were not conserved, probably due to different dose-response 
relationships for each metric. Standardizing the concentrations in some fashion, perhaps 
through non-dimensionalization with respect to EC50 values, may facilitate the ability to 
merge the independent observations. Despite this drawback, these preliminary data 
highlight the potential for developing a data-driven model for mapping platelet responses 
due to various PAR agonists across multiple common activation methods, which has yet 




Figure 7-2. Matching of various platelet activation markers for PAR agonists 
Platelet stimulation of dilute PRP was performed with either thrombin or a cocktail of SFLLRN and 
AYPGKF. Characteristic data for specific concentrations of each agonist condition are shown for 
calcium mobilization (A), GPIIb/IIIa activation measured by PAC1 binding (C), and P-selectin 
expression detected by anti-CD62P antibody (E). Data from other experiments with fixed agonist 
ratios are quantified and plotted to show strong correlations between the thrombin concentrations 
and peptide concentrations that span two orders of magnitude. The basis of quantification was 
area-under-the-curve for calcium assays (B), or mean fluorescent intensity for measuring PAC1 





7.2.2 Training machine learning model to generalize PAR signaling events 
Using the pairwise agonist scanning (PAS) method with neural network training as 
motivation, an area of future interest would be to develop a computational model for 
describing multiple aspects of PAR signaling. Initial hypotheses present several possible 
model designs, one of which is shown below in Figure 7-3. The models would ideally be 
trained and validated with data generated in experiments similar to those discussed in the 
previous section, and then could be used to predict outcomes from diverse scenarios. 
Though inputs to the model would likely be agonist concentrations and outputs would be 
traditional metrics of platelet activation, once the model is sufficiently trained it could be 
used for making other interesting predictions. For example, if the thrombin concentration 
and corresponding calcium release profile are known and these variables are used as 
inputs, the model would then be able to generate predictions of the concentration of 
synthetic peptides required to mimic the calcium response as well as expected levels of 
PAC1 binding and P-selectin expression. This differs from the traditional PAS method in 
that the new model doesn’t rely on the same inputs and outputs, but rather is versatile 
depending on the known information.    
 
 
Figure 7-3. Proposed structure of machine learning model for PAR-specific signaling 
Data collected from experiments using thrombin and PAR-specific peptides as stimuli to trigger 
platelet activation events can be used to train computational models as predictive tools for complex 




 Since this model will involve data of different visual contexts (kinetic data traces 
for calcium experiments vs histogram distributions of cell function in flow cytometry), the 
model will likely require an image recognition feature in order to reliably learn trends in the 
data. Though many machine learning models exist and have been developed for various 
applications, models capable of deep learning, such as convolutional neural networks 
(CNN), are great for image analysis because of the capability to handle “big data” [178]. 
As was done for the PAS-NN method described at length throughout this work, 
optimization of the internal architecture of this model in terms of the number of hidden 
layers and nodes per layer would have to be performed at length to develop the most 
efficient and accurate algorithm possible.   
 
7.3 Extension of PAS to studying toll-like receptors 
7.3.1 Toll-like receptors (TLR) 
 Toll-like receptors (TLR) are a class of receptors primarily involved in the innate 
immune system and inflammatory responses. TLRs are comprised of a family of 
transmembrane proteins present in a variety of cell types. Immune cells, such as dendritic 
cells and macrophages, as well as non-immune cells like fibroblasts and epithelial cells, 
are known to express TLRs [179]. Recognizing a plethora of foreign signals known as 
pathogen-associated molecular patterns (PAMPs) or danger-associated molecular 
patterns (DAMPs), TLRs transmit intracellular signals upon activation to induce the 
expression of genes to initiate host defense. The majority of TLRs signal through proteins 
like myeloid differentiation primary response gene 88 (MyD88), Toll-interacting protein 
(TOLLIP), IL-1R-associated kinase (IRAK), and TNF-receptor-associated receptor 6 
(TRAF6). These signaling proteins work in concert to elicit downstream activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-
activated protein kinase (MAPK) which tend to generate experimentally detectable signals 
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[179]. Specifically, NF-κB is a transcription factor for regulation of genes responsible for 
both innate and adaptive immune response, pro-inflammatory cytokine production, and 
other cell survival functions. 
 Though their primary function is not linked directly to the immune system, platelets 
have also been shown to express the full TLR transcriptome [180,181]. The activation of 
these receptors in platelets, of which there are known to be at least 10, contributes to both 
hemostatic and inflammatory responses, though only a subset is known to be involved in 
platelet function. These include TLRs 1, 2, 3, 4, 6, 7, and 9, and each receptor is uniquely 
expressed on either the extracellular platelet surface or within the platelet’s intracellular 
endosome compartments (Table 7-1). One TLR present on the cell surface is TLR4, which 
recognizes a variety of PAMPs and DAMPs, the most notable of which being 
lipopolysaccharide or LPS. Sometimes referred to as endotoxin, LPS is derived from 
gram-negative bacteria and is typically recognized by CD14 when in the presence of LPS-
binding protein (LBP). CD14, which can also exist as a soluble form, then shuttles the 
bound LPS to TLR4 to trigger the immune response [180].  
 The other well-characterized TLR present extracellularly is TLR2, but its functional 
activity requires heterodimer formation with TLR1 (denoted TLR2/1) or TLR6 (TLR2/6) in 
order to be able to recognize its specific pathogenic ligands. These ligands include gram 
positive-derived lipoteichoic acid and other bacterial lipoproteins, some of which have 
been successfully mimicked by synthetically developed molecules. TLR2/1 and TLR2/6 
both detect microbial PAMPs, though the former targets triacylated lipoproteins while the 
later focuses more on diacyl forms [180]. Another difference between these two receptor 
constructs is their respective effects on platelet function, which will be discussed further in 
the next section. TLR2/1 activation is often studied through the use of Pam3CSK4, a 
synthetic triacylated lipoprotein that mirrors the amino terminus of bacterial lipopeptides, 
which has been shown to positively impact platelet function. Conversely, the diacylated 
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macrophage activating lipoprotein-2 (MALP-2), agonizes the TLR2/6 complex but exerts 
inhibitory effects on platelet activation [180].        
 




TLR1 PAM3CSK4 Yes (via heterodimer 
with TLR2) 
Extracellular 
TLR2 PAM3CSK4  
MALP-2  
Zymosan 
Yes (via heterodimer 
with TLR1 or TLR6) 
Extracellular 
TLR3 Poly (I:C) Yes Intracellular (endosomes) 
TLR4 LPS 
HMGB1 
Histones (H3, H4) 
Yes Extracellular 
TLR5 Flagellin No n/a 










TLR9 CpG ODN Yes Intracellular (endosomes) 
TLR10 -- No n/a 
 
Table 7-1. Expression of toll-like receptors in platelets 
Platelets feature all 10 known TLR transcripts, though only a select few are involved in platelet 
function (shown in bold). The table lists the important receptors with identified ligands, as well as 
whether the receptor is present on the cell surface (extracellular) or within the cell (intracellular). 
 
 The remaining three TLRs that have been implicated to affect platelet function—
TLR3, TLR7, and TLR9—are found within the cell and respond to viral PAMPs. Each of 
these receptors recognizes different forms of genetic material; TLR3 responds to double-
stranded RNA (dsRNA) produced during the life cycle of a virus, TLR7 recognizes single-
stranded RNA (ssRNA), and TLR9 detects viral DNA containing the unmethylated 
cytidine-phosphate guanosine (CpG) sequence [180]. Similar to TLR2 and TLR4, these 
intracellular receptors can also be activated through mimetics of physiologic entities. For 
example, TLR3 activation can be mediated with polyinosinic:polycytidylic acid, or 
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Poly(I:C), which serves as an analog for dsRNA replication products, and TLR7-
dependent inflammatory signals can be initiated with imiquimod, a prescription drug known 
to treat genital warts in addition to its capability to boost the immune system. 
 
7.3.2 TLR activation involvement in platelet activation and signaling 
 As has been discussed, only a selection of the TLR transcripts carry platelet 
function implications upon activation, and even some of the reported effects are 
contradictory. Table 7-2 lists platelet activation signals that have been reported in the 
literature for each of the functional TLRs. When activated, most of the receptors lead to 
platelet activation events such as adhesion, aggregation, and intracellular granule release 
in addition to their usual pro-inflammatory signals through the NF-κB pathway. Other 
receptors exhibit antiplatelet activity; the TLR2/6 heterodimer complex competes with 
TLR2/1 to balance the effects, and TLR7 activation has been shown to induce 
thrombocytopenia as a result of the formation of platelet-neutrophil aggregates [180]. More 
interesting and applicable to the work in this dissertation, however, a few TLRs have been 
reported to elicit increases in calcium mobilization in platelets.  
TLRs specifically identified to play a role in platelet calcium signaling are TLR2/1 
and TLR3. A few groups have shown positive results for Pam3CSK4 stimulation of 
platelets through TLR2/1 to elicit rises in calcium concentrations [182,183]. In fact, the 
calcium mobilization level in response to the TLR2/1 agonist was comparable to that 
induced by thrombin, and was inhibited if platelets were also stimulated simultaneously 
with MALP-2 [183]. However, a separate group attempted similar experiments in which 
platelets were stimulated with Pam3CSK4 or LPS to study calcium signaling in the two 
known surface TLRs. Their results implied TLR activation fails to effectively mobilize 
calcium, and have no effects on subsequent challenge with traditional agonists like ADP 
or platelet-activating factor (PAF) [184]. This lack of agreement may be attributed to the 
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different calcium detection systems used in the referenced studies, but also provides an 
opportunity to apply the methods we have developed to further understand the potential 
physiological significance of TLR signaling in platelets. 
 
TLR Signals for Platelet Activation 
TLR2/1 NF-KB pathway, Syk/Src pathway 
Increased Ca2+, TXA2 production, p38 phosphorylation, PI3K/AKT activation, 
PLCγ2 activation 
Platelet aggregation, adhesion, granule secretion, NET formation  
TLR2/6 Anti-platelet activity  inhibitory towards TLR2/1 signaling 
TLR3 NF-KB pathway 
Increased Ca2+, PI3K/AKT activation, alpha granule secretion, potentiation 
of activation via other agonists 
TLR4 NF-KB pathway, MAPK pathway 
PI3K/AKT activation, PKG expression through cGMP signaling 
Platelet aggregation, adhesion, granule secretion, NET formation 
TLR7 Granule secretion, platelet-neutrophil aggregation, thrombocytopenia 
TLR9 PI3K/AKT activation, Src signaling 
Alpha granule secretion, integrin activation, aggregation, thrombosis 
acceleration 
 
Table 7-2. Platelet biochemical signaling mediated by TLR activation 
For the specific TLR’s involved in platelet activation, some require heterodimer formation (e.g. 
TLR2/1, TLR2/6), while most lead to activation of the NK-KB pathway. Other receptors are reported 
to lead directly to rises in calcium mobilization, or other indicators of platelet activity like 
aggregation, adhesion, or granule release.    
 
7.3.3 Application of PAS to study TLR-mediated platelet function 
To this point, our study of platelet function has focused on traditional agonists and 
receptors whose sole purpose is hemostatic in nature. Several other surface receptors 
commonly involved in other processes like inflammation, such as toll-like receptors, may 
also play an important role in platelet activation, as has been described in the previous 
sections. Our literature review of TLRs has revealed several ligand-receptor interactions 
to consider in platelets, some of which have already been studied by other groups, and 
our lab’s capability to interrogate countless signaling pathways in a single experiment 




Figure 7-4. Proposed set of experiments for investigating TLR activation in platelets 
Preliminary studies of TLR-mediated platelet activation will begin with characterization of several 
of the known agonists listed in Table 7-1, specifically for ability to induce calcium mobilization. If 
necessary, other platelet function assays can also be incorporated for the most promising agonists. 
Dose-response experiments will be conducted to determine appropriate concentration ranges to 
use in future studies, which will include PAS-inspired experiments with multiple TLR ligands 
(orange boxes) as well as combinations with traditional platelet agonists (blue boxes).  
 
Since this area of research is unfamiliar and relatively poorly understood, several 
preliminary experiments can be designed to establish how to proceed with future studies. 
A general outline for the proposed sequence of events in this study is presented in Figure 
7-4, however this is not an exhaustive list and tangential investigation should certainly be 
pursued as initial results are obtained. Each of the TLR agonists listed in Table 7-1 is 
commercially available and can be purchased for laboratory use. The first step upon 
acquisition of these reagents, as with most studies in this work, is to characterize their 
ability to activate platelets. Calcium mobilization experiments in systems of dilute PRP 
should be conducted in which varying doses of each reagent are used as activating stimuli. 
Ideally, some of the TLR agonists will yield dose-dependent calcium profiles, and these 
candidates will progress to the next stage of testing. For those agonists that don’t 
successfully mobilize calcium in platelet suspensions, they should not necessarily be 
omitted from future work but simply put on the back burner until studies with the more 
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promising reagents are complete. At that point, other assays can be designed (e.g. platelet 
aggregometry, flow cytometry) to investigate other mechanisms of platelet activation. 
After dose-response experiments inform appropriate concentrations to use, PAS 
studies can be designed to investigate synergies between individual TLR agonists as well 
as crosstalk between TLRs and traditional platelet receptors. It is difficult to predict the 
number of TLR agonists that will be used for this second set of tests, so we show a few 
that should produce some platelet reactivity (LPS and Pam3SK4). Procedures should 
follow those documented previously [50,84,110], and this pilot study will be novel in that 
high-throughput experimentation of combined inflammatory and hemostatic receptor 
activation has not been performed previously to our knowledge.  
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CHAPTER 8: APPENDIX I (SUPPLEMENTAL FIGURES) 
 
 
Supplemental Figure 1. Dasatinib, a Syk inhibitor, blocks the GPVI-signaling pathway, confirming 
that convulxin or collagen activates GPVI with concomitant calcium mobilization and platelet 
activation dependent on Syk signaling. (A) Stimulation of platelets with convulxin (2 nM) is inhibited 
by Dasatinib (1 µM) when measuring calcium mobilization. (B) Platelet deposition on a collagen 





Supplemental Figure 2. Pretreatment of PRP with thrombin blocks subsequent platelet activation 



















Supplemental Figure 3. Vorapaxar is a specific PAR-1 inhibitor. Vorapaxar (100 nM) reduced 
PAR-1 agonist peptide induced platelet calcium mobilization in a dose-dependent manner (A), but 







Supplemental Figure 4. Thrombin activation of washed platelets does not exhibit attenuation of 
GPVI activation as is observed in PRP. (A) Incubation of 12% (v/v) PRP with thrombin (5 nM) 
results in initial platelet activation and subsequent down-regulation of the GPVI signal when 
compared to a buffer control. (B) Isolation and preparation of washed platelets (a plasma-free 
background) shows initial thrombin-induced platelet activation but no significant downstream effect 




















Supplemental Figure 5. Inhibition of fibrin polymerization with GPRP completely eliminates down-
regulation of convulxin-induced platelet activation. (A) When GPRP (5 mM) is present in platelets, 
the attenuation of calcium fluorescence through GPVI signaling is no longer observed after platelets 
have been activated with thrombin. (B) At several dosage levels of thrombin (2-20 nM) the 



















Supplemental Figure 6. Inhibition of glycoprotein IIb/IIIa-mediated platelet aggregation via 
GR144053 does not prevent GPVI down-regulation after thrombin treatment of PRP. (A) Upon 
pretreatment with GR144053 (5 µM), platelets exhibit calcium mobilization due to thrombin 
stimulation but show convulxin-insensitivity similar to that of the negative control (no GR144053 
treatment) (n=3 replicates for each condition). (B) Aggregometry shows the effect of GR144053 on 








Supplemental Figure 7. Characterization of soluble fibrin via dynamic light scattering. Purified 
fibrinogen (final concentration = 10 nM) was stimulated with low-dose thrombin (1 nM) for 10 min. 
The first peak (42.7±7.4 nm) reflects unreacted fibrinogen and the second peak (1095±347.7 nm) 
















Supplemental Figure 8. Low-dose thrombin treatment (2 nM) of PRP results in ~35% decrease in 
platelet aggregation in response to convulxin (orange curve). However, full GPVI-mediated platelet 
aggregation is restored when PRP is incubated with 5 mM GPRP, preventing fibrin polymerization 
(grey curve). This result is representative of at least three independent experiments and similar 

















Supplemental Figure 9. Factor Xa is an effective mediator of GPVI shedding, though the process 
is relatively slow and requires >60 min to exhibit ~80% of the original GPVI signal. Washed platelets 
were isolated from apixaban-treated whole blood, incubated with calcium dye, and resuspended in 
HBS buffer, then pretreated with FXa (10 µg/mL) for the times indicated above. Convulxin-induced 
(10 nM) calcium mobilization was measured at three timepoints (0, 30, 60 min) of FXa incubation 
















Supplemental Figure 10. Platelet signaling pathways and ligand-receptor binding. Platelet 
activation is mediated by several surface receptors, each with specific ligands that are either 
presented to cells upon endothelial disruption or produced following the first stages of the 
hemostatic response. Major receptors are shown above (GPVI, TP, PAR-1/4, P2Y1 and P2Y12, and 
IP) with commonly used activating agents and respective signaling pathways (right), all of which 
converge upon intracellular calcium mobilization [Ca2+(t)]. Dose-response experiments have been 
conducted previously to determine the EC50 values for each platelet agonist and antagonist listed 
above and combinations of one or two agonists can be prepared as detailed in the concentration 
map (left) to build a subject-specific phenotypic profile of platelet activation. This technique is called 
pairwise agonist scanning (PAS) and has been documented extensively for healthy donors 



















Supplemental Figure 11. Validation of restricted combinatorial space in trauma patient studies of 
total platelet calcium mobilization. Full (n=154 agonist conditions) and restricted (n=31) PAS 
experiments were conducted on healthy donors (N=8) and neural network models were trained 
using data from the restricted space. Up to 10 NNs were trained on each unique donor’s data, and 
the models were averaged together to predict the responses to the full PAS space. The prediction 










Supplemental Figure 12. Experimental setup for monitoring platelet function following 
resuspension of washed platelets in platelet-poor plasma (PPP). Anticoagulated whole blood (WB) 
is centrifuged to isolate platelet-poor plasma (PPP; 2000g, 10min), which can be stored at -80°C 
for future use, or platelet-rich plasma (PRP; 120g, 10min). PRP can then be incubated with a 
fluorescent calcium dye, Fluo-4, and centrifuged further to concentrate a platelet pellet which can 
be washed and resuspended in a medium of choice. Frozen plasma is thawed, reconstituted, and 









Supplemental Figure 13. Representative flow cytometry results for healthy donor. Platelet function 
was monitored using antibodies against activated αIIbβ3, P-selectin, and phosphatidylserine (PS). 
Results were quantified as mean fluorescent intensity (MFI) or % PS-postive cells as determined 
by a pre-determined gating function. Dilute PRP (1%) was activated by buffer control, ADP (2 µM), 
or CVX (4 nM) and results were compared between trauma patients and healthy donors (Figure 















Supplemental Figure 14. D-dimer ELISA results. Plasma concentrations of D-dimer were 
measured via a Human D-dimer ELISA Kit (Abcam, Cambridge, MA). A standard curve was 
constructed for a range of D-dimer concentrations (left) and used to determine levels in a cohort of 
healthy donor and trauma patient plasma samples (right). Trauma patient samples showed ~30-


















Supplemental Figure 15. Total platelet calcium mobilization as a function of patient injury severity 
score (ISS). Each enrolled trauma patient was assigned an ISS to denote the seriousness of the 
presenting conditions. To determine if this unitless parameter was correlated with the level of 
platelet dysfunction observed in the calcium mobilization assay, the data in Figure 4-1,E was plotted 
against the ISS for each patient. The top panel includes all collected data, while the bottom panel 
is the same data labeled with the collection time point. There appears to be no significant 
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Supplemental Figure 16. (A) Protocol for replication of fibrinolysis in well plate-based calcium 
mobilization assay. Thrombin is added to fluorescent dye-loaded PRP in the presence and absence 
of inhibitors, followed by dispenses of tPA and convulxin. (B) Experimental setup for measurement 
of platelet-mediated consumption of D-dimer. Washed platelets were isolated from healthy whole 
blood and incubated with sources of D-dimer (trauma patient-derived plasma or pure human D-
dimer recombinant protein). Sample supernatants following centrifugation were analyzed for final 


















Supplemental Figure 17. (A) Addition of tPA to fibrin-containing systems reduces platelet reactivity 
to CVX stimulation at several low initial thrombin concentrations. (B) D-dimer generation is 





Supplemental Figure 18. Measurements of dense granule activity via ATP release in the presence 
and absence of D-dimer. When stimulated with 2 µg/mL collagen (A) or 10 µM ADP (B), platelets 
released less ATP when pre-incubated with D-dimer (50 µg/mL). The traces shown are averages 















Supplemental Figure 19. Visual representation of data presented in Figure 3 with raw datasets. 
(A) The calcium experiment begins with the preparation of several (n=31) conditions containing 
different doses of six common platelet agonists, shown schematically where each condition is 
represented as a row in the first heatmap (e.g. first condition: buffer control; second condition: low-
dose AYPGKF only, etc). After the agonists are dispensed into PRP, each condition generates a 
calcium time trace, which can also be vectorized and concatenated as a heatmap in the same order 
as the concentration map. Each of these vectors contributes to the Total Platelet Calcium 
Mobilization calculation. The datasets obtained from healthy controls (B, above) and trauma 
patients (C, next page) shows stark differences in platelet response between the two populations 










Supplemental Figure 20. Agonist-specific correlations of platelet function and D-dimer 
concentration. Black solid lines show correlation of all data (healthy/trauma), and dotted line 
represents 95% confidence interval bounds on the line of best fit. Agonist-receptor pairs include 






Supplemental Figure 21. Representative calcium traces showing effect of APAC (12.5 µg/mL) on 
activity of various platelet agonists. (A: T=thrombin, B: C=convulxin, C: A=ADP, D: U=U46619, E: 





Supplemental Figure 22. Platelet aggregation profiles for several platelet agonists in the presence 
and absence of APAC (200 µg/mL). Taken with Figure 6-2, only thrombin- and collagen-mediated 




CHAPTER 9: APPENDIX II (DATA ANALYSIS SCRIPTS) 
 
Copies of various MATLAB scripts used for data analysis, figure generation, and machine 
learning model development are stored in an online Github repository entitled ‘Diamond-
Lab-MATLAB-Codes’. For more information, please email cverni13@gmail.com.  
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